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Abstract
The skeletal muscle channelopathies are a group of inherited disorders due to the
dysfunction of voltage gated channels in the sarcolemma resulting in abnormal
membrane excitability. Simplistically they are broadly divided into those that result from
an “over excited” membrane (the non-dystrophic myotonias) and those due to an
inexcitable one (the periodic paralyses). Skeletal muscle channelopathies were described
clinically long before they were genotyped or hypotheses regarding pathogenesis fully
evolved. This thesis explores all three, the phenotype, the genotype and recent insights
into the pathogenesis.
Detailed clinical and neurophysiologic examination of a large group of patients identified
new aspects of the phenotype including neonatal presentations with important
implications for early life care. Morphological findings are also expanded with the
presence of inflammatory infiltrates, not previously described in the channelopathies.
Extensive DNA sequencing of causative genes was undertaken in a carefully genotyped
cohort. In hypokalaemic periodic paralysis an exclusive relationship between mutations
and the channel voltage sensor emerged which relates closely to recent
electrophysiological evidence of a “gating pore” disease mechanism. A small but
significant minority of cases remain however where no mutation is found. The
implication of other potential genetic mechanisms or even undescribed genes in these
cases is discussed.
Current drug therapies are also examined in three separate cohorts and evidence suggests
acetazolamide, a commonly prescribed treatment, may only be effective in 50-60% of
those with hypokalaemic periodic paralysis. A tentative relationship between efficacy and
genotype also emerges.
Patch clamp studies show significant loss of function of the main alpha pore of the
sodium channel in periodic paralysis but the implications of this in light of the “gating
pore” hypothesis are discussed. Tentative explorations are made as to the viability of
performing future studies in myoctes as opposed to the traditional HEK cell model with
early experiments illustrating limitations.
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 1 
Introduction 
 
The skeletal muscle channelopathies are a rare group of episodic neuromuscular disorders 
including the periodic paralyses and the non-dystrophic myotonias. Mutations in different 
genes are responsible for each sub-group but they are all genes that code for voltage gated 
skeletal muscle ion channels. These ion channels regulate muscle membrane excitability, 
and consequently these diseases share a common pathology of altered sarcolemmal 
excitability. The resultant symptoms include episodes of muscle stiffness as well as 
episodes of weakness. The stiffness, or myotonia is associated with hyper-excitability of 
the membrane. In contrast, weakness, or paralysis, arises when muscle membranes 
become inexcitable.  
Given these two major types of symptoms, these channelopathies can be classified in two 
broad groups: The first are the non-dystrophic myotonias, in which myotonia is the 
predominant symptom, this group encompasses myotonia congenita, paramyotonia 
congenita and the sodium channel myotonias.  The second group is characterised 
predominantly by paralysis rather than myotonia, and includes the primary periodic 
paralyses hyperkalemic periodic paralysis, hypokalaemic periodic paralysis and 
Andersen-Tawil Syndrome.  
 
Skeletal Muscle 
Channelopathy 
Disease Causing Gene Mode of Inheritance 
Myotonia Congenita CLCN-1 Autosomal Dominant or 
Recessive 
Paramyotonia Congenita SCN4A Autosomal Dominant 
Sodium Channel Myotonia SCN4A Autosomal Dominant 
Hyperkalaemic Periodic 
Paralysis 
SCN4A Autosomal Dominant 
Hypokalaemic Periodic 
Paralysis 
SCN4A (10% of cases) 
CACNA1S (70% of 
cases) 
Autosomal Dominant 
Andersen-Tawil Syndrome KCNJ2 Autosomal Dominant 
  
Table 1: Skeletal muscle channelopathies associated with voltage-gated ion channels 
and their causative genes 
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This thesis focuses primarily on the muscle channelopathies due to mutations of the 
SCN4A and CACNA1S genes. For practical reasons I will consider these in two 
categories: 
 
1. SCN4A only: Paramyotonia congenita, sodium channel myotonia and 
hyperkalaemic periodic paralysis 
 
2. SCN4A or CACNA1S: Hypokalaemic periodic paralysis 
 
 
1.0 The role of voltage-gated channels in muscle cells 
 
Skeletal muscle is an electrically excitable tissue. Changes in the muscle membrane 
potential due to the movement of charged ions in and out of the cell stimulate a cascade 
of reactions that result in co-ordinated muscle contraction and subsequent relaxation.  
Nav1.4, the voltage gated sarcolemmal sodium channel encoded by SCN4A supports the 
rising phase of action potentials in skeletal muscle (Fig 1). In cardiac muscles, Nav1.5 
(SCN5A) predominates, while in neurons several different isoforms of sodium channel 
are used, but not Nav1.4. Thus mutations or drugs targeting Nav1.4 can be expected to 
have relatively specific effects on skeletal muscle excitability. 
CACNA1S encodes the skeletal muscle voltage-dependent calcium channel, Cav1.1. Like 
Nav1.4, expression of Cav1.1 is predominantly restricted to skeletal muscle, with cardiac 
muscle expressing Cav1.2 (CACNA1C), and neurons utilising a diverse group of voltage 
gated calcium channels but not Cav1.1. Upon depolarisation by Nav1.4, Cav1.1 channels 
are activated. These channels, although designated voltage-gated calcium channels, are 
physically coupled to ryanodine receptors (RyR1) in the sarcoplasmic reticulum, and the 
activation of Cav1.1 leads to opening of RyR1 and release of calcium from intracellular 
stores (Fig 2). It is thought that the activation of RyR1 via physical coupling, not via 
calcium influx, is the main function of Cav1.1 in healthy muscle cells(Catterall., 1995; 
Brini., 2004). 
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The other two genes associated with similar muscle disorders are CLCN1, which encodes 
the voltage-gated chloride channel ClC-1, and KCNJ2, which encodes an inward 
rectifying potassium channel, Kir2.1. ClC-1 is restricted to skeletal muscle cells where it 
is thought to help set the muscle resting potential and facilitates repolarisation when 
potassium accumulates in T-tubules(Cannon., 2006). As is consistent with its restricted 
expression in skeletal muscles, mutations in CLCN1 lead to a purely muscular disorder, 
myotonia congenita. 
KCNJ2, in contrast, is expressed in a variety of cell types, including cardiac myocytes, 
and mutations in this gene lead to Andersen-Tawil syndrome which has symptoms 
associated with this relatively wide distribution, including long QT, facial dysmorphia, 
and a muscle phenotype of periodic paralysis. In skeletal muscle cells, it has recently 
been proposed that mutations in KCNJ2 that disrupt the expression of Kir2.1 lead to an 
elevation of the resting membrane potential of myoblasts, indicating that in healthy cells 
this channel may be required to maintain resting membrane potential(Sacconi et al., 
2009).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 1: Schematic representation of a muscle action potential 
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Fig 2: Schematic representation of the skeletal muscle voltage gated ion channels 
 
1.1 Structure of Nav1.4 and Cav1.1 
 
Nav1.4 and Cav1.1 channels both consist of a core α subunit and one or more accessory 
subunits. In both cases, the α-subunits form the ion conducting pore of the channel and 
thus far only mutations in the α-subunits have been associated with the skeletal muscle 
channelopathies. As such only the α-sub-units are considered in detail here. The α sub-
units of Nav1.4 and Cav1.1 have similar structures consistent with a shared evolutionary 
history linked to a single ancestral channel(Cannon., 2007). Both subunits are comprised 
of four domains, each of which contains six transmembrane segments. The four domains 
fold together to form a single ion-conducting pore (Fig 3).   
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Fig 3: Schematic representation of the A:Cav 1.1 and B: Nav 1.4 channels. C: 
representation of the alignment of the four domains to form a single ion selective 
pore. 
 
 
1.2 Elements determining the ion selectivity of Nav1.4 and Cav1.1  
 
Although Nav1.4 and Cav1.1 are structurally related, they are permeable to different ions. 
In both channels the S5 and S6 segments from each domain assemble together to create a 
central channel pore through which ions enter the cell(Varadi et al., 1999; Catterall., 
1995). However, Nav1.4 is highly selective for sodium, while Cav1.1 is most permeable 
to calcium ions. The loops between segments S5 and S6 are known as the P loops and 
site-directed mutagenesis experiments have revealed that a small number of amino acid 
residues in these P loops determine the ion selectivity for each respective channel. For 
calcium channels four glutamic acid residues (EEEE) have been identified as the key 
amino acids in determining selectivity for calcium(Tang et al., 1993; Mikala et al., 1993). 
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The amino acids occupying the comparable positions in the voltage gated sodium 
channels (aspartate, glutamate, lysine, alanine, DEKA) have similarly been implicated in 
setting the selectivity of sodium channels(Heinemann et al., 1992; Favre et al., 1996)(See 
Figs 4 and 5).  
 
 
 
 
 
 
 
 
 
 
Fig 4: Schematic representation of Cav1.1 highlighting amino acid residues 
responsible for channel ion selectivity. 
 
 
 
 
 
 
 
 
 
 
 
Fig 5: Schematic representation of Nav1.4 highlighting amino acid residues 
responsible for channel ion selectivity and the IFM motif/inactivation gate. 
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1.3 Channel activation and inactivation 
 
Both Nav1.4 and Cav1.1 are activated by depolarisation of the muscle membrane. In the 
case of Nav1.4 the activation is rapid, and the main role of the channel is to allow sodium 
ions to enter the cell, further depolarizing it, and allowing more voltage-gated channels to 
open. In the case of Cav1.1, it appears the structural change upon activation is sufficient 
to mediate the main effect, a physical activation of the ryanodine receptors, however 
Cav1.1 proteins still contain a channel pore that is opened in response to depolarization, 
and which allows calcium to enter the muscle cell.  
In common with many voltage gated channels, both Nav1.4 and Cav1.1 use positively 
charged segments within the pore-forming α subunits to detect changes in membrane 
voltage(Catterall., 2010). The S4 segments of both channels contain positively charged 
residues (arginines or lysines) at every third position surrounded by hydrophobic 
residues. These segments with their abundance of electrical charge behave as the voltage 
sensors(Yang et al., 1996a) by moving towards the cytoplasmic side of the membrane in 
response to membrane depolarisation. It is this outward movement that produces a 
conformational change at the intracellular surface of the channels(Catterall., 1995), and 
opens the central pore of the channel to allow influx of ions (Fig 6).  
 
 
 
 
 
 
 
 
 
 
Fig 6: Outward movement of the S4 segment in response to depolarization produces 
a conformational change in the channel which opens the central pore. 
 
6
5
4 3
2
1
4
6
5
3
2
1
4
Pore closed Pore open
 8 
Although significant advances in understanding the function of the S4 segments as the 
voltage sensors have been made the exact role of each segment is not fully 
understood(Catterall., 2010). It is likely that individual segments may have slightly 
different roles e.g. in the sodium channel evidence suggests the S4 segments of domains 
III and IV play a more significant role in fast inactivation(Cha et al., 1999). 
In basic terms the channels can be in one of three states: closed, open or inactive. When 
the sarcolemma is at its resting potential the channels are closed and allow no movement 
of sodium or calcium across the membrane. In response to depolarisation the S4 segments 
(voltage sensors) move outwards and the pore undergoes a responding conformational 
change such that the channel moves into the open state and allows the influx of ions 
through the central pore. With sustained depolarisation, the channels inactivate stopping 
the flow of ions. As the sarcolemma repolarises the channels return to the closed state and 
recover from inactivation (see Fig 7). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 7: States of activation and inactivation of Nav1.4 in response to changes in 
membrane potential. 
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The sodium channels can undergo two forms of inactivation. After a brief depolarisation 
of the muscle membrane the channel undergoes fast inactivation which occurs in 
milliseconds and is mediated by the cytoplasmic linker between domains III and IV that 
acts as a hinged “inactivation gate” swinging across and blocking the cytoplasmic side of 
the pore to inactivate the channel. The specific inactivation particle consists of three 
residues in the DIII-IV linker (see Fig 5) known as the “IFM motif” (isoleucine, 
phenylalanine, methionine) that are thought to bind to an acceptor site on the cytoplasmic 
mouth of the pore blocking the passage of sodium ions(Vassilev et al., 1988; Patton et al., 
1992; McPhee et al., 1994). After longer depolarisations the channel inactivates over a 
period of seconds to minutes by a process of slow inactivation. Fast and slow inactivation 
are thought to be structurally independent processes, but the mechanism for slow 
inactivation is less well understood and no specific structural part of the channel has been 
identified as a slow inactivation gate(Vedantham et al., 1998). 
While ion selectivity, activation and inactivation are thought to be processes which are 
intrinsic to α subunits the full physiological function of these channels, as is common to 
most ion channels, is dependent on the assembly of several proteins, including multiple 
accessory subunits(Catterall., 1995). However since this project is focused on the clinical 
manifestation of diseases which are so far only associated with mutations in the α 
subunits, the accessories will not be considered here. 
 
1.4 Clinical features of diseases associated with voltage gated ion channel 
dysfunction in skeletal muscle 
 
The non-dystrophic myotonias 
 
Paramyotonia Congenita 
Eulenberg first described and named Paramyotonia Congenita (PMC) in 1886 after 
studying six generations of a German family affected with the disease(Eulenberg A., 
1886). PMC is due to mutations of the SCN4A gene and is inherited in an autosomal 
dominant manner. 
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Symptoms usually present in the first decade. Affected individuals experience episodes of 
muscle stiffness (myotonia) and weakness or paralysis that are markedly worsened or 
precipitated by cold environments and with periods of exercise. The muscles of the face 
and hands tend to be most severely affected. The myotonia commonly lasts seconds to 
minutes but the paralysis can last hours.  
 
Sodium Channel Myotonia 
Before the recognition of SCN4A as the disease causing gene for paramyotonia congenita 
there were many reports of other myotonic phenotypes that did not fit the typical 
presentation for PMC.  These phenotypes were united by features such as a delayed onset 
of myotonia following rest after exertion, little or no cold exacerbation but significant 
exacerbation following potassium ingestion. They were purely myotonic phenotypes with 
no associated episodes of muscle paralysis. Individually they were described as 
acetazolamide responsive myotonia congenita(Trudell et al., 1987; Ptacek et al., 1994b), 
myotonia fluctuans(Ricker et al., 1990; Lennox et al., 1992; Ricker et al., 1994) and 
myotonia permanens(Lerche et al., 1993; McClatchey et al., 1992b). Together due to 
their shared features they are termed the potassium aggravated myotonias (PAM).  
Other phenotypes were reported that had overlapping features of PMC and PAM in that 
they were purely myotonic and often exacerbated by potassium ingestion but also by 
exposure to cold(Heine et al., 1993; Koch et al., 1995; Wu et al., 2001). 
The distinguishing feature between all these collective phenotypes and PMC has been 
that, unlike PMC, they are purely myotonic disorders with a lack of any associated 
episodes of muscle paralysis. As all of these phenotypes have been shown to be allelic to 
PMC and due to mutations in SCN4A some authors collectively use the term sodium 
channel myotonia (SCM)(Fournier et al., 2004) to encompass all of these purely 
myotonic phenotypes. 
Predominantly it is the face and limb muscles affected by these two groups of myotonic 
disorders (PMC and SCM) but respiratory compromise which can be severe has been 
reported as has dysphagia(Lerche et al., 1993);(Colding-Jorgensen et al., 2006). 
The sodium channel myotonias can be generally relatively easily separated from 
paramyotonia congenita by their absence of episodic weakness but they can have 
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considerable clinical overlap with the dominant form of myotonia congenita (MC) due to 
mutations in the CLCN-1 gene. Table 2 outlines the pertinent clinical features for each 
sub group of non-dystrophic myotonia. The major features of overlap between SCM and 
dominant MC are the presence of the “warm-up” phenomenon used to describe an 
improvement in myotonia with repetitive activity. This is often described as the 
distinguishing feature of myotonia congenita but it can be present in the sodium channel 
myotonias. If so however, it often fluctuates with paramyotonia, (myotonia that worsens 
with repetition as is seen in PMC), whereas in myotonia congenita only the warm up 
phenomenon will be seen. The distribution of muscle involvement can also be very 
similar for SCM and dominant MC and often episodic weakness is also absent in 
dominant myotonia congenita. The recessive form of myotonia congenita is not easily 
confused with sodium channel myotonia but the clinical features are outlined in Table 2 
for comparative purposes.   
 
Development of a progressive proximal myopathy is described in PMC and  SCM 
although whether the onset or severity of this correlates to age or episodes of myotonia 
and/or paralysis is unknown(Schoser et al., 2007).  
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*Myotonia typically develops after a short period of exercise e.g. 10 minutes or on 
resting after a period of exercise. 
 
Table 2: Pertinent clinical features of the non-dystrophic myotonias
 
 
Recessive MC Dominant MC Paramyotonia 
Congenita 
Sodium Channel 
Myotonia 
Inheritance Recessive Dominant Dominant Dominant 
Causative gene CLCN-1 CLCN-1 SCN4A SCN4A 
Myotonia 
distribution 
Lower limbs 
more than 
upper limbs 
Upper limbs 
more than 
lower limbs 
Facial muscles 
may be 
involved 
Upper limbs and 
face  
more than lower 
limbs 
Upper limbs, 
face , 
extraocular, 
more than lower 
limbs 
Myotonia  cold 
sensitivity 
None or 
minimal 
None or 
minimal 
Yes – often 
dramatic 
Variable – 
ranging from 
none to severe 
Warm up 
phenomenon 
Present Present Absent May be present 
Paradoxical 
myotonia 
Absent Absent Present May be present 
Delayed onset 
myotonia  
after exercise* 
Absent  Absent Absent May be present 
Characteristic of 
myotonia 
fluctuans   
Episodic 
muscle 
weakness 
Common, 
develops on 
initiation of 
movement but 
transient and 
improves 
rapidly 
Uncommon Common often 
exacerbated by 
cold and/or 
exercise and 
frequently  
prolonged for 
several hours 
Not reported 
Eyelid 
myotonia 
Infrequent Infrequent Common Common 
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The Periodic Paralyses 
 
Hyperkalaemic Periodic Paralysis 
The periodic paralyses are thought to be the most common of the skeletal muscle 
channelopathies although the exact incidence is unknown(Venance et al., 2006). 
Hyperkalaemic periodic paralysis is due to mutations in SCN4A and is inherited in an 
autosomal dominant manner. Onset of symptoms is usually within the first decade. The 
prominent symptom is episodic muscle paralysis frequently occurring after exercise or 
following the ingestion of potassium rich foods e.g. bananas and tomatoes. Attacks 
usually last from a few minutes to hours and myotonia can occur. ECG abnormalities 
secondary to raised serum potassium levels may be seen during an attack of paralysis.  
Paramyotonia congenita, sodium channel myotonia and hyperkalaemic periodic paralysis 
are all allelic disorders due to mutations of the SCN4A gene. There are often overlapping 
clinical features and it has been proposed that these disorders represent different ends of a 
spectrum rather than being individual diseases(Cannon., 2000). 
 
Hypokalaemic Periodic Paralysis 
Hypokalaemic periodic paralysis (hypoPP) is also inherited in an autosomal dominant 
manner. It is characterised by attacks of flaccid skeletal muscle paralysis in association 
with reduced serum potassium levels. Onset is commonly in the first or second decade 
although presentation in the third decade has been described(Miller et al., 2004). Attacks 
of muscle paralysis are precipitated by factors that reduce serum potassium levels such as 
a large carbohydrate meal. Attacks occur most commonly following strenuous exercise or 
during the night or early morning. They typically last in the region of hours to days 
although some patients will report it is weeks to months before full muscle strength 
returns.  
It is predominantly the limb muscles which are affected in hypoPP but occasionally 
severe respiratory muscle involvement is described(Kil et al., 2009b; rzel-Hezode et al., 
2009b). Cardiac muscle is not inherently affected but potassium levels outside the normal 
range can cause ECG changes(Kim et al., 2005; Kil et al., 2009a; Hecht et al., 1997) 
(flattened ST segments, U waves, prolonged QT interval) that may be pro-arrhythmic and 
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require cardiac monitoring while potassium levels are restored. One case of severe sinus 
bradycardia requiring temporary pacemaker has been reported during an episode of 
hypokalaemia(Maffe et al., 2009) and another case report has described sudden death 
amongst relatives of a genetically confirmed individual with hypoPP(Hecht et al., 1997). 
Whether such severe outcomes are directly or exclusively attributable to hypokalaemia is 
not fully established. 
Many patients with hyperPP and hypoPP will function independently between attacks of 
paralysis but in a significant number a fixed myopathy develops that can be 
debilitating(Fouad et al., 1997; Miller et al., 2004; Biemond et al., 1934)
.
 It is of note that 
three independent series all reported abnormal morphological findings in 100% of 
hypoPP patients who had been biopsied(Fouad et al., 1997; Sternberg et al., 2001; Miller 
et al., 2004). In a minority these were non-specific myopathic changes with vacuolar 
myopathy and tubular aggregates accounting for the majority. The reports of permanent 
muscle weakness were more varied from 25% to 72% of genotyped individuals. The 
mechanism of this myopathy is not understood. It is postulated that it is independent of 
paralytic attack frequency or severity(Buruma et al., 1978; Links et al., 1990) although 
there is evidence that increasing age is associated with the myopathy(Links et al., 1990). 
Only 10% of cases of hypokalaemic periodic paralysis are due to mutations of the 
SCN4A gene with the majority being caused by mutations in the CACNA1S gene(Fouad 
et al., 1997; Miller et al., 2004; Sternberg et al., 2001). Approximately 20% remain 
genetically undefined. There is no clear clinical distinction between hypoPP arising from 
the different genetic sources. 
 
Andersen-Tawil Syndrome 
Andersen-Tawil syndrome is the only muscle channelopathy in which the causative gene, 
KCNJ2(Plaster et al., 2001), is expressed in tissue other than skeletal muscle. As such the 
triad of periodic paralysis, dysmorphic features and cardiac conduction defects comprise 
the characteristic phenotype(Andersen et al., 1971; Tawil et al., 1994). As with nearly all 
the channelopathies it is an autosomal dominant disorder. The type of periodic paralysis 
can be either hyper or hypokalaemic although most commonly it is hypoPP(Davies et al., 
2005). The dysmorphic features include mandibular micrognathia, short stature, 
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clinodactyly, syndactyly, hypertelorism and low set ears(Andersen et al., 1971; Tawil et 
al., 1994; Davies et al., 2005; Haruna et al., 2007) but can be very subtle and easily 
missed. Likewise there are often no cardiac symptoms and unless an ECG is performed 
for unrelated circumstances the cardiac conduction defects are often undetected. For these 
reasons hypokalaemic periodic paralysis may be the only obvious presentation and some 
individuals may be clinically misdiagnosed. This can have significant consequences as 
the cardiac conduction defects described include abnormal U waves, prolonged QUc 
interval, prolonged QTc interval, bigeminy and bidirectional VT. Rarely sudden death 
can occur(Tawil et al., 1994; Davies et al., 2005; Zhang et al., 2005; Haruna et al., 2007).  
 
There is very little data as to the natural history of any of the skeletal muscle 
channelopathies, particularly with regards to the proximal myopathy. Additionally, there 
are few phenotype-genotype correlations, something which is exacerbated by significant 
variability in the severity of the phenotype amongst individuals with the same mutation. 
There are even examples of this occurring amongst members of a single kindred. The 
skeletal muscle channelopathies are generally considered to be more severe in males than 
females. A significant worsening of symptoms is also commonly reported during 
pregnancy. Both of these factors imply there may be a hormonal influence on the 
phenotype. There is some suggestive in vitro evidence to support this(Fialho et al., 2008) 
but it is yet to be fully established or understood.  
 
An allied disease where hormones are clearly shown to be of significance is thyrotoxic 
periodic paralysis. This is most common in Asian males and represents a form of 
hypokalaemic periodic paralysis in which attacks only occur in relation to deranged 
thyroid function. It is not to be missed as treatment of the thyrotoxicosis and return to a 
euthyroid state will abolish the attacks of muscle paralysis. Equally although the thyroid 
function may be abnormal, the patient may not be obviously thyrotoxic and diagnosis 
requires a degree of suspicion.  
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The first aim of this thesis is to study the phenotypes among a large cohort of 
genotyped channelopathy patients to explore any additional recurring features and 
assess phenotype-genotype correlations.  
 
 
 Hyperkalaemic PP Hypokalaemic PP Andersen-Tawil 
Syndrome 
Causative 
gene 
SCN4A CACNA1S 
SCN4A 
KCNJ2 
Inheritance Autosomal dominant Autosomal dominant Autosomal dominant 
Episodic 
skeletal 
muscle 
paralysis 
Yes Yes Yes 
Duration of 
paralysis 
Commonly minutes to 
hours 
Commonly hours to 
days 
Variable, minutes to 
days 
Ictal 
potassium 
levels 
High Low Low, high or normal 
Precipitators 
of paralysis 
Potassium rich foods 
Rest after exercise 
Large carbohydrate 
load 
Rest after exercise 
Dependant on ictal 
potassium 
Typical time 
of attacks 
Any time of day During night or early 
morning 
Any – dependant on 
ictal potassium 
Cardiac 
conduction 
defects 
Only those attributable 
to severe 
hyperkalaemia; resolve 
with restoration of 
normal potassium 
values 
Only those 
attributable to severe 
hypokalaemia; resolve 
with restoration of 
normal potassium 
values 
Common especially 
abnormal u waves, 
prolonged QUc 
interval and 
ventricular 
arrhythmias, 
irrespective of 
potassium levels 
Dysmorphic 
features 
No No Common especially 
short stature, 
mandibular 
hypoplasia, 
clinodactyly and low 
set ears 
 
Table 3: Summary of clinical features of the primary periodic paralyses 
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1.5 Clinical Neurophysiology 
 
Recently specialized clinical neurophysiology protocols have aided precise diagnosis in 
muscle channelopathies by directing genetic testing based on genotype specific 
electrophysiological patterns.   Sarcolemmal excitability can be measured indirectly as 
the variability of the compound muscle action potential (CMAP) following different 
stimuli. The CMAP size varies in skeletal muscle channelopathies in response to short 
(10-20seconds) or long (3-5 minutes) exercise tests (Streib EW., 1982; McManis et al., 
1986). Using these exercise protocols in combination with muscle cooling distinct 
electrophysiological patterns, termed patterns I, II, III, IV and V are now recognized for 
the major skeletal muscle channelopathy sub-groups (Fournier et al., 2004; Fournier et 
al., 2006). The details of these patterns will be discussed for each channelopathy below. 
For clinical diagnosis the repeat short exercise test with muscle cooling is of particular 
value in the non-dystrophic myotonias. 
 
Neurophysiologic patterns in the non-dystrophic myotonias 
Patients with paramyotonia congenita (PMC) typically have a gradual and prolonged 
decrement in CMAP after exercise, termed pattern I(Fournier et al., 2004). This 
decrement is exacerbated with repeat testing and muscle cooling (Fig 8A) reflecting the 
clinically observed cold- and exercise-induced weakness. Some genotypes only display 
this typical pattern when the short exercise test is performed with the muscle 
cooled(Fournier et al., 2006). 
The sodium channel myotonias are separated clinically from PMC by their lack of 
weakness. This is illustrated by pattern III, normal responses to all provocative tests (Fig 
8B) and EMG myotonia is usually the only positive electrophysiological finding. This is 
the characteristic finding in SCM but is not absolute and there are some variations for 
certain genotypes(Fournier et al., 2006). 
Patients with chloride channel myotonia (MC) can show one of two patterns. The most 
common  is pattern II(Fournier et al., 2004) in which at room temperature there is an 
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immediate CMAP decrement after the short exercise test which recovers quickly and 
diminishes with repetition, reflecting the transient weakness observed clinically (Fig 8C). 
This pattern is most frequently seen in recessive MC but can be observed in any muscle 
ion channel disorder in which there is a loss of sarcolemmal chloride conductance. It is 
therefore also seen in dominant MC and in both DM1 and DM2. There is now clear 
evidence that the myotonia in DM1 and DM2 is secondary to reduced chloride 
conductance(Charlet et al., 2002). In recessive MC cooling has little further effect (Fig 
8C). However, in dominant MC the CMAP decrement may be worsened or only seen 
with cooling(Fournier et al., 2006) making it essential to perform the short exercise test at 
both room temperature and with the muscle cooled (Fig 8D). However, some patients 
with dominant MC show a normal response (pattern III)(Fournier et al., 2006) to all 
provocative tests (Fig 8B), even with muscle cooling which is indistinguishable 
electrophysiologically from sodium channel myotonia. Clinical history and examination 
usually helps to distinguish between the two and guide genetic analysis but both of these 
can have considerable overlap between the two groups as discussed earlier (see Table 2). 
Table 4 outlines the most common electrophysiological pattern observed in the repeat 
short exercise test with muscle cooling for each of the NDMs. Variability exists and 
where muscle cooling has already proven useful in improving diagnosis, repetitive nerve 
stimulation may have a future role to play in distinguishing the sub-types of NDM. There 
is some evidence that a reduction in CMAP may be provoked by repetitive nerve 
stimulation in certain cases of recessive MC where exercise testing even with the muscle 
cooled has failed to produce any such decrement(Michel et al., 2007). In this way 
repetitive nerve stimulation may become an additional future tool to guide the genetic 
analysis towards recessive MC in cases that may otherwise be thought to be dominant 
MC or SCM.  
 
 
Neurophysiologic patterns in the primary periodic paralyses 
For hyperkalaemic periodic paralysis and hypokalaemic periodic paralysis due to calcium 
channel mutations electrophysiological patterns IV and V were determined (Table 4). In 
summary, pattern IV describes an increase in CMAP that is exaggerated by repetition in 
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the short exercise test, and an immediate increase in CMAP followed by a later reduction 
in CMAP in the long exercise test. Pattern V illustrates the lack of change observed in 
CMAP during the short exercise test and the prolonged decrement in CMAP during the 
long exercise test of patients with HypoPP due to calcium channel mutation. It is 
important to note that while these patterns are undoubtedly useful in each group they 
were performed in a relatively small number of individuals all carrying the same 
causative gene mutation (6 T704M and 13 R528H). Only two hypoPP patients with 
sodium channel mutations were studied each with a different mutation and each showing 
a different electrophysiological pattern. No large scale studies have been performed in 
those with Andersen-Tawil syndrome. As a result the electrophysiological patterns are 
perhaps less clearly defined for the periodic paralyses than the myotonic disorders. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 8: Common electrophysiological patterns seen in the repetitive short exercise 
test at room temp and with the muscle cooled in the NDMs (produced by Dr Tan) 
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 Paramyotonia 
congenita 
Sodium 
channel 
myotonia 
Dominant MC Recessive MC HyperPP HypoPP 
Myotonic 
potentials 
Yes Yes Yes Yes Yes – less 
frequent/florid than 
NDMs 
No 
Repeat SET 
at room 
temp 
Gradual and persistent 
reduction in CMAP 
Enhanced by repetition 
No significant 
change of the 
CMAP from 
baseline* 
Little or no 
decrement in CMAP 
Early decrement 
in CMAP with 
rapid recovery 
Improves with 
repetition 
Increase in CMAP 
exaggerated by 
repetition 
No change 
in CMAP 
Repeat SET 
with muscle 
cooling 
Gradual and persistent 
reduction in CMAP 
enhanced further by 
cooling (see Fig ) 
 
No significant 
change of the 
CMAP from 
baseline * 
(see Fig ) 
 
Early decrement 
with rapid recovery 
and reduction with 
repetition may be 
seen   
(see Fig ) 
 
Cooling has little 
further effect 
(see Fig ) 
 
ND ND 
Long 
exercise test 
Prolonged decline in 
CMAP 
No change in 
CMAP 
No change in 
CMAP or slight 
early decrement 
only 
No change in 
CMAP or slight 
early decrement 
only 
Early increase in 
CMAP followed by 
prolonged decline in 
CMAP 
Prolonged 
decrease in 
CMAP 
Fournier 
pattern 
I III II/III II IV V 
*Note: this same pattern may be observed in dominant MC    SET: short exercise test, CMAP: compound muscle action potential 
 
Table 4: Electrophysiological patterns seen in the non-dystrophic myotonias and the primary periodic paralyses
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1.6 Genetics of the skeletal muscle channelopathies 
 
The Skeletal Muscle Sodium Channelopathies 
The SCN4A gene has 24 exons that code for the α-subunit of the voltage gated skeletal 
muscle sodium channel, Nav1.4. All of the disorders due to mutations in this gene are 
inherited in an autosomal dominant manner. Every mutation, with the exception of one 
small deletion, associated with the sodium skeletal muscle channelopathies has been a 
point mutation. Mutations have been reported throughout the gene although exons 13, 22 
and 24 are recognised as “hotspots”. Table 5 outlines all reported SCN4A mutations 
including the described phenotypes and functional consequences. Briefly, the most 
common mutations associated with PMC are T1313M and substitutions at the R1448 
position in exons 22 and 24. The most frequently occurring SCM mutations are G1306A 
and V1589M in exons 22 and 24.The mutations most commonly seen in hyperkalaemic 
periodic paralysis are the T704M and M1592V mutations in exons 13 and 24. Although 
these exons represent hotspots (Fig 9), mutations have been reported throughout the gene 
and there is no clustering or discernible pattern to their position in the protein (Fig 10). 
 
 
 
 
 
 
 
 
 
 
 
Fig 9: Common Nav1.4 mutations associated with PMC, SCM and HyperPP.
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Fig 10: Distribution of all point mutations in Nav1.4 associated with PMC, SCM and 
HyperPP 
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Mutation Exon Protein 
Position 
Phenotype Clinical Features Major Pathomechanism Reference 
I141V 4 DI/S1 SCM Myotonia following rest 
after exertion 
Cold exacerbated myotonia 
No weakness 
Enhanced activation 
Enhanced slow 
inactivation 
(Petitprez et al., 
2008) 
L250P/V 6 DI/S5 SCM Myotonia with warm up 
phenomenon 
No response to cooling 
Unknown (Trip et al., 
2008) 
L266V 6 DI/S5 SCM Cold exacerbated myotonia 
No weakness 
Impaired fast inactivation 
Accelerated recovery 
from fast inactivation 
(Wu et al., 
2001) 
Q270K 6 DI/S5 PMC Cold exacerbated myotonia 
Cold exacerbated paralysis 
Unknown (Fournier et al., 
2006) 
V445M 9 DI/S6 SCM – painful congenital 
myotonia 
Painful myotonia 
No weakness 
Enhanced activation 
Impaired fast inactivation 
Enhanced slow 
inactivation 
(Rosenfeld et 
al., 1997; 
Takahashi et 
al., 1999) 
E452K 9 DI-II PMC Myotonia 
Episodic weakness  
No cold exacerbation 
clinically 
Unknown (Dupre et al., 
2009) 
F671S 12 DII/S4 SCM Severe myotonia 
Generalised hypertophy and 
joint retraction 
No weakness reported 
Unknown (Dupre et al., 
2009) 
L689I 13 DII/S4-5 HyperPP Episodic muscle weakness 
especially following rest 
after exercise 
Positive K challenge 
Pseudomyotonic discharges 
on EMG, no myotonic 
discharges 
Enhanced activation 
Impaired slow 
inactivation 
(Bendahhou et 
al., 2002) 
L689F 13 DII/S4-5 SCM Myotonia with warm up 
No response to cooling 
Unknown (Trip et al., 
2008) 
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I693T 13 DII/S4-5 PMC Cold and exercise induced 
weakness 
Myotonia on EMG 
Enhanced activation 
Impaired slow 
inactivation 
(Plassart et al., 
1996; Plassart-
Schiess et al., 
1998; Hayward 
et al., 1999) 
I693T 
Different kindreds 
   Neonatal hypotonia 
Cold and exercise induced 
myotonia and weakness 
 
 (Matthews et 
al., 2008a) 
T704M 13 DII/S5 HyperPP Episodic muscle weakness 
exacerbated by rest after 
exercise 
Positive K challenge 
Enhanced activation 
Impaired slow 
inactivation 
(Ptacek et al., 
1991; 
Bendahhou et 
al., 1999a) 
A715T 13 DII/S5 SCM Cold exacerbated myotonia 
Myotonia worse after rest 
Warm up phenomenon 
No weakness 
Unknown (Fournier et al., 
2006) 
S804F 14 DII/S6 SCM Cold exacerbated myotonia 
Severe myotonia after 
anaesthesia 
Impaired fast inactivation (McClatchey et 
al., 1992a; 
Green et al., 
1998) 
S804F different 
kindred 
  SCM – myotonia fluctuans Fluctuating myotonia 
Delayed onset myotonia  
following rest after exercise 
No cold exacerbated 
myotonia  
No weakness 
 (Ricker et al., 
1994) 
S804N 14 DII/S6 SCM Cold exacerbated myotonia 
Myotonia worse after rest 
Warm-up phenomenon 
No weakness 
Unknown (Fournier et al., 
2006) 
A1152D 19 DIII/S4-5 SCM* Cold exacerbated myotonia 
No weakness 
Impaired fast inactivation (Bouhours et 
al., 2005) 
A1156T 19 DIII/S4-5 HyperPP Episodic muscle weakness 
following rest after exertion 
associated with raised 
Impaired fast inactivation 
Slow inactivation 
indistinct from WT 
(McClatchey et 
al., 1992a; 
Hayward et al., 
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serum K levels 
Muscle stiffness (hands and 
face) 
EMG myotonia  
1999) 
I1160V 19 DIII/S4-5 SCM – acetazolamide 
responsive myotonia 
Fluctuating severe painful 
myotonia 
Potassium aggravated 
myotonia 
Paradoxical myotonia and 
warm up phenomenon 
No weakness 
Marked response to 
acetazolamide 
Enhanced recovery from 
fast inactivation 
Slower deactivation 
(Trudell et al., 
1987; Ptacek et 
al., 1994b; 
Richmond et 
al., 1997)  
V1293I 21 DIII/S6 SCM* Cold exacerbated myotonia 
Occasional myotonia after 
heavy exercise 
No weakness 
Enhanced activation 
Accelerated recovery 
from fast inactivation 
(Koch et al., 
1995; Green et 
al., 1998) 
N1297K 21 DIII-DIV SCM-severe neonatal non-
dystrophic myotonia 
Neonatal onset 
Cold induced severe 
myotonia and weakness 
Hypoxia from resp muscle 
myotonia 
Psychomotor retardation 
Fatal outcome 
Unknown  (Gay et al., 
2008) 
G1306A 22 DIII-DIV SCM – myotonia fluctuans Myotonia of fluctuating 
severity and frequency 
Myotonia exacerbated by 
potassium, rest after 
exertion and anaesthesia 
No cold exacerbation 
No weakness 
Impaired fast inactivation (Lerche et al., 
1993; Ricker et 
al., 1994; 
Mitrovic et al., 
1995) 
G1306E 22 DIII-DIV SCM – myotonia 
permanens 
Severe permanent myotonia 
Respiratory muscle 
myotonia causing episodic 
hypoxia and acidosis 
without treatment 
No weakness 
Impaired fast inactivation 
Enhanced activation  
  
(Lerche et al., 
1993; Mitrovic 
et al., 1995) 
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G1306E 
Different kindred 
  SCM Exercise, cold and 
potassium exacerbated 
myotonia 
No significant respiratory 
myotonia 
No weakness 
 (Colding-
Jorgensen et al., 
2006) 
G1306V 22 DIII-DIV SCM  Cold exacerbated myotonia 
or chronic myotonia 
(different kindreds) 
No weakness                               
Impaired fast inactivation (Van den Bergh 
P et al., 991; 
McClatchey et 
al., 1992b; 
Mitrovic et al., 
1995) 
G1306V 
Different kindred 
  SCM Exercise exacerbated 
myotonia 
Impaired fast inactivation (Lerche et al., 
1993) 
I1310N 22 DIII-DIV SCM Cold exacerbated myotonia 
Myotonia worse after rest 
Warm-up phenomenon 
No weakness 
Unknown (Fournier et al., 
2006) 
T1313A 22 DIII-IV PMC Cold and exercise induced 
myotonia 
Occasional cold and 
exercise induced paralysis 
Impaired fast inactivation 
 
(Bouhours et 
al., 2004) 
T1313M 22 DIII-IV PMC Cold and exercise 
exacerbated myotonia and 
weakness 
Impaired fast inactivation 
Enhanced recovery from 
inactivation 
(McClatchey et 
al., 1992b; 
Ptacek et al., 
1993; Hayward 
et al., 1996; 
Yang et al., 
1994) 
M1360V 23 DIV/S1 HyperPP Episodic weakness 
especially early morning 
and following rest after 
exercise 
Clinical weakness observed 
following K challenge and 
cooling forearm muscles 
EMG myotonia 
Impaired inactivation 
 
(Wagner et al., 
1997) 
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M1370V 23 DIV/S1 HyperPP Episodic limb weakness 
Muscle stiffness face and 
hands when exercising in 
cold 
Positive K challenge 
EMG myotonia 
Unknown (Okuda et al., 
2001) 
L1433R 24 DIV/S3 PMC Cold and exercise 
exacerbated myotonia 
Paralysis induced by 
exercise when muscles 
cooled 
Impaired fast inactivation 
Enhanced recovery from 
inactivation 
(Ptacek et al., 
1993; Yang et 
al., 1996b; 
Yang et al., 
1994) 
L1436P 24 DI/S3 SCM Cold and exercise 
exacerbated myotonia 
Unknown (Matthews et 
al., 2008b) 
R1448C 24 DIV/S4 PMC Cold exacerbated myotonia 
and paralysis 
Impaired fast inactivation 
Impaired deactivation 
Enhanced recovery from 
inactivation 
(Ptacek et al., 
1992; Yang et 
al., 1994; 
Featherstone et 
al., 1998) 
R1448H 24 DIV/S4 PMC Cold exacerbated myotonia 
and paralysis 
Potassium aggravated 
myotonia following 
potassium challenge 
No potassium aggravated 
weakness 
Impaired fast inactivation 
Enhanced recovery from 
inactivation 
(Ptacek et al., 
1992; Yang et 
al., 1994) 
R1448L 24 DIV/S4 PMC Cold and exercise 
exacerbated myotonia 
Unknown (Matthews et 
al., 2008b) 
R1448P 24 DIV/S4 PMC Cold exacerbated myotonia 
and weakness 
Impaired fast inactivation 
Impaired deactivation 
(Featherstone et 
al., 1998; Wang 
et al., 1995) 
R1448S 24 DIV/S4 PMC Myotonia 
Exercise exacerbated 
weakness 
Impaired fast inactivation 
Impaired deactivation 
(Bendahhou et 
al., 1999b) 
G1456E 24 DIV/S4 PMC Cold and exercise 
exacerbated myotonia 
Cold induced weakness 
Unknown (Sasaki et al., 
1999) 
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F1473S 24 DIV/S4-S5 PMC Cold and exercise 
exacerbated myotonia 
Cold induced weakness 
Impaired fast inactivation (Mitrovic et al., 
1996; 
Fleischhauer et 
al., 1998) 
M1476I 24 DIV/S4-S5 SCM** Variable myotonia, 
majority of cases 
asymptomatic (myotonia on 
EMG) or mild symptoms 
Cold exacerbated and in 
some painful myotonia 
Rare paralytic episodes in 
1/44 patients 
Unknown (Rossignol et 
al., 2007) 
M1476I   SCM Mild to asymptomatic 
myotonia (detected on 
EMG) 
Warm up present 
No weakness clinically and 
no CMAP decrement with 
SET 
Unknown (Dupre et al., 
2009) 
A1481D 24 DIV/S4-S5 SCM Cold aggravated myotonia 
Myotonia profoundly worse 
after anaesthetic 
Occasional exercise 
exacerbated myotonia 
No weakness 
Unknown (Schoser et al., 
2007) 
F1490L_M1493I 24 DIV/S5 HyperPP Episodic muscle weakness 
especially on waking 
Myotonia muscles of hands 
and face 
EMG myotonia 
Enhanced slow 
inactivation 
(Bendahhou et 
al., 2000) 
I1495F 24 DIV/S5 HyperPP Episodic muscle weakness 
following rest after exertion 
Positive K challenge 
Enhanced slow 
inactivation 
(Bendahhou et 
al., 1999a) 
V1589M 24 DIV/S6 SCM Cold and potassium 
aggravated myotonia 
Myotonia also exacerbated 
by anaesthetic 
Enhanced recovery from 
inactivation 
(Heine et al., 
1993; Mitrovic 
et al., 1994) 
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No weakness 
V1589M 
Different kindred 
  PMC Cold and exercise 
exacerbated myotonia 
Subjective cold and 
exercise exacerbated 
weakness  
EMG reduced CMAP after 
repeat exercise but no 
CMAP decrement  with 
muscle cooling 
 (Ferriby et al., 
2006) 
M1592V 24 DIV/S6 HyperPP  Impaired slow 
inactivation 
 
Q1633E 24 C-terminus SCM Cyanotic attacks in infancy 
Myotonia exacerbated by 
cold and potassium 
No paralytic attacks 
Impaired fast inactivation (Kubota et al., 
2009) 
T1700_E1703 del 24 C-terminus PMC Paradoxical myotonia of 
hand muscles 
Significant reduction in 
CMAP with muscle cooling 
Unknown (Michel et al., 
2007) 
E1702 K 24 C-terminus PMC Very brief symptoms,10-
15secs several times a day 
or night 
Unknown (Miller et al., 
2004) 
F1705I 24 C-terminus SCM Cold induced myotonia 
Warm up phenomenon 
described 
No weakness 
Impaired fast inactivation (Wu et al., 
2005) 
The distinction used to classify phenotype as PMC or SCM was myotonia with the presence (PMC) or absence (SCM) of episodic muscle weakness or paralysis. 
Classification was based only on available published data. If episodic paralysis was the predominant/only feature the phenotype was classified as HyperPP. 
* Denotes phenotypes that were originally reported as PMC but that have been classified as SCM using the above criteria. 
** This phenotype was considered overall to be classified as SCM based on the lack of weakness reported in all but 1/44 individuals.  
 Table 5: Summary of clinical features and pathophysiological consequences of reported SCN4A mutations associated with 
PMC, SCM and HyperPP. 
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Hypokalaemic Periodic Paralysis 
Only approximately 10% of cases of hypokalaemic periodic paralysis are due to 
mutations in the SCN4A gene(Sternberg et al., 2001). This less frequent genotype is 
sometimes referred to as HypoPP 2. The majority of cases, estimated at between 60-70%, 
are due to mutations in the CACNA1S gene that codes for the voltage gated skeletal 
muscle calcium channel Cav1.1 (the dihydropyridine receptor). Approximately 20% of 
cases are genetically undefined(Fouad et al., 1997; Miller et al., 2004; Sternberg et al., 
2001). All mutations that have been reported in either gene associated with hypokalaemic 
periodic paralysis have been substitutions of positively charged arginine residues in the 
voltage sensors (S4 segments) of the channels(Ptacek et al., 1994a; Jurkat-Rott et al., 
1994; Bulman et al., 1999; Jurkat-Rott et al., 2000; Bendahhou et al., 2001; Sternberg et 
al., 2001; Davies et al., 2001; Kim et al., 2004; Wang et al., 2005). In total substitutions 
of only 5 arginine residues have been reported in association with hypokalaemic periodic 
paralysis. Substitution of a sixth arginine residue has been reported as causing a 
potassium sensitive normokalaemic periodic paralysis (Fig 11). 
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Fig 11: Voltage sensor mutations of A: Cav1.1 and B: Nav1.4 associated with 
HypoPP. *These mutations are associated with a different phenotype described as 
potassium sensitive normokalaemic periodic paralysis. 
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Mutation Gene Exon Protein 
position 
Reported 
Phenotype 
Major 
Pathomechanism 
Reference 
R528G/H CACNA1S 11 DII/S4 Hypokalaemic 
periodic paralysis 
Slower kinetics of 
activation 
Reduced current 
density 
(Lapie et al., 
1996; Morrill 
et al., 1999) 
R1239G/H CACNA1S 30 DIV/S4 Hypokalaemic 
periodic paralysis 
Slower kinetics of 
activation 
Reduced current 
density 
(Morrill et al., 
1999) 
R669H SCN4A 12 DII/S4 Hypokalaemic 
periodic paralysis 
Enhanced slow 
inactivation 
Enhanced fast 
inactivation 
Reduced current 
density 
(Struyk et al., 
2000; 
Kuzmenkin et 
al., 2002) 
R672G/H SCN4A 12 DII/S4 Hypokalaemic 
periodic paralysis 
Enhanced slow 
inactivation 
(R672G only) 
Enhanced fast 
inactivation 
Reduced current 
density 
(Kuzmenkin et 
al., 2002) 
R675G/Q/W SCN4A 13 DII/S4 Potassium 
sensitive 
normokalaemic 
periodic paralysis 
Unknown (Vicart et al., 
2005) 
R1132Q SCN4A 18 DIII/S4 Hypokalaemic 
periodic paralysis 
Enhanced fast and 
slow inactivation 
(Carle et al., 
2006) 
   
Table 6: Summary of pathophysiological consequences of voltage sensor mutations 
associated with HypoPP 
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The second aim of this thesis is to address whether a carefully phenotyped cohort of 
channelopathy patients can be 100% genotyped by exomic sequencing of known 
disease causing genes. 
 
 
1.7 Pathogenesis of the skeletal muscle channelopathies 
 
The skeletal muscle sodium channelopathies 
The mutations in the SCN4A gene associated with PMC, SCM and HyperPP are scattered 
throughout the gene affecting all domains of the Nav1.4 channel (see Fig 10). The 
functional consequence of all these mutations is to produce a “gain of function” effect of 
channel activity. This is achieved either by enhanced activation or impaired inactivation 
of the sodium channel (see table 5). 
Normally when the sodium channel is activated from its resting state by depolarization, 
the channel opens rapidly, allowing an influx of sodium ions through the sodium 
selective central pore into the cell. This rapid influx of positively charged sodium ions 
depolarises the cell, and produces an action potential that triggers muscle contraction.  
Sodium channels usually inactivate rapidly, stopping the influx of sodium ions, and, in 
conjunction with potassium and chloride channels, promoting a return to resting 
potentials (see Fig 1).   
Normally a single action potential in a neuron leads to a single contraction in its target 
muscle fibre. Myotonia results when a sequential train of action potentials is evoked in 
the muscle in response to a single action potential nerve stimulus. Mutations that cause 
myotonia do so by delaying inactivation of the sodium channel (see Table 5 and Fig 12) 
which results in a hyper-excitable muscle cell. When inactivation is delayed the sodium 
channel is open for longer and the resulting influx of sodium ions consequently persists 
for longer. The persistent inward depolarising sodium current produces a comparable 
increase in the outward repolarising potassium current which leads to a greater 
accumulation of potassium ions in the t-tubules. This accumulation of positive charge 
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makes the sarcolemma susceptible to further spontaneous depolarisations with 
accompanying muscle contraction.  
In contrast to the hyper-excitable sarcolemma associated with myotonia the episodes of 
flaccid muscle paralysis experienced in the sodium skeletal muscle channelopathies 
reflect an unexcitable sarcolemma. This occurs due to incomplete inactivation of the 
sodium channel (see Table 5 and Fig12). Once the sodium channel has opened there is 
large persistent inward sodium current due to the inability of the channel to close. This 
persistent current leads to sustained depolarisation of the sarcolemma and an inability to 
support any further action potentials. 
The key difference between these two situations is that in the unexcitable state, the 
sodium channels fail to shut, preventing the cell from repolarising, while in the hyper 
excitable state the channels do inactivate completely, only more slowly than normal.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 12: Diagrammatic representation of impaired inactivation of Nav1.4 in PMC 
and HyperPP.  
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Hypokalaemic Periodic Paralysis 
Hypokalaemic periodic paralysis is due to dysfunction of two voltage gated skeletal 
muscle ion channels, the sodium channel Nav1.4 and the calcium channel Cav1.1.  These 
channels have similar structures and it has been noted that the only mutations shown to 
cause the hypoPP phenotype are substitutions of arginine residues in the voltage sensors 
of both channels(Cannon., 2006). In contrast to the myotonic phenotypes all of these 
mutations were initially thought to cause a “loss of function” effect on channel gating 
(see Table 6). 
Attacks of paralysis occur in conjunction with reduced serum potassium levels in 
hypoPP. In vitro studies of muscle fibres from individuals affected by hypoPP have been 
shown to paradoxically depolarise when placed in low potassium solution (in contrast to 
muscle fibres from normal controls which hyperpolarise)(Ruff., 1999; Rudel et al., 1984). 
Early functional studies of the voltage sensor mutations demonstrated reduced current 
density and relatively small shifts in the voltage dependence of inactivation(Struyk et al., 
2000; Kuzmenkin et al., 2002) suggesting that a loss of channel function may be 
important. However, this mild loss of function did not explain the paradoxical 
depolarization seen in native muscle and did not explain how the episodes of paralysis in 
lowered extracellular potassium were triggered.  
 
The gating pore in hypokalaemic periodic paralysis 
Recently studies examining the role of the S4 voltage sensors of the sodium channel in 
more detail revealed a potential additional pathomechanism for hypoPP. The S5 and S6 
segments of each of the four domains of the sodium channel fold together to line the 
sodium selective central, or ‘alpha’ pore of the channel. In response to a depolarising 
stimulus the S4 segments undergo a conformational change moving outwards from the 
sarcolemma. This movement is coupled to the opening of the alpha pore that is lined by 
the S5/6 segments (see Fig 6).  
The S4 segment itself however contributes to a second pore known as the omega pore, 
which is formed by its interaction with the surrounding S1, S2 and S3 segments (Fig 13). 
The S4 segments have an abundance of positively charged amino acids, either an arginine 
or a lysine occurring at every third position in the segment. The total number of positive 
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charges varies for each S4 segment. The omega pore is not uniform in diameter and the 
narrowest portion is occupied by different positively charged residues depending on 
whether the membrane is resting (S4 down) or depolarised (S4 up). 
 
 
 
 
 
 
 
Fig 13: The movement of the S4 segment through the omega pore  
 
Under normal conditions the charged residues in the S4 segments form salt bridges with 
other segments which effectively block any free ions from flowing through the omega 
pore. Recent work has shown that neutralisation of either of the two outer arginine 
residues in the DII/S4 segment of SCN4A has led to a loss of integrity of the omega pore 
and allows monovalent cations to “leak” through the omega pore and into the cell when 
the cell is hyperpolarised.  
It is known that the amino acid that is substituted for the arginine residue affects the size 
of this leak. If the arginine is replaced by a histidine, a proton leak through the omega 
pore is favoured. Any other amino acid substitution at this site allows less selectivity and 
a greater variety of monovalent cations can pass including sodium(Sokolov et al., 2007; 
Struyk et al., 2007).  
While the omega pore leak has been hypothesised as an additional pathomechansim in 
hypoPP the precise consequences of this “gain of channel function” on muscle cell 
homeostasis and sarcolemmal excitability are not yet fully understood. It is suggested that 
movement of protons and other ions including sodium via the gating pore may disrupt pH 
homeostasis and lead to intracellular sodium accumulation via activation of several ion 
transporters including the sodium-hydrogen anti-port exchanger (see Fig 14)(Struyk et 
al., 2008b; Jurkat-Rott et al., 2009). However, the cause of the paradoxical membrane 
depolarisation in low potassium solution and the stimulus for the low serum potassium 
Hyperpolarised Depolarised 
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itself that occurs in HypoPP remains less clear although possible mechanisms are 
discussed.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 14: An aberrant current permeable to protons could stimulate the NHE and 
NBC transporters with a resultant increase in intra-cellular sodium ions. 
Stimulation of the monocarboxylate transporter would result in increased lactate 
efflux from the cell which has been proposed as contributory to vacuolar formation 
in HypoPP. 
 
 
A further aim of my thesis was to examine the functional consequences of Nav1.4 
hypoPP mutations in light of the recently described gating pore current. 
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Role of inward rectifying potassium channels in hypokalaemic periodic paralysis 
Muscle fibre resting membrane potential (VREST) is controlled by the membrane  
permeability to K
+
 ions. It has been suggested that inhibition of the outward component 
of the inward rectifying potassium channels could account for the abnormal membrane 
response to low serum potassium and also for the lowered serum potassium itself due to 
intracellular accumulation of potassium(Hofmann et al., 1970; Ruff., 1999). Furthermore, 
barium which blocks inward rectifying potassium channel current(Standen et al., 1978) 
produces reduced twitch force in the skeletal muscles of mammals in vitro in low 
potassium solution.(Gallant., 1983) Reduced ATP dependant potassium channel (a 
subgroup of IRK channel) current has also been identified in vitro from muscle biopsies 
of hypoPP patients.(Tricarico et al., 1999) The aberrant inward depolarizing gating pore 
current has recently been shown to contribute to the probability of the membrane 
paradoxically depolarising in the presence of low potassium solution and also to the 
reduced outward current component of the IRK channels.(Jurkat-Rott et al., 2009; Struyk 
et al., 2008a) However, it is not clear why the potassium conductance should be reduced 
by dysfunction of the voltage sensors of Cav1.1 or Nav1.4. One possible explanation is 
that a proton selective gating pore causes an acidic intracellular environment and IRK 
channels are known to be inhibited at this pH(Struyk et al., 2008a). 
 
 
1.8 Treatment of the skeletal muscle channelopathies 
 
Some patients with the skeletal muscle channelopathies feel their symptoms are not 
restrictive enough to take medication and will manage their illness by avoiding 
precipitating factors as far as possible. When drug therapy is considered a number of 
therapeutic agents exists. 
 
Myotonic disorders: early treatments 
Where treatment is considered numerous membrane stabilising agents have been 
employed in the myotonic disorders. These are currently mainly use dependant blockers 
of sodium channels e.g. anti-convulsants, local anaesthetics or anti-arrhythmics. As these 
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target persistent sodium currents they are ideal to inhibit the abnormal sodium channels 
with impaired inactivation seen in PMC, SCM and hyperPP but have little or no effect on 
the functioning of wild type sodium channels.  
In early studies, procainamide, quinine and glucocorticosteroids were employed. A small 
randomized double blind trial compared the efficacy of each of these treatments in 
relation to placebo in 20 individuals with myotonic disorder (16 myotonic dystrophy, 
4 myotonia congenita). The diagnosis was made on a clinical basis without genetic 
confirmation. The trial lasted 12 weeks and all participants received each of the four 
treatments for a 3 week period with no washout period. An end-point of at least 
a 50% reduction in the duration of hand grip myotonia, measured by EMG and timed 
clinically, was employed. Using this endpoint, 6/20 participants taking quinine, 15/20 
taking procainamide, 15/19 taking prednisone (one patient did not receive prednisone) 
and 0/20 taking placebo showed improvement(Leyburn et al., 1959). This study, although 
imperfect, illustrated a low efficacy of quinine. Despite the suggested benefits of 
procainamide and prednisone the side effect profile of both these drugs restricts their use 
and they are no longer recommended as therapeutic agents in the non-dystrophic 
myotonias.  
The carbonic anhydrase inhibitor acetazolamide is commonly used in the periodic 
paralyses and has been reported to be beneficial in the non-dystrophic myotonias.(Trudell 
et al., 1987; Ferriby et al., 2006) In a small series of nine patients with myotonia, seven 
diagnosed clinically with myotonia congenita and two with paramyotonia congenita, all 
cases reported a subjective and objective (timed measurements of myotonia) 
improvement in myotonia with acetazolamide. However, one individual with 
paramyotonia congenita developed quadriparesis 12 h after the ingestion of 
acetazolamide.(Griggs et al., 1978) Larger studies of acetazolamide use in the non-
dystrophic myotonias have not been performed, and while there is evidence of some 
benefit, it is not generally considered as a first line agent for the treatment of myotonia. 
The anti-convulsant phenytoin has been shown to improve the righting time of myotonic 
mice turned onto their backs.(Aichele et al., 1985) Ricker et al.(Ricker et al., 1978) 
reported subjective improvement in muscle stiffness and an improved timed walk in one 
patient with myotonia congenita and a dose dependant improvement in isometric force in 
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another. The lidocaine derivative tocainide gave encouraging results initially(Rudel et al., 
1980; Streib., 1987) but was eventually withdrawn from the market due to the risk of 
potentially fatal agranulocytosis.(Volosin et al., 1985) Synthesis of tocainide analogues 
has been attempted in vitro and may be of value for future study as anti-myotonic agents 
if the efficacy and side effect profiles are favourable.(Catalano et al., 2008) 
 
 
Myotonic disorders: Class I anti-arrhythmics 
More recently class I anti-arryhthmics have offered potential for treatment. Flecainide, a 
class Ic anti-arrhythmic, has been shown to be effective in vitro(Aoike et al., 2006) 
although its use in clinical practice as an anti-myotonic agent is rarely 
reported.(Rosenfeld et al., 1997) An improvement in clinical symptoms and cold induced 
EMG findings with propafenone, another class Ic anti-arrhythmic has been reported in a 
single case of paramyotonia congenita.(Alfonsi et al., 2007) 
The class Ib anti-arrhythmic mexiletine is generally considered to be the first-line 
treatment of choice by myologists but a randomized controlled trial is required. It is 
usually well tolerated with only minor side effects reported. Importantly it has 
proarrhythmic potential and therefore pre- and post-treatment ECGs are essential to 
ensure satisfactory QT interval. More extensive cardiac evaluation prior to 
commencement is important if there is an abnormal baseline ECG or a history of cardiac 
disease. Single case reports have shown that mexiletine is effective in treating myotonia 
in both sodium and chloride channel disorders.(Ceccarelli et al., 1992; Jackson et al., 
1994) However, a recent Cochrane review highlighted the lack of adequate randomized 
double blind placebo controlled trials to prove efficacy.(Trip et al., 2006)  
The ability to conduct such trials is partly hampered by the difficulty in quantitating 
myotonia(Torres et al., 1983; Hammaren et al., 2005; Logigian et al., 2005; Moxley, III 
et al., 2007; Hogrel., 2009) and in recruiting adequate numbers of patients to achieve 
statistical power. A recent study employed trunk sway analysis to measure the warm up 
phenomenon in recessive myotonia congenita and proposed that with further evaluation 
this may offer an alternative potential end-point for therapeutic trials.(Horlings et al., 
2009) Sodium MRI has also recently been proposed as a possible outcome measure in 
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patients with sodium channel diseases. An increase in intramuscular sodium content was 
demonstrated to accompany muscle weakness following exercise of cooled muscles in 
paramyotonia congenita. In a small group of patients this increase was significantly 
reduced following treatment with mexiletine.(Weber et al., 2006) It is possible this 
technique could be used to monitor response to treatment in both a clinical and research 
setting.  
In vitro studies continue to identify pharmacological agents that preferentially block 
sodium channels in the open state, thereby targeting persistent sodium currents.(Wang et 
al., 2008b; Wang et al., 2008a) These studies may identify future therapies. No safe drugs 
are currently available which specifically act on the ClC-1 channel. A number of 
experimental approaches may have future implications for the treatment of myotonia 
congenita including oligonucleotides to promote exon skipping, trans-splicing and 
restoration of normal protein  trafficking.(Cleland et al., 2008)  
 
 
Hypokalaemic periodic paralysis: potassium supplements and potassium sparing 
diuretics 
In the 1930s it was recognised that lowered potassium levels were associated with attacks 
of paralysis(Biemond et al., 1934) prompting treatment of these episodes with potassium 
supplements and dietary modification to limit carbohydrate intake. It was realised 
however that although often effective in aborting or reducing the duration and severity of 
paralytic attacks, potassium supplementation had no effect on their frequency or on the 
development of a permanent muscle weakness.   
In the late 1950s Conn performed extensive experiments on 2 patients with hypokalaemic 
periodic paralysis and reported that the attacks of paralysis were not only associated with 
hypokalaemia but also hypernatraemia. He proposed that it was even possible the 
hypernatraemia was the primary stimulus for the paralytic attacks with hypokalaemia 
being secondary(Conn et al., 1957). While he did not suggest hyperaldosteronism was the 
cause per se he did identify raised aldosterone levels during attacks in his patients. 
However others did not corroborate these findings(Poskanzer et al., 1961). Conn 
suggested a low sodium diet was beneficial in reducing both paralytic attacks and 
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myopathy. He also proposed carbonic anhydrase inhibitors may be effective due to their 
ability to increase sodium excretion in the urine. In practical terms the restrictive sodium 
diet proposed by Conn was difficult for patients to tolerate and others did not find sodium 
restriction to be as beneficial(Poskanzer et al., 1961).  
Based on his research however spironolactone, a known inhibitor of aldosterone, was 
trialled as therapy for hypokalaemic periodic paralysis. In the initial patient studied, 
subjective and objective observations of not only reduced paralytic attacks but also 
improved inter-attack muscle strength were noted. This treatment with spironolactone did 
produce a slight increase in sodium excretion with normal potassium serum levels being 
maintained  but the authors argued the effects on sodium and potassium balance were too 
minimal to adequately explain the full mechanism of action of spironolactone in 
producing such significant symptom reduction in hypokalaemic periodic 
paralysis(Poskanzer et al., 1961). Spironolactone and other potassium sparing diuretics 
are still used today as therapy for hypoPP although often not as first line agents(Kim et 
al., 2001; Bendahhou et al., 2001; Kim et al., 2005; Kim et al., 2007). Gynaecomastia 
can limit the tolerability of spironolactone for male patients.  
 
 
Carbonic anhydrase inhibitors  
Acetazolamide was first used in 1962 to lower the elevated potassium levels associated 
with paralytic attacks in hyperkalaemic periodic paralysis(McArdle., 1962). A few years 
later, despite seeming paradoxical in terms of potassium balance, it was also noted to be 
an effective prophylactic agent in hypokalaemic periodic paralysis(Resnick et al., 1968). 
An observational study further suggested acetazolamide may improve inter-attack muscle 
strength in some patients(Griggs et al., 1970). Although no randomised controlled trials 
have been performed using acetazolamide a plethora of case reports and series support its 
beneficial effects (see Table 13 in Results). Another carbonic anhydrase inhibitor, 
dichlorphenamide is the only therapy for hypoPP to have undergone a randomised double 
blind placebo controlled cross over trial. The results of this trial showed a significant 
efficacy of dichlorphenamide in reducing attack frequency although the inclusion criteria 
were based on clinical diagnosis of hypoPP and not genetic confirmation(Tawil et al., 
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2000; Sansone et al., 2008). Others have reported a benefit of dichlorphenamide on inter-
attack weakness(Dalakas et al., 1983). There are no trials comparing the use of 
dichlorphenamide to acetazolamide in periodic paralysis. 
Acetazolamide rapidly became the treatment of choice for hypokalaemic periodic 
paralysis, and almost half a century later remains the frontline treatment. However with 
genetic advances and the discovery of two causative genes it was noted that some patients 
did not respond to acetazolamide treatment or indeed found it to be 
detrimental(Bendahhou et al., 2001; Sternberg et al., 2001). It was initially suggested that 
it was only the minority of patients with hypoPP 2 due to mutations in SCN4A who 
reacted adversely to acetazolamide therapy but other reports of hypoPP 2 patients who 
benefited from acetazolamide refuted this(Bulman et al., 1999; Kim et al., 2004; Venance 
et al., 2004). Despite its popularity as a therapeutic agent for hypokalaemic periodic 
paralysis the disease specific mechanism of action of acetazolamide is not understood.  
Importantly despite some suggestive case reports it is not established in either the 
myotonic disorders or hypokalaemic periodic paralysis if currently available treatments 
have any influence on the development of permanent myopathy. 
 
In my thesis I attempt to quantify the efficacy of acetazolamide in hypokalaemic 
periodic paralysis and whether genotype has any influence on treatment response. 
 
 
1.9 Mechanisms of action of acetazolamide   
 
Carbonic anhydrase inhibition 
Carbonic anhydrase is an enzyme that catalyses the reversible reaction converting carbon 
dioxide and water into protons and bicarbonate. 
 
 
 
Acetazolamide is a sulphonamide that inhibits carbonic anhydrase (CA) and it is 
generally considered that its main therapeutic mechanism of action in hypoPP is 
CO2 + H20               H2CO3                H
+
 + HCO3 
 44 
somehow linked to this capacity. Inhibition of CA in the renal tubules by acetazolamide 
leads to increased urinary loss of bicarbonate, sodium and some potassium with a 
resultant metabolic acidosis (Fig 15). It remains unclear how this alteration of pH could 
reduce paralytic attacks or prevent the development of myopathy. One study did examine 
the effect of pH on the R669H SCN4A mutation and pH on the R672H/G SCN4A 
mutations expressed in a HEK cell system. The deleterious effects of the histidine 
substitutions could be ameliorated by a more acidic pH whereas the glycine substitution 
was insensitive to alterations in pH. The authors proposed this may predict that those 
hypoPP patients with a glycine substitution would not benefit from acetazolamide 
(Kuzmenkin et al., 2002).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 15: Acetazolamide(ACZ) inhibits the carbonic anhydrase(CA) present in the 
tubular lumen preventing the conversion of H2CO3 to CO2 and H2O. H2CO3 
dissociates to H
+
 and HCO3. Bicarbonate is lost in the tubular lumen producing a 
metabolic acidosis. Within the proximal tubular cell itself ACZ blocks the CA 
preventing the conversion of CO2 and H20 to H
+
 and HCO3. The reduction in 
protons reduces the re-absorption of sodium ions which are excreted in the urine.  
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Carbonic anhydrase isoenzymes  
At least 14 isoenzymes of CA exist in humans. Different isoenzymes are preferentially 
expressed in the cytosol, cell membranes or mitochondria of different tissues. Each 
isoform demonstrates a different degree of catalytic activity and affinity for 
sulfonamides.(Clare et al., 2006; Supuran et al., 2000)
 
The subcellular localisation of several isoforms has been studied in animal models and 
shown to be present at variable levels in the sarcolemma and sarcoplasmic reticulum of 
skeletal muscle(Wetzel et al., 1998; Wetzel et al., 2007; Scheibe et al., 2008). The 
presence of different isoforms of CA in skeletal muscle raises questions about how the 
contribution of each isoform may influence CA treatment response and how this might be 
influenced by the proposed proton permeable gating pore. Intracellular isoforms of CA 
can only be reached by the lipophilic membrane permeable sulphonamides. Hydrophilic 
sulphonamides such as acetazolamide or the alternative carbonic anhydrase inhibitor 
dichlorphenamide, which is also used in hypoPP, cannot easily cross the sarcolemma and 
would not be expected to have any significant direct effect on the intracellular isoforms. 
This suggests any benefit derived from acetazolamide relies on inhibition of extracellular 
carbonic anhydrase or carbonic anhydrase on the extracellular surface of the membrane.  
 
Acetazolamide and activation of sarcolemmal calcium activated potassium channels 
[KCa2+] 
Tricarico et al used the potassium depleted rat as an animal model of hypoPP to explore 
the hypothesis that the mechanism of action of acetazolamide and other carbonic 
anhydrase inhibitors was not exclusively related to their inhibition of CA(Tricarico et al., 
2004). A dose dependant increase of calcium activated potassium channel [KCa
2+
] 
activity and restoration of the serum potassium levels to within the normal range was 
observed in the muscle fibres of potassium depleted rats in whom treatment with 
acetazolamide prevented insulin induced attacks of paralysis(Tricarico et al., 2000; 
Tricarico et al., 2004). The ability of acetazolamide to enhance the sarcolemmal 
conductance of potassium seems particularly relevant when considered in light of the 
studies discussed that implicate inhibition of IRK channel conductance in the 
pathomechanism of hypoPP. 
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Effects of acetazolamide on inter-attack weakness 
The reported clinical benefit of acetazolamide in preventing or improving inter-attack 
weakness has also been explored using the K depleted rat model. Vacuoles are a common 
morphological finding in primary and secondary hypokalaemic periodic paralysis. They 
are considered to represent localised swelling and vacuolation of the t-tubules secondary 
to increased osmolarity caused by the local accumulation of ions or metabolites 
(including lactate). The rat model demonstrated a vacuolar myopathy and an increased 
efflux of lactate from muscle fibres in vitro. Muscle biopsies from rats treated with 
acetazolamide demonstrated significantly reduced vacuoles and lactate efflux(Tricarico et 
al., 2008).  
These observations are particularly interesting when considered in light of the proposed 
proton leak described in hypoPP. Accumulation of intracellular protons could produce an 
increased efflux of lactate by stimulating the proton linked monocarboxylate transporter 
(Fig 14). Potentially this pathway may partly explain the reports of acetazolamide 
ameliorating inter-attack muscle weakness. 
 
1.10 Mechanisms of muscle degeneration in the skeletal muscle channelopathies 
 
Patients with periodic paralysis have been frequently reported to exhibit vacuoles and/or 
tubular aggregates on muscle biopsy(Venance et al., 2006) and as discussed there is some 
evidence suggesting lactate efflux may contribute to this. However, the myopathological 
findings  in NDMs are not defined well and often reported to be non-specific(Miller et 
al., 2004). Furthermore, with the characteristic clinical history and examination findings 
coupled with the recent advances in electrophysiological techniques a diagnosis of NDM 
is usually apparent and it is now rare that a muscle biopsy will be performed in such 
patients other than as a research procedure. 
It is clear muscle damage can occur in the NDMs but its pathomechansim and frequency 
are unknown. It has been postulated that the abnormally prolonged intramuscular influx 
of sodium that is known to occur via the mutant sodium channels may be responsible for 
muscle degeneration(Bradley et al., 1990) but the specifics of such a mechanism have not 
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been shown.  However, it is of note that there is evidence for increased intracellular 
sodium contributing to cell necrosis in the mouse model of Duchenne muscular 
dystrophy(Hirn et al., 2008).  One recent study has employed ultrasound to assess 
permanent muscle changes in the NDMs. Using ultrasound measurements of eight 
muscles, (four upper limb and four lower limb) in a group of 63 genetically confirmed 
NDM patients an increase in the mean echo intensity compared with controls from all 
muscles examined except the rectus femoris was observed. The ultrasound changes were 
considered to indicate structural muscle damage such as fatty infiltration or fibrosis. This 
change was most marked in the forearm flexors where the increased echogenicity 
correlated negatively with muscle power. There was no positive correlation between echo 
intensity and age for individual muscles except the rectus femoris although the sum of the 
scores did show a significant positive correlation(Trip et al., 2009b). 
Recently, a mouse model of hyperkalaemic periodic paralysis has been engineered by 
introducing the murine equivalent of the SCN4A mis-sense mutation M1592V(Hayward 
et al., 2008). This mutation causes both myotonia and paralysis in humans(Rojas et al., 
1991; Kelly et al., 1997) and was demonstrated to produce these same symptoms in the 
mouse verifying its use as a model of the human disease. At a few months of age the mice 
heterozygous for this mutation already displayed subtle myopathic changes. In those that 
were homozygous significant muscle abnormalities were seen including an increase in 
fibre size variability, frequent internal nuclei and large scattered vacuoles.  These early 
changes were present at a few months of age before any spontaneous episodes of 
paralysis had been observed.  Furthermore, they were shown to increase with age in the 
heterozygotes while muscle force generation declined(Hayward et al., 2008). This 
supports the clinical observations that myopathy increases with age in humans(Links et 
al., 1990; Plassart et al., 1994) and may be independent of paralytic attacks in the 
periodic paralyses(Buruma et al., 1978; Links et al., 1990). 
Although this animal model is of a hyperkalaemic periodic paralysis genotype the same 
symptoms of myotonia and muscle weakness occur in the allelic disorders PMC and 
SCM. The pathomechanism is also a gain of function of the sodium channel in both. It is 
likely that future insights into muscle degeneration gained from the study of this model 
will also have implications for our understanding of PMC and SCM. The possibility that 
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myopathy develops independently of symptom frequency or severity may influence 
future approaches to therapy which is currently aimed at relieving symptoms. As such, 
many patients with minimal or manageable symptoms decline pharmacological treatment. 
 
 
1.11 Morbidity in the skeletal muscle channelopathies 
 
Very little is known about the impact of the muscle channelopathies on quality of life and 
these disorders have often been regarded as benign. A single study has recently examined 
this in a group of 62 genetically confirmed NDM patients and found painful myotonia 
and fatigue to be the best predictors of poor general health perception and physical 
functioning(Trip et al., 2009a). In this study painful myotonia was reported in 28% of 
those with myotonia congenita and 57% with sodium channelopathy. In addition, there 
are numerous case reports where pain which is often severe, is described in the 
NDMs(Vicart et al., 2004; Rosenfeld et al., 1997; Ptacek et al., 1994b; Colding-
Jorgensen et al., 2006; Fialho et al., 2007; Walsh et al., 2007; Wang et al., 2008c). This 
suggests that pain is a frequent symptom that may have been previously under-recognised 
and possibly undertreated in the NDMs.  
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1.12 Summary of Aims 
 
The specific aims of this thesis were: 
 
1. To examine the phenotype of the skeletal muscle channelopathies in patients referred 
to the NCG service for channelopathies at the NHNN to determine 
a. if there were any clinically useful phenotype-genotype correlations that 
could be made and  
b.  if there were more extensive aspects to the phenotypes than is currently 
recognised. 
 
2. To genetically characterize patients to assess if new mutations in known genes existed 
and if these genes could account for 100% of a carefully phenotyped cohort or if new 
genes may be implicated. 
 
3. To ascertain the efficacy of acetazolamide therapy in hypokalaemic periodic paralysis 
and if genotype has any influence on treatment response. 
 
4. To functionally characterize mutations in hypokalaemic periodic paralysis in light of 
the recently described gating pore seen in some of the Nav1.4 mutations. 
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Methods 
 
2.0 Examining the phenotype of the skeletal muscle channelopathies 
 
Information on the phenotype of patients with skeletal muscle channelopathies was 
examined from several sources. Where possible, patients were seen and examined 
personally through the specialist neuromuscular clinic at the MRC Centre for 
Neuromuscular Diseases (under the government funded NCG scheme for rare diseases) 
when they attended for clinical care or when they participated in a natural history trial of 
non-dystrophic myotonias. The natural history trial was a collaborative effort between the 
MRC Centre for Neuromuscular Diseases and five other American and Canadian centres. 
All participants consented to the study which had ethical approval from local ethics 
committee and included DNA analysis to allow correlation of genotype with any 
emergent phenotypic features. Data collected included history of illness and symptoms, 
relevant past medical history, family history and drug therapy. Patients were examined 
for the presence of myotonia, and muscle strength was recorded by Elizabeth Dewar 
(senior physiotherapist) using standardised tests. All patients seen at the centre also 
underwent electrophysiological testing with Dr Veronica Tan including standard NCS, 
EMG and specialised short and long exercise tests. All patients enrolled in the natural 
history trial also completed quality of life questionnaires. 
The majority of patients were personally examined by me, e.g. all of the participants in 
the natural history trial, the English adults detailed in the neonatal phenotypes and all 
others who attended the clinic who have been described in this thesis. When it was not 
possible to personally examine individuals (e.g. the family in Australia, the individuals 
with inflammatory biopsies) information was obtained from a clinical and genetic 
database of all those referred to the diagnostic NCG service. In selected cases the 
referring clinician was contacted to request supplemental information and in some cases, 
a muscle biopsy and DNA samples. Muscle biopsies were reviewed with Dr Janice 
Holton (consultant pathologist). DNA samples were analysed as detailed in the following 
sections. Data gathered on patients seen during the thesis was added to the clinical and 
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genetic database held at the MRC Centre for Neuromuscular Diseases. A record was kept 
of all unusual phenotypes and endeavours made to obtain complete details as above. 
 
2.1 Gene Sequencing 
 
Direct automated sequencing of all 24 exons of SCN4A, 44 exons of CACNA1S and one 
exon of KCNJ2 was carried out for all patients with available DNA and no pre-existing 
genetic diagnosis. Selected samples were additionally analysed for the presence of the 
quadruplet nucleotide repeat expansion in intron 1 of the ZNF9 gene associated with 
myotonic dystrophy type 2 (DM2). A small number of samples had direct automated 
sequencing performed of all exons of CLCN 1 associated with myotonia congenita and 
the RYR 1 gene. These two genes were analysed by the diagnostic labs at the NHNN and 
GOSH.  
 
Primer Design 
KCNJ2 primers had been previously designed and optimised by the diagnostic genetic 
laboratory at the NHNN. Aliquots of these primers were kindly given to me by the lab. 
Primers for SCN4A and CACNA1S were designed and PCR conditions optimised as 
follows.  
Gene sequences were identified using the Ensemble database: 
http://www.ensembl.org/index.html. Using these sequences forward and reverse primers 
were designed for each exon using the Primer 3 web-based programme: 
http://frodo.wi.mit.edu/primer3/. Optimal primers were designed to begin within 
approximately 100 base pairs from the beginning or end of each exon and to produce a 
fragment size of approximately 450 base pairs. Primers were then blasted against the 
human genome to ensure specificity using another website: http://genome.ucsc.edu/cgi-
bin/hgPcr?org=Human&db=hg18&hgsid=90948004. Any non-specific primers were 
redesigned. Finally all primers were analysed for the presence of single nucleotide 
polymorphisms (SNPs) using:http://ngrl.man.ac.uk/SNPCheck/SNPCheck.html. Any 
primers containing SNPs were also re-designed. Once optimised, primers were tagged 
with M13 universal primer sequences before ordering from SIGMA. 
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Exon Forward Primer Reverse Primer 
M13 TGTAAAACGACGGCCAGT CAGGAAACAGCTATGACC 
Ex1 GCACATCTCCCAGTCCTGAT TGGATGGCAGACAGACAGAG 
Ex2_3 CTCTGTCTGTCTGCCATCCA CCACACAGAGGTGCAAACAC 
Ex4 GCCACCTGAGTGGCATATTT GGGCTGCCTCATGTGATTAT 
Ex5 AGGAGCTTTGGGGGTGTCT ATCTGCCCTCTGGTCACG 
Ex6 CAAGCCTTGAAGATGGAGTAGG GAGGCTACCCTAGGGACTGG 
EX7_8 GTGTCCATGTGGGTGACTTG CCAGCTGGAAGAGGTTCTCC 
Ex9 ATGTATGGAAAGGGGCACTG ACCCTGGGTCCTCTATCTCC 
Ex10 CTTTGGTCCCTACCCTGTCA TCCTCCTGAATCCAGTCCAG 
Ex11 GCTTGGAAGGTGGAACAAAA CATACAGCCAGACAGCTCCA 
Ex12 CTCTGTGACAGGGCCTCATG TCCTCACCCCACCCCCATCC 
Ex13 CTGCCTTGGGTGGTGGTC TTGGGGAGATAGAAAACAGTCA 
Ex14a TGCCCAACATGTGGTAGTTT GCGGCTCCTTCTTCTCATC 
Ex14b CCCAAGGACATCATGCTCA GCTCCAGGTCACAGGAGAAT 
Ex15 AGGGCTGGATGAATGAATGA GCTCCAAGCTAGGTCTGCAC 
Ex16 TGTTGGATCCAGCTGTGAAG CCCTTCCTGTGTGTGGAGAC 
Ex17 ATGGCAATTTGCTGTTGTTG TGACAGCCTCTGGATGTAGC 
Ex18 GTGCCAGGCTCCTACAGGT CTCTGGTGGTGGTTGGAGTA 
Ex19 AGGAAGCCCTCCCTAATTGA AGTGACACTGGGGTTGGGTA 
Ex20 GTTGTACCCAACCCCAGTGT CTGAGGGCAGGACCCATC 
Ex21 CGTTCTGTCCCCGAGACTT GGGTTTGTGCAATGGAGAGT 
Ex22 GCTGCCTTAAAGGTGAGGT GGGTGGAAGGCAGGAAAC 
Ex23 CTGCCTGTCCATGTCCTGT GTCTTCCCGAGTGCCTCA 
Ex24a CTCTGAGACTTGAGCAGAGCAC TCTCGAACAGGCAGATGATG 
Ex24b TTGCCTACGTCAAGAAGGAGTC AAGTCTGAGAGGCGGCTGTA 
Ex24c TCTCCTTCCTCATCGTGGTC ACCTCCTCGTGCTTCCTCTT 
Ex24d AAGCAGACCATGGAGGAGAA AGGCACAGTCCCAGATTCAA 
Table 7: SCN4A Primer sequences 
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Exon Forward Primer Reverse Primer 
M13 TGTAAAACGACGGCCAGT CAGGAAACAGCTATGACC 
1 GGCTGGGTGGAATGACAG TGTGATCACCCCGAATCC 
2 GGCATCAGAGTCACAGTCCA GACCAATGAGTGCGTGCTTA 
3 TTCCATCAGCAAGTGCAAAC TGATCCACTCTCCACCAACA 
4 TATTTGCCGTCTCTCCCCTA TAGGAAGGGGACCCAGAACT 
5 AGTTCTGGGTCCCCTTCCTA CCAGGAGAAACCCATTCTCA 
6 TTCACTGTCACCGTCTGCTC GTGGTCACGCAAGTCAGAGA 
7 CAGGGTTGGGTGGAGTCTTA AATTGAAGGGCTCCTGTGTG 
8 GGTGAGCAGGAAGTGAGAGG ACCATTTTGAGCCATTTTGC 
9 TGGGCTCTTTAGCTCTTGGA GTCCCTCAGAGCAGGAACTG 
10 GCCTGGAGTTTGTCTGAAGG GGGTATGTTGCTTTGCCACT 
11 GGGAGTCAGGAGAAGGGAAG AACCTGCACAGATCCCAGAC 
12 CCCTCCCTCTGTGTCACATC CCCACCTTGATCTTGAAGGA 
13 AGTAACAGGCGTGAGCCACT GGGCCTGGCTACCTAGAAAC 
14 TGAGGGCCTTCCACTATGTC CCAGAAGGCCAACTTGTCTC 
15 GCCCTCTCACCACAGAGAAG AGGAGTCCCTGGAGATGGAT 
16 CCAAGCAGTGGGTATGTGAA ATGGAGGGGTACAGGTAGGG 
17 CAACATGCAGCCACAAAGTT AGATGAGAGCCGCATCAATC 
18 GGAGCAGGAGGTGTATTCCA CAGCATAAAGCAGGCAGTCA 
19 CTTCACCCTCTCTGCCACTC TGCCAGTCTCCACCTCTTTT 
20 TGTTCTCCAAGCTCCTCCAT CTGTGGGTGGCTAGAAGCTC 
21 GGAAGGTGGGAGTGTTTTCA AGACTTGCTGCCTCCTGATG 
22 AGGAATGGGAGGGGTTACAG GGCTCCTTGTGCTTGAGAGT 
23 GAGCTGTGGGAATGAACGAT AGCCTAAAGGCTGAGCTTCC 
24 AGGAGGGACACTCACAGAGG AGGAGGGACACTCACAGAGG 
25 CTTCCCAGCCTGACTCTCTG CACCCTTAGGCCTCTCTTCC 
26 TTCACAGTCCTCAGCCACAG TCCATGTAGCACCTCAGCAC 
27 CCCCTCCCCTTCTGTGTTAT GAGCAAGTTGGGAGCAGAAG 
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28 AAGAGCAAAGGGGAGAGGAG AGTTACCTCTCTGCCCAGCA 
29 CCCACAGAGCTTCAGTCCTC AAGCCGCTATATCCATGCAC 
30 AGTTCCTCCATGCCACAAAC GAGCGCCAGTCAGTGTCTTA 
31 GACCCTGGAAACTGCACGTA ATCTGACACTCCAGCCATCC 
32 CCCCCACACATTGACTTACC CAGGTCACACACCCATGAAG 
33 AGGCAGGAGCAGATAGGTGA TGGCAGCCTCTCTGGAGTAT 
34 GTGTGATGTGGGTGGTTCAG AAATGAAGGGGGAAGGAGAA 
35 TCCCATATCTGAGGGAATGC CCATCAGGTCCTCACCAGTT 
36 TCAGCAATGTCACCCAACTC TGGGGTCCTCCCTCTACTTC 
37 GCCTGTGGGGAGAAAGTACA CTGGTCCGTTCTCAGATTCC 
38 CGGACCAGATCCTCCATAAA CTTCTGGGCTTCCTTTTTCC 
39 TCTCCTGGGCTGGAGAGATA TGGTAGGGAAATGTGGGAAA 
40 CCATCCTCCTTTGGCCTTAT GCTGACATTGTCCTCCCAGT 
41 TGAGGGAAAAGGATGTTTGG TTAGCATGAATGGGCTTTCC 
42 AAGCGAGCCTCTGTTGACTC CCACCAATGAGCAAAATTCC 
43 CCTGGCCTGATACTTGGAGT CTGTTGGCCCTACCCTCTCT 
44 AGAGGGTAGGGCCAACAGAG TTTTGAGGTGGTTCCTGACC 
 
Table 8: CACNA1S Primer Sequences 
 
 
PCR Reagents and Reactions 
PCR reactions to amplify each exon of SCN4A and CACNA1S were performed using a 
number of different reagents and conditions but the optimal methods most commonly 
used were: 
 
1. A 25μL reaction contained 200ng genomic DNA, 12.5μL of Amplitaq 360 MasterMix 
(Applied Biosysytems), 10pmol of each primer (forward and reverse) and 9.5μL of 
ddnH20.  
2. A 25μL reaction contained 200ng genomic DNA, 5μL of 10 x PCR buffer without 
MgCl2 (Applied Biosystems), 4μL of 25mM MgCl2, 5μL of 2mM dNTPs, 15pmol of 
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each primer (forward and reverse), and 2.5 units of AmpliTaq Gold polymerase (Applied 
Biosystems).  
For each method all constituents except the DNA were pipetted into a 1.5ml eppendorf 
and vortexed for 5 secs. 24μL were then pipetted into each well of a 96 well PCR plate. 
1μL of DNA was added to each well at this stage. A control well substituting sterilized 
H20 for DNA was included for each exon (i.e. each set of primers).  The 96 well plate 
was sealed with a transparent self-adhesive seal and centrifuged for 1min at low speed to 
collect samples at the bottom of the wells. 
9700 PCR machines were used. Variable PCR cycling conditions were also trialed but the 
optimum conditions consisted of an initial denaturing step of 95°C for 10 minutes 
followed by 30 cycles of 95°C for 30 seconds, 55°C(for CACNA1S primers)/60°C(for 
SCN4A primers) for 30 seconds, 72°C for 30 seconds, and a final extension step of 72°C 
for 7 minutes.  
 
Agarose Gels 
PCR products were run on 2% agarose gels. Gels were made using 2g of agarose powder 
per 100ml of 1 x TBE (Tris Borate EDTA) which was microwaved on full power for 2-3 
mins to dissolve. Ethidium bromide (5μL) was added to the gel. The gel was stood to  
cool for a further 3-5 mins before being poured into a tray with gel combs and end plates 
and allowed to set for 1 hour. 5μL of PCR product from each well of the 9700 PCR plate 
was mixed with 3μL of orange G (as a loading dye) and transferred to the gel chambers. 
A DNA size marker was placed in the first well of each row of samples. Additional 1 x 
TBE was poured over the gel as a buffer and the lid placed on the tray. Electrodes were 
connected to the power supply and 65Volts run through the tray. Gels were left to run for 
45mins or until the loading dye had run ¾ of the length of the tray.  The gel was then 
carefully removed from the tray and placed under UV light in a light box to identify the 
presence of DNA fragments of expected size (using the DNA size marker for 
comparison) bound to ethidium bromide and hence success or failure of the PCR 
reaction.   
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PCR Clean Up 
If the PCR was successful the remainder of the PCR product was cleaned to remove all 
constituents except the DNA fragments. The PCR plate was first centrifuged for 1min to 
collect samples at the bottoms of wells. 30μL of sterilized water was added to each well 
and the plate was resealed and re-spun on the centrifuge for a further 1min. The diluted 
product was then transferred to a 96 well PCR clean up plate and placed on a vacuum for 
5-10mins or until dry. The dry DNA was re-constituted with 40μL of sterilized water and 
placed on a rotator for 30mins before being transferred to a clean 96 well PCR plate. 
 
Sequencing Reagents and Reactions 
Samples were sequenced (bidirectionally) using the ABI Big Dye Terminator Sequencing 
Kit version 1.1, M13 universal primers, and an ABI Model 3730xl Automated DNA 
Sequencer.  
Each 10μL sequencing reaction contained the following reagents: 1μL of Big Dye, 2μL 
of 5 x sequencing buffer, 10pmol of M13 universal primer (forward or reverse), 3.5μL of 
the clean PCR product and 2.5μL of sterilized ddnH20. All constituents with the 
exception of PCR product were pipetted into a 1.5ml eppendorf in volumes adequate for 
100 reactions and vortexed for 5secs. 6.5μL was then pipetted into each well of a 96 well 
9800 PCR plate and 3.5μL of PCR product added to the sequencing reagents. The plate 
was sealed and centrifuged for 1 min to collect samples at the bottom of the wells. 
A 9800 PCR machine was used and the following cycling conditions: an initial step of 
96°C for one minute, followed by 25 cycles of 96°C for 10secs, 50°C for 5secs, 60°C for 
1min 15secs, and then held at 4°C.  
After sequencing the samples were cleaned in order to remove all reagents. The clean up 
plates were centrifuged for 3mins at 2150rpm and the flow though discarded. The 
samples were centrifuged for 1 min at low speed to ensure they collected in the bottom of 
the wells. 10μL of sterilized ddnH20 was added to each well, the plate resealed and 
centrifuged for a further 1 min. All samples were then transferred to the clean up plate 
which was placed on top of a clean PCR plate. Plates were spun together for 3 mins at 
2150rpm so that the cleaned sequencing product was filtered into the clean PCR plate.  
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The samples were sequenced bidirectionally using an ABI Model 3730xl automated DNA 
sequencer. All primers were initially tested and all conditions optimized on control DNA 
samples that were known to be of good quality before proceeding to research samples. 
 
2.2 Analysis of genetic data 
 
Data was analyzed using the version 2.5 SeqScape Analysis software (ABI). A reference 
data group and project template was created for each gene using the seqscape manager 
software. The reference data group is the sequence against which the analysis programme 
compares the sample sequence. In essence this involves importing and accurately 
numbering the coding sequence flanked by a small portion of intron for each exon.  
If a sequence variant was identified that predicted an amino acid change it was compared 
to the reference gene sequence in Ensemble for any known single nucleotide 
polymorphisms. A second database, dbSNP: http://www.ncbi.nlm.nih.gov/projects/SNP/, 
was additionally searched. If neither database identified the sequence variant as a 
polymorphism it was entered into a SIFT (sorting intolerant from tolerant) prediction 
programme:  http://sift.jcvi.org/www/SIFT_BLink_submit.html to prioritise which 
changes were most likely to be deleterious and therefore of a pathological nature. A more 
laborious but similar approach was employed by also checking isoform sequences of 
other animal species to determine the conservation of the amino acid change. If these 
combined efforts indicated the change was likely to be pathological control samples were 
analysed (minimum of 166 chromosomes) for the presence of the amino acid substitution. 
 
 
2.3 ZNF9 anlaysis 
 
One of the aims of this work was to assess whether known disease genes accounted for 
all cases examined with EMG proven myotonia. A minority of samples were identified in 
whom testing of the CLCN1 gene (performed by the diagnostic lab) and SCN4A revealed 
no pathogenic changes. These samples were analysed for the presence of the quadruplet 
nucleotide repeat expansion in intron 1 of the ZNF9 gene associated with myotonic 
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dystrophy type 2 (DM2). These primers and methods had been optimized by my 
predecessor Dr Doreen Fialho. 
A 2-step fluorescent PCR based method was used. In the initial step primers flanking the 
repeat sequence (ZNF9F and ZNF9R) were used for amplification. Samples which 
showed only one allele size (apparent homozygous) were amplified in the second step 
using a quadruplet primed PCR. 
 
PCR step 1 (ZNF9 PCR with primers flanking the repeat sequence): 
A 25µl PCR mixture contained: 10x Amplitaq Gold Buffer (2.5µl), MgCl2 (1.5µl), 10x 
dNTPs (2.5µl), 10 pmol/µl forward/reverse primer (0.5 µl each), Amplitaq Gold 
Polymerase (0.15µl), ddnH2O (16.85µl), DNA (1µl). The PCR conditions were: 95
◦
C 10 
min (94
◦
C 45 sec, 57
◦
C 45 sec, 72
◦
C 1 min) x 30 cycles, 72
◦
C 10 min.  
 
Primer sequences for step 1: 
ZNF9F: 5’- 6 – FAM – GCCTAGGGGACAAAGTGAGA - 3’ 
ZNF9R: 5’- GGCCTTATAACCATGCAAATG - 3’ 
 
PCR step 2 (ZNF9 quadruplet primed PCR): 
A 20µl PCR mixture contained: 10x FastStart Taq Buffer (2µl), MgCl2 (1.2µl), 10x 
dNTPs (1µl), primer mix (1µl), 5U/µl FastStart Taq DNA polymerase (0.2µl) (Roche), 
5M Betaine (8µl), np H2O (5.6µl), DNA (1µl). The primer mix contained 5 µM ZNF9F + 
5µM ZNF9_Tail_R + 0.5 µM ZNF9_Tail_CCTG_R. 
 
Primer sequences for step 2: 
ZNF9F as above 
ZNF9_Tail_R: 5’- TACGCATCCCAGTTTGAGACG - 3’ 
ZNF9_Tail_CCTG_R: 5’ – 
TACGCATCCCAGTTTGAGACGCCTGCCTGCCTGCCTG - 3’ 
 
An aliquot of the PCR product (2-3µl) from PCR step 1 and subsequently step 2 was 
added to 12µl HiDi Formamide and 0.2 µl LIZ500 size standard (ABI) and heated to 95
◦
C 
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for 5 min and then immediately transferred onto ice for a minimum of 5 min.  The resulting 
denatured single stranded DNA was processed with an automated DNA analyser 3730 
(ABI). 
 
 
2.4 Mutagenesis experiments 
 
The human SCN4A clone was supplied within a pCDH vector as a gift from H Lerche. 
Site directed mutagenesis was performed using the Quick Change II Site Directed 
Mutagenesis Kit (Stratagene) to create a construct with the R675G mutation.  
 
Design of primers for mutagenesis of the SCN4A clone 
The reference SCN4A sequence was provided with the clone. The relevant segment was 
highlighted and then altered to introduce the nucleotide change that would produce the 
desired mutation. This mutant sequence was used to design the primers such that the 
desired mutation was in the middle of the primer with 10-15 base pairs of normal 
sequence either side. 
 
R675G 
 
          F     R      L      L     G      V      F     K 
CTCCTTCCGTCTGCTGGGAGTCTTCAAGC      Forward primer 
GCTTGAAGACTCCCAGCAGACGGAAGGAG   Reverse primer 
 
Primers were reconstituted to a concentration of 10pmol per μL. The mutagenesis 
reaction required 125ng of each primer. This was calculated using the formula: 
 
125ng of oligonucleotide    
X1000 = 1.3microL 
330 x 29(no of base pairs in primer) 
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Synthesis of mutant DNA 
The mutagenesis PCR reaction was prepared with the following reagents to a total 
volume of 50μL: 5μL of 10x buffer, 1μL (11.78ng) of DNA, 1.3μL of forward primer, 
1.3μL of reverse primer, 1μL of DNTPs, 3μL of Quick solution and 37.4μL of ddnH2O. 
Once the constituents were mixed, 1μL of PfuUltra HF DNA polymerase (2.5U/μL) was 
added. Cycling conditions were as follows: 95°C for 1min, followed by 18 cycles of 95°C 
for 50secs. 60°C for 50secs and 68°C for 7mins(1min/kb of plasmid) with a final 
extension step of 68°C for 7mins. 
 
Dpn I digestion of the amplification product 
1μl of the Dpn I restriction enzyme (10U/μl) was added directly to the amplification 
product. The reaction mixture was mixed by gently pipetting the solution up and down 
several times. The reaction mixture was spun in a microcentrifuge for 1 minute and 
immediately incubated at 37°C for 1 hour to digest the parental (i.e., the nonmutated) 
supercoiled dsDNA. 
 
Transformation of TOP – 10 Cells 
Aliquots of the TOP 10 bacterial cells were removed from the freezer and placed 
immediately on ice to thaw. 1μl of the sample DNA was pipetted into the cell vial and 
mixed gently by pipetting up and down. The mixture was left on ice for a further 30mins. 
It was then heat pulsed at 42°C for 30secs and placed back in ice. 250μl of SOC (Super 
Optimal broth with Catabolite repression) medium was added and the vial incubated at 
37°C for l hour. Sterile inoculating loops were then used to spread the cell mixture over a 
prepared agar plate and incubated overnight at 37°C.  Agar plates were prepared using 
LB (lysogeny broth) agar at a concentration of 35g/L with the addition of ampicillin 
1μl/ml. 
Plates were inspected the following day for growth of any cell colonies. If colonies were 
present they were individually “picked” using a sterile pipette and the pipette placed into 
a 15ml falcon tube containing 4ml of LB Broth with ampicillin 1μl/ml. The falcon tube 
was incubated overnight in an incubator with shaking tray at 37°C.  
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Plasmid DNA purification 
Bacteria that had multiplied overnight and were suspended in the falcon tubes were 
transferred to a 1.5 mL tube and spun in a microcentifuge for 5mins. This produced a 
pellet of bacterial cells and the remaining supernatant was discarded. Plasmid DNA 
purification was performed using a Qiaprep mini-prep kit (Qiagen) and according to the 
kit manual.  
The bacterial cells were resuspended by adding 250μl of Buffer P1 (resuspension buffer) 
and mixed by gently pipetting up and down. An additional 250μl of Buffer P2 (lysis 
buffer) was then added and the solution gently mixed by inverting the eppendorf. The 
lysis reaction was left for 5mins then neutralized by adding 350μl of Buffer P3 
(neutralization buffer) and the tube immediately mixed by inverting 5 times. The solution 
was then spun in a microcentrifuge for 10mins at 13 000rpm.  
While the lysed bacteria were spinning new tubes were labeled and binding columns 
placed inside. The binding columns were washed by adding 500μl of Buffer PB and 
centrifuged for 60secs. The flow through was discarded.  
The original tubes were removed from the centrifuge and a white pellet could be 
observed. The supernatant was transferred to the pre-prepared binding columns and the 
columns spun for 60secs. The flow through was discarded. 750μl of Buffer PE (wash 
buffer) was added to the binding column which was spun again for 30-60secs. The flow 
through was discarded and the tube spun for a further 60secs. Any additional flow 
through was discarded. Columns were placed in clean labeled tubes. The DNA was eluted 
by adding 50μl of Buffer EB. Columns were left to stand for 1min and then spun for 
1min. The flow through comprised of purified DNA which was frozen. 
 
Confirming successful mutagenesis of the SCN4A clone 
Purified DNA was digested using the following reagents: 1.5μl DNA, 1.5μl 10 x buffer, 
0.15μl 100x BSA, 0.3μl Enzyme ACC 65I, 12μl of H20 and incubated at 37°C for 
60mins. A 1% agarose gel was prepared as previously detailed and digestion samples run 
on the gel with a lkb DNA ladder. The presence of 2 fragments of 4.5kb and 7.0kb 
indicated successful DNA mutagenesis. To further confirm, DNA was also directly 
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sequenced using the methods outlined above as this also ensured no unintentional 
additional mutations had been introduced. 
 
Maximising the purified DNA sample 
Once it was confirmed the DNA sample contained only the intended mutant sequence, 
maxipreps were prepared using a Qiagen Maxiprep kit and protocol. TOP-10 cells were 
transformed using the methods described above with 1μl of purified mutant DNA. Agar 
plates were incubated overnight. If there was successful growth of colonies the colonies 
were “picked” using a sterile pipette and the pipette placed in a 1L flask containing 
200ml of LB broth (with 1mg/ml of ampicillin). The flask was incubated overnight at 
37°C on a shaking tray. 
Maxipreps were prepared using the Qiagen maxiprep protocol as follows: 
 
1. Broth was poured into a plastic centrifuge bottle and spun for 15mins at 5000 rpm. 
2. Supernatant was poured off and bacterial pellet resuspended in 10 ml Buffer P1. 
Resuspended pellet solution was transferred to a plastic centrifuge tube. 
3.10 ml of Buffer P2 was added, mixed gently, and incubated at room temperature for 5 
minutes. 
4.10 ml of cold Buffer P3 was added, mixed immediately but gently by inversion, and 
incubated on ice for 20 minutes. 
5. The tube was then spun for 30mins at 12,000 rpm at 4°C . During the last 10mins of 
the spin, Qiagen-tip 500 columns were equilibrated by adding 10 ml Buffer QBT and 
allowing the column to drain. 
6. The supernatant was decanted into 2 Falcon 50ml tubes.  
7. Decanted supernatant was added to the column and allowed to flow through. 
8. The column was washed twice with 30 ml Buffer QC. 
9. DNA was eluted by adding 2 x 5 ml Buffer QF and the eluate caught in a fresh plastic 
centrifuge tube. 
10. DNA was precipitated with 7 ml room-temperature isopropanol and the tube spun for 
30secs at 12,000 rpm at 4°C. 
 63 
11. The supernatant was poured off, 5ml 70% ethanol added and the tube spun for 5mins 
at 12, 000 rpm at 4°C. 
12. Supernatant was poured off; the tube respun for 5mins at 12, 000 rpm at 4°C. 
13. DNA was allowed to air-dry for 5mins; resuspended in 500l dH20 and, transferred to 
an eppendorf.  
 
Confirmation of the correct DNA sequence was again performed by restriction digest and 
direct DNA sequencing. 
 
 
2.5 Cell culture methods 
 
All cell work was performed under sterile technique in sterile tissue culture cabinets 
within a dedicated tissue culture facility. 
 
Thawing human embryonic kidney (HEK) cells 
Stocks of HEK cells were stored in a liquid nitrogen facility. Prior to removing cells from 
storage flasks for cell culture were prepared in the fume hood. Growth medium 
constituted DMEM, 10% FBS and 1% glutamax (Invitrogen). 50ml aliquots were stored 
in the fridge and removed to warm to room temperature. 5ml were transferred using bulb 
pipettes to a pre-labeled sterile cell culture flask. A further 5mls were pipetted to a 10ml 
falcon tube. At this stage cell vials were removed from the liquid nitrogen tank and 
immediately transferred to the water tank (37°C) in the cell culture laboratory until 
thawed. The cells in solution were transferred to the falcon tube and mixed gently with 
the fresh medium. The falcon tube was spun down at 12 000rpm for 5mins to create a cell 
pellet. The supernatant was discarded and 5mls of fresh warm growth medium gently 
mixed with the cells using a bulb pipette. This solution was transferred to the prepared 
culture flask and the solution gently washed repeatedly over the flask base 20 times in an 
attempt to create an even distribution of cells and avoid “clumps”. The flask was placed 
in the incubator at 37°C. 
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Splitting HEK cells 
HEK cells were split when approximately 80% confluent. This was guided by direct 
observation of the flask under a microscope on a daily basis but as a general guide cells 
were split three times a week. A new flask was prepared by labeling and loading with 
5mls of fresh growth medium warmed to room temperature. Growth medium was 
removed from the flask containing the HEK cell culture with a bulb pipette and 
discarded. 1ml of trypsin was added to the flask and the flask rolled gently to coat the 
whole cell layer. Effectiveness of the trypsin was guided by sight as the cell layer could 
be seen to detach from the flask base but as a general guide this took approximately 3-
5mins. The reaction was terminated at this point by the addition of 5mls of fresh growth 
medium. The cells now in trypsin/growth medium solution were transferred to a 10ml 
falcon tube and the tube spun at 12 000rpm for 5mins. A cell pellet was now visible and 
the medium was discarded. 5mls of fresh media was added to the pellet and mixed gently 
by pipetting up and down. Approximately 1ml of this solution (volume transferred 
depended on confluency of cells and size of the pellet) was transferred to the prepared 
flask containing fresh growth medium and washed twenty times over the bottom of the 
flask to achieve an even distribution of cells. The new flask was returned to the incubator 
at 37°C. 
 
Myoblast cultures 
Aliquots of a healthy culture of normal myoblasts were given to me by Dr Carl Adkin at 
the Institute of Child Health. These had been cultured from healthy muscle donated by a 
teenager undergoing scoliosis surgery. Thawing, culture and splitting of cells was 
performed along similar methods to the HEK cells but a different growth medium was 
used comprising of: 500ml Skeletal Muscle Cell Growth Medium(Promocell C-23060), 
25ml supplement mix(Promocell), 50ml FBS and 7.5ml L-glutamine. Myoblasts were 
also split at approx. 50% confluence to prevent fusion and formation of myotubes. 
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Reverse transcription PCR 
RNA was extracted from robust myoblast cell culture using an RNAeasy kit (Quiagen). 
Reverse transcription PCR was performed using an ABI high capacity cDNA RT kit. 
Each 10l reaction contained: 2l 10xbuffer, 0.8l dNTPs, 2l primer, 1l RT and 4.2l 
of H20.   
 
 
2.6 Transfection of human embryonic kidney cells 
 
HEK cells were split in the manner described above 24hours prior to cell transfection. 
When the cell pellet was reconstituted with 5mls of fresh growth media one drop of the 
solution was added to six 5ml petri dishes which each contained three 1cm circular glass 
coverslips that had been pre-coated with poly-D-lysine, and 2-3mls of growth media. 
Petri dishes were incubated overnight at 37°C to allow for early growth of the cells. 
Human Embryonic Kidney cells (HEK cells) were transfected using the calcium 
phosphate precipitation method. The purified mutant SCN4A DNA, WT SCN4A DNA, 
SCN1B DNA samples and GFP aliquots were analysed with a nanodrop to assess the 
DNA concentration in each sample. This was to allow calculation for the transfection 
reaction such that each mixture contained a 1:1:1 ratio of SCN1A, SCN1B and GFP 
(green fluorescent protein). As such 12.7l of calcium chloride, 4l of GFP, 4l of WT 
SCN4A DNA, 1.5l of SCN1B DNA and 77.8l of H2O were pipetted into a sterile 
eppendorf to a total volume of 100l. 100l of BES  
(bis-hydroxyethylaminoethansulfonate) was added to the mixture and gently pipetted up 
and down. Constituents for the mutant DNA transfection were mixed in a second sterile 
eppendorf: 12.7l of calcium chloride, 4l of GFP, 20l of mutant SCN4A DNA, 1.5l 
of SCN1B DNA and 61.8l of H2O to a total volume of 100l and mixed gently with 
100l of BES. Each reaction was left to stand at room temperature for 10mins. The 
mixture was then distributed evenly between three of the prepared petri dishes containing 
glass cover slips and the dish gently swirled before being placed back in the incubator for 
8-10hours. After this time the media was changed to replenish the dish with fresh growth 
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media. Transfected cells were incubated for 48hrs before being used in patch clamp 
experiments. 
 
 
Coating cover slips with poly-D-lysine 
50ml of poly-D-lysine was poured into a sterile autoclaved glass bottle and made up to 
100ml with autoclaved water. This was then divided into 10ml aliquots in falcon tubes for 
freezing. 200 cover slips were placed in a 50ml falcon tube with one 10ml aliquot of 
poly-D-lysine. This was placed on a rotator for 1hour to evenly coat all the cover slips. 
After one hour the poly-D-lysine was poured off and the cover slips rinsed several times 
with sterile water. The cover slips were then autoclaved to sterilise prior to use in patch 
clamp experiments.  
 
2.7 Patch clamp experiments 
 
Patch clamp experiments were performed on HEK cells 48-72 hours post-transfection. 
Standard whole-cell patch clamp recordings were performed at room temperature. The 
external bath solution used to bathe the coverslips and cells was prepared as a 1L solution 
containing: 
 
 
mM    1L 
145  NaCl    8.47g 
4  KCl  2ml(2M) 
1.8  CaCl2  1.8ml(1M) 
1  MgCl2   1ml(1M) 
10  HEPES 2.383g 
 
The external solution was pH tested and brought to a pH of 7.35 with NaOH(1M), usually 
requiring approximately 3-5ml. 
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Several pipette solutions were trialed but the internal pipette solution used for all cells in 
the final analysis contained CsCl (150mM); Hepes (10mM) and EGTA (10mM) at a pH 
of 7.3.  Pipettes were fabricated using capillary glass and a pipette puller using pipettes 
with resistances of between 2.5-5MΩ. Cells with series resistance above 10MΩ were 
discarded. To control variability, recordings from WT SCN4A cells were routinely 
intercalated with recordings from mutant SCN4A cells. Leak subtracted currents were 
recorded using –P/4 protocol with an Axopatch 200B amplifier (Molecular Devices, 
Sunnyvale, CA, USA). Data was sampled at 20kHz and filtered at 5kHz, and analysed 
using LabView software (v. 8.0, National Instruments, Austin, TX, USA) with programs 
written by Prof D Kullman. 
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Results - Phenotyping 
 
 
Phenotype can be markedly diverse in the skeletal muscle channelopathies even among 
individuals with the same genotype. An example of the phenotypic variability that can be 
observed is provided by the SCN4A G1306E mutation associated with sodium channel 
myotonia. The original phenotype reported with this mutation was so severe the 
individual suffered permanent myotonia that included the respiratory muscles and led to 
hypoxia and acidosis requiring ventilatory support(Lerche et al., 1993). In contrast, a 
more recent report observed that although affected individuals had relatively severe 
myotonia they did not exhibit respiratory involvement and were able to carry out daily 
activities including work without treatment.(Colding-Jorgensen et al., 2006) As a 
consequence of this wide variability there are few clinically useful genotype-phenotype 
correlations. The channelopathy database was updated and reviewed regularly to identify 
potentially informative phenotypes and any possible genotype-phenotype correlations 
that emerged were explored further. 
 
3.1 Observation of neonatal hypotonia in paramyotonia congenita due to the I693T 
SCN4A mutation 
 
A female patient, BWL, referred to the clinical service for skeletal muscle 
channelopathies with PMC and seen by me described her mother reporting that she had 
been “paralysed” and floppy for the first four days after birth with an inability to 
breastfeed. The lady’s mother was deceased so further details could not be sought. 
Attempts to obtain the birth records proved unsuccessful as they had been destroyed.  
This lady was known to have genetically confirmed paramyotonia congenita with the 
point mutation I693T having been identified in exon 13 of the SCN4A gene by the 
diagnostic clinical service. Due to the unusual birth history and a rather severe phenotype 
causing biopsy proven evidence of myopathy at the age of 15 with subsequent use of a 
wheelchair from her late twenties this lady was presented as an “interesting case” at an 
international meeting of the Non-Dystrophic Myotonias. This led to collaboration with 
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Bertrand Fontaine’s group who attended the meeting and also reported neonatal 
hypotonia occurring in families they had seen with the same SCN4A mutation (I693T). 
Details of the four French children from two unrelated families were sent to me by 
Damien Sternberg. 
 
Phenotype of neonates carrying the I693T SCN4A mutation 
Four unrelated families in total (2 in the UK, 2 in France) were identified who all carried 
the I693T mutation and reported cases of neonatal hypotonia with variable difficulties in 
feeding and respiratory compromise (see Table 9). Symptoms were self-limiting within 
10 days in each case. All affected individuals later went on to develop the typical 
symptoms of cold and exercise exacerbated myotonia seen in PMC. The mutation was 
inherited from the mother in two cases, the father in one and was apparently sporadic in 
the other although parental DNA was not available to confirm this.  
The proband identified in one of the UK families became pregnant shortly after the 
recognition of neonatal hypotonia with this mutation. Advice was given to her and to the 
obstetric and paediatric teams involved in her care regarding the possible development of 
neonatal hypotonia, feeding or respiratory difficulties along with reassurances that these 
symptoms were most likely to be self-limiting and would require only supportive care. 
She went on to deliver a healthy baby boy who did display hypotonia and feeding 
difficulties requiring a short term nasogastric tube. Symptoms were self limiting and he 
was later able to breast feed and to date has had normal development. Subsequent genetic 
testing confirmed he had inherited the I693T mutation from his mother. 
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 Sex Year 
of 
birth 
APGAR 
at birth 
Onset of 
Hypotonia 
Impairment 
of sucking-
swallowing 
Desaturation Kalemia 
(mmol/l) 
Motor 
Development 
Family 1 
(English) 
Female 
1-1 
1950 NA Birth Day1-
bottle 
fed,unable 
to breast 
feed 
No NA Walking  
delayed 
(19/12) 
Family 2 
(English) 
Female 
2-1 
1975 NA Birth No 
(hypotonia 
limited to 
limbs) 
No NA Walking 
delayed 
(22/12) 
Family 3 
(French) 
Female 
3-1 
1987 10 Day1, 
some 
hours after 
birth 
Day1-3 
some hours 
after birth, 
nasogastric 
tube 
Day1, some 
hours after 
birth 
(cyanosis) ; 
no reported 
treatment 
5.1 then 
normal 
Normal 
 Male 
3-2 
1997 10 Day1, 
some 
hours after 
birth when 
bathed 
Day1-3 
onset in 
bath 
No Normal NA 
Family 4 
(French) 
Male 
4-1 
2004 NA Day1 Day1-3  
no 
treatment 
reported 
No NA Normal 
 Male 
4-2 
2007 10 Day1,some 
hours after 
birth 
Day1-6, 
some hours 
after birth 
nasogastric 
tube  
Day2-6, 
nasal 
oxygen 
required 
Normal NA 
NA-Not Available 
 
Table 9: Features of hypotonia and motor development in six neonates carrying the 
Nav1.4 I693T mutation. 
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3.2 Stridor expands the neonatal presentations of skeletal muscle sodium 
channelopathy 
 
Following on from the observation of this neonatal presentation of paramyotonia 
congenita a patient seen by me in clinic and enrolled in the natural history trial with 
paramyotonia congenita described her second son as having severe stridor with some 
respiratory and feeding difficulties at birth. She queried whether his stridor was related to 
PMC. Initially this was uncertain as although the defective Nav1.4 channel would be 
present in all skeletal muscles including the larynx, neonatal stridor is common for 
numerous other reasons and it was not possible to draw conclusions from a single case. 
His medical records were reviewed with permission. Discussion once again with Bertrand 
Fontaine and Damien Sternberg’s group in France identified two additional French cases 
however which suggested the association was not co-incidental and the stridor may be a 
direct result of the myotonic disorder.  
 
 
Features of neonatal stridor 
The lady’s four year old son was referred to paediatric services following the diagnosis of 
paramyotonia congenita (PMC) in her. The boy was the mother’s second child and was 
born by ventouse delivery at 39 weeks following an uncomplicated pregnancy. APGAR 
scores were normal and post natal examination was unremarkable. Within 24 hours of 
delivery he was transferred to the neonatal intensive care due to inspiratory stridor and 
poor feeding. Over the following week he was unable to take sufficient oral feeds and 
required supplemental nasogastric feeding. Stridor persisted and he required intermittent 
oxygen therapy for desaturations that occurred while attempting to bottle feed or when 
crying. Laryngoscopy showed findings consistent with laryngomalacia. 
The infant continued to have persistent inspiratory stridor for the first six months of life. 
Feeds were prolonged but he gained weight appropriately and had no further apnoeic 
episodes. Motor milestones were mildly delayed, sitting independently at nine months 
and walking at 19 months. From the age of one year exotropia was noted. This is 
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currently under investigation by an opthalmologist and possibly reflects myotonia of the 
extraocular muscles. 
At the age of 23 months he fell in the garden on a cold day and complained of leg 
weakness, refusing to stand or walk. The weakness recovered spontaneously within five 
hours. A second similar episode occurred at age 27 months after playing in the garden in 
winter. In addition to these two episodes of muscle weakness his mother noted muscle 
stiffness occurring on an almost daily basis from age two. Both muscle stiffness and 
weakness were exacerbated by cold weather and exertion.  
At the age of four he continues to have episodes of inspiratory stridor exacerbated by 
viral illness, cold weather, and prolonged laughter or crying.  A humidifier is helpful in 
aborting such episodes.  
He has recently been treated with the sodium channel blocker mexiletine which has had 
some beneficial effect on his degree of myotonia and exotropia. 
The child’s mother, grandfather and great uncle all reported similar episodes of muscle 
stiffness and weakness exacerbated by cold and exercise. There was no prior family 
history of stridor. All affected family members including the child described had DNA 
sent to the diagnostic genetic lab at the NHNN under the NCG scheme for 
channelopathies by the specialist responsible for their clinical care and were shown to 
have the SCN4A mutation T1313M associated with PMC(McClatchey et al., 1992b). 
In addition to this case two further adult cases of PMC in France in whom neonatal 
stridor was documented in their medical records were identified by Damien Sternberg 
although no further details were available. The first carried an E1702K familial mutation, 
and the other an A444D de novo mutation.  
 
Neonatal myotonia was recorded in Eulenburg’s first description of PMC but distinct 
neonatal phenotypes of sodium channelopathy have not previously been recognised. A 
case of fatal infantile myotonia with severe respiratory compromise was recently reported 
in a child carrying a new SCN4A mutation N1297K(Gay et al., 2008). Since describing 
the case of stridor another series has reported more severe laryngospasm in three infants 
with sodium channel mutations, one of whom also died(Lion-Francois et al., 2010). 
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This emerging evidence of neonatal presentations is of paramount importance when 
counselling expectant families with a history of sodium channel disorder and is important 
to bear in mind in children presenting with these features even if family history is lacking 
as de novo mutations occur. In the milder phenotypes I have described symptoms 
generally only required supportive care and invasive investigations are not required. The 
recently published more severe cases generally responded to mexiletine therapy. 
Ultimately the delivery of neonates at risk of inheriting sodium channel disorders should 
be considered relatively high risk and appropriate obstetric, anaesthetic and paediatric 
services must be available. The recognition of these phenotypes will limit unnecessary 
investigation and prompt early appropriate therapy.  
 
 
3.3 Observation of inflammatory infiltrates in skeletal muscle channelopathies  
 
Advances in specialised electrophysiological tests and genetic analysis although not 
infallible have significantly improved the ability to diagnose skeletal muscle 
channelopathies. Many of the reported histopathological findings in the channelopathies 
predate the availability of genetic testing and commonly include a vacuolar myopathy or 
tubular aggregates in the periodic paralyses although it must be noted that these occur in 
all of the sub groups. Biopsy findings in the non-dystrophic myotonias are non-specific 
myopathic changes. Morphological analysis is ultimately not diagnostic but prior to the 
availability of less invasive investigations it was used to support a diagnosis of 
channelopathy and much of the data available is from typical cases without severe or 
unusual symptoms. It is rare in the UK that a diagnostic biopsy is now performed in the 
channelopathies. 
Regular searches of the database of patients referred to the channelopathy service 
identified three cases of genetically confirmed skeletal muscle channelopathies who all 
underwent muscle biopsies due to reports of either proximal weakness or severe muscle 
pain in conjunction with a raised creatine kinase (CK).  In each case the biopsies were 
reported as showing inflammatory infiltrates which are not a recognised or described 
finding in channelopathies. The referring clinicians were contacted in each case to request 
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further clinical details and any available biopsy slides. All three kindly responded with 
clinical details and in two cases biopsy material was sent for review by Dr Janice Holton. 
In the remaining case biopsy material had unfortunately been destroyed but detailed 
biopsy reports were obtained.  
 
 
Histopathology 
Each patient had undergone a muscle biopsy in another centre and tissue sections stained 
for haematoxylin and eosin (H&E), Gomori’s trichrome method, lipid and glycogen in 
addition to enzyme histochemical preparations for succinic dehydrogenase, cytochrome 
oxidase and nicotinamide adenine dinucleotide dehydrogenase tetrazolium reductase 
were available for review. Immunohistochemical preparations submitted for review were: 
Case 1: CD3 and MHC class I; Case 2: immunohistochemical staining for CD3, CD20, 
spectrin, dystrophin, merosin, dysferlin, sarcoglycans, emerin and desmin; and Case 3: 
MHC Class I, CD3, CD68 and CD20. 
 
 
Clinical features of channelopathy patients with inflammatory biopsies 
 
Case One 
An 80 year old man complained of episodes of muscle weakness after periods of 
prolonged rest from the age of four. Initially only the lower limbs were affected but by 
his late teens the upper limbs were also involved. The episodes usually lasted hours and 
occasionally days.  A clinical diagnosis of familial periodic paralysis was made when he 
was aged 21 following reports of similar episodes of weakness in his mother and sister.  
From his early 50s mild proximal muscle weakness was noted on examination. At the age 
of 56, following a positive potassium challenge his diagnosis was revised to 
hyperkalaemic periodic paralysis and he was treated with salbutamol. Creatine Kinase 
(CK) at this time was noted to be 436U/L. At the age of 65 he began complaining of 
difficulty rising from a chair and climbing stairs. Examination confirmed limb weakness 
greater proximally than distally. Clear difficulty rising from a chair without using his 
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hands for leverage was observed and a degree of thigh atrophy was noted. EMG showed 
myopathic changes and minimal myotonic discharges. His CK was 2729U/L. Muscle 
biopsy showed internal nuclei, fibre atrophy, fibre hypertrophy with occasional split 
fibres, some regenerating fibres and an increase in endomysial connective tissue. In 
addition there was a dense inflammatory cell infiltrate focused around small capillaries 
and necrotic fibres which was demonstrated by immunohistochemistry to consist mainly 
of T-lymphocytes with restricted MHC 1 expression.  Diagnoses of vasculitis and 
polymyositis were considered from the biopsy findings but the overall clinical picture 
was felt most consistent with a diagnosis of polymyositis and he was started on 
prednisone 60mg once daily. A few hours after the initial dose of steroids he suffered a 
severe attack of paralysis lasting 48 hours. Following recovery from this he was restarted 
on prednisone 10mg once daily with gradual improvement of his muscle weakness.  
Ten years later he re-presented with further complaints of leg weakness and difficulties in 
mobilisation. At this time he was on 5mg of prednisone although it is not clear if this had 
been continuous since commencement 10 years earlier. Azathioprine 50mg bd was added 
to his therapy but he continued to deteriorate and was admitted to hospital where 
proximal lower limb power was documented as ranging from 3/5 to 4/5. The azathioprine 
dose was further increased to 100mg bd and he was discharged from hospital. When he 
was reviewed in clinic 2 months later he reported no real change in his mobility 
difficulties although only “mild” proximal leg weakness was recorded. Genetic analysis 
by the diagnostic channelopathy service confirmed the presence of the common T704M 
point mutation in the SCN4A gene associated with hyperkalaemic periodic 
paralysis(Ptacek et al., 1991). 
 
Case Two 
A 42 year old lady with the F167L mutation in the CLCN1 gene associated with 
myotonia congenita(George, Jr. et al., 1994) complained of daily muscle cramps affecting 
all muscle groups but predominantly the limbs from early childhood. This was confirmed 
to be myotonia on EMG. Family history revealed similar symptoms in her mother and 
two maternal aunts. The patient complained of severe cramps with increasing age and 
began to experience episodes of muscle weakness after exertion although in between 
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episodes reported normal muscle power. Examination was generally unremarkable but a 
CK was raised at 1109U/L.  
Muscle biopsy was performed and demonstrated increased variation in fibre size, 
evidence of fibre regeneration and 1 necrotic fibre. Two small foci of inflammation 
composed of CD3 immunoreactive T lymphocytes were noted in perimysium and 
endomysium (Fig 16). Invasion of intact myofibres by T cells was not evident and MHC 
Class I immunohistochemistry was not available for review. There was no evidence of a 
vacuolar myopathy and tubular aggregates were not present. She was started on 
prednisone with a resultant reduction in CK to 3-400U/L. All attempts to reduce 
prednisone were unsuccessful and the patient was unable to tolerate other 
immunosuppressants.  
 
Case Three 
A 38 year old man complained of episodes of muscles stiffness when exposed to the cold 
affecting predominantly his tongue, hands and feet from early childhood. This was 
confirmed by electrophysiological testing to be myotonia. There was no family history of 
note. Myotonia occurred daily but symptoms remained fairly static until his late teens 
when he additionally complained of episodes of acute muscle swelling predominantly 
affecting his forearms and thighs. Initially these were non-painful, and CK and muscle 
power were normal. Later however he complained of myalgia accompanying the episodes 
of swelling which could occur 2-3 times a month and last up to a week. An ultrasound 
scan confirmed hypoechoic regions within the muscles but normal subcutaneous tissue. 
An intermittent peripheral eosinophilia was noted in conjunction with the episodes of 
myalgia. A muscle biopsy showed no evidence of regeneration, necrosis, vacuolation of 
fibres or tubular aggregates. Inflammatory infiltrates composed of a mixture of T 
lymphocytes and macrophages were present in the perimysium with a single endomysial 
cluster (Fig 16B and 16C). Invasion of intact muscle fibres by T cells was not apparent. 
Immunohistochemical staining for MHC Class I demonstrated an increase in 
sarcolemmal and sarcoplasmic expression (Fig 16D). The biopsy findings were 
interpreted as being compatible with polymyositis although the clinical history was not 
typical. 
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He had an excellent response to prednisone, 20mg od reduced to 5mg od which reduced 
the frequency and severity of the muscle swelling and myalgia although he unfortunately 
developed osteopenia.  Attempts to introduce other steroid sparing immunosupressive 
agents were unsuccessful as he did not respond to methotrexate, cyclosporine, imatinib or 
hydroxyurea and did not tolerate azathioprine. Genetic analysis by the diagnostic 
channelopathy service confirmed the presence of the L1436P mutation in the SCN4A 
gene associated with sodium channel myotonia(Matthews et al., 2008b). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 16: In case 2 a prominent focus of perimysial inflammation was found (A).  Similarly 
the inflammation in case 3 was predominantly perimysial (B) with focal extension into 
the endomysium (arrow in C). The inflammatory cells included abundant T lymphocytes 
(C) and increased expression of MHC Class I at the sarcolemma and within the 
sarcoplasm of fibres was demonstrated (D). A: case 2; B – D: case 3. A & B: 
haematoxylin and eosin, C: CD3 immunohistochemistry; D: MHC Class I 
immunohistochemistry. Bar in A represents 50µm in A – D. 
A B
C D
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Case Predominant 
clinical features 
Examination 
findings 
Investigations Biopsy Findings Response to 
steroid therapy 
1 Episodic 
muscle 
paralysis 
Progressive 
proximal limb 
weakness 
Proximal limb 
weakness, 
MRC grade 3/5 
to 4/5 
CK 2729U/L 
 
EMG:  
polyphasic units + short 
duration units, 
fibrillations, 
fasciculations and 
myotonic discharges 
Internal nuclei, fibre atrophy, fibre 
hypertrophy with occasional split fibres, 
some regenerating fibres and an increase in 
endomysial connective tissue.  
Dense inflammatory cell infiltrate focused 
around small capillaries and necrotic fibres 
composed mainly of T-lymphocytes. 
MHC I upregulation on occasional muscle 
fibres. 
High dose 
prednisone 
(60mg) led to 
severe paralytic 
attack lasting 
48hrs  
10mg better 
tolerated with 
improved 
muscle strength 
2 Muscle cramps 
and severe 
myalgia 
Myotonia 
Normal muscle 
power 
CK 1109U/L 
 
EMG: massive myotonic 
discharges at every 
insertion point that 
precluded analysis of 
MUAP configuration, 
voluntary recruitment or 
interference pattern. 
Increased variation in fibre size, evidence 
of fibre regeneration and 1 necrotic fibre.  
Two foci of inflammation composed of 
CD3 immunoreactive T lymphocytes noted 
in perimysium and endomysium. 
Immunohistochemistry unavailable for 
review. 
Reduction in 
CK to 3-400. 
3 Muscle cramps 
and episodic 
limb oedema 
with myalgia 
Myotonia 
Normal muscle 
power 
CK normal 
 
EMG: myotonic 
discharges 
Inflammatory infiltrates composed of a 
mixture of T lymphocytes and macrophages 
were present in the perimysium with a 
single endomysial cluster (Fig 16). 
Immunohistochemical staining for MHC 
Class I demonstrated an increase in 
sarcolemmal and sarcoplasmic expression 
Excellent 
response with 
significant 
reduction in 
symptoms of 
oedema and 
myalgia 
 
Table 10: Summary of clinical, biochemical, neurophysiologic and histological findings in each case
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Channelopathies are rare disorders and for the reasons outlined biopsy samples are 
scarce. It is impossible to be certain that the observation of inflammatory infiltrates in 
these three cases is not merely co-incidental. To try to ascertain the likelihood of this 
however I consulted Dr Gareth Ambler, statistician at UCL who reviewed the data. The 
prevalence rates of both skeletal muscle channelopathies and idiopathic inflammatory 
myopathy (IIM) have each been estimated to be 1 in 100,000(Emery., 1991; Fontaine., 
1994; Hilton-Jones., 2001). A null hypothesis was taken that the development of both 
diseases in these three cases was coincidental. Considered statistically, if the likelihood of 
developing a skeletal muscle channelopathy and an IIM is independent then the chance of 
having both is one in 10
-10
.  The probability of observing UK patients with both diseases 
(if this association were by chance alone) can be calculated using the Poisson distribution 
since p is small and the UK population is large; Poisson lambda = 10
-10 
(independent 
probability of two events in an individual) x 6.5 x 10
7 
(UK population) = 0.0065, and the 
probability of observing three or more patients with both diseases (assuming 
independence) is 4.5 x 10
-8
. This small p value indicates that the occurrence of both 
diseases in the same individual is highly unlikely to be independent. 
Whether such inflammatory changes are present in a greater number of channelopathy 
patients will be difficult to establish but it is reasonable to suggest that a muscle biopsy 
be considered in those in whom a CK>1000IU/L is observed in conjunction with 
significant myalgia or weakness. Steroid use has to be interpreted cautiously as in one 
case high dose steroids caused significant exacerbation of the periodic paralysis but lower 
doses may be beneficial.  
 
 
3.4 Pain and morbidity in the non-dystrophic myotonias 
 
There is little in the literature that gives consideration to the morbidity of the skeletal 
muscle channelopathies. Multiple case reports and one recent series(Trip et al., 2009a) do 
suggest pain may be an overlooked feature in the non-dystrophic myotonias. It was a 
personal observation that many patients who attended clinic or participated in the natural 
history trial of non dystrophic myotonia often volunteered pain as a troubling symptom. 
 80 
To look at this more subjectively all participants enrolled in the natural history study 
were asked about their symptoms. In the first year of enrollment of UK based participants 
the majority (16/19) reported stiffness as their most prominent symptom which would be 
as predicted for these myotonic disorders. All 19 had EMG evidence of myotonia and 
in18/19 pathogenic mutations associated with myotonic disorders have been identified. 
However 3/19 (16%) reported pain was their most prominent symptom (see Fig 17). Of 
these 3, 1 carried a sodium channel mutation and 2 chloride channel mutations. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 17: NDM patient reports of their most prominent clinical symptom 
 
Participants were then asked about specific symptoms in detail including whether they 
experienced pain in association with muscle stiffness or even in the absence of muscle 
stiffness. If they answered yes they were asked to rate the severity of their maximum 
level of pain and their average level of pain on a pain scale of 0 – 9, 9 being the most 
severe pain imaginable and 0 being no pain. Of 19 patients 16/19 (84%) reported some 
pain, 7 of these associated only with stiffness, 7 both with and without stiffness and 2 
without any stiffness exacerbation. Mean maximum and average severities are detailed in 
fig 18. There was no discernible difference in severity of pain whether it occurred with 
stiffness i.e. painful myotonia or in the absence of stiffness. 
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Fig 18: Mean maximum and average severity of pain scores in NDM patients 
 
When considered by genotype, 100% (11/11) of patients with sodium channel mutations 
reported some pain, and 50% (3/6) of those with chloride channel mutations. This 
indicates that pain is significantly more likely to be reported by patients carrying sodium 
channel mutations than patients carrying chloride channel mutations (p = 0.029; Fisher’s 
exact test). Of the remaining two patients who reported pain, one was diagnosed with 
DM2 and in the other no mutation has yet been identified. This data contributes to the 
emerging evidence that pain and its severity is a common and significant feature of non-
dystrophic myotonia which may increase morbidity. It also suggests it may be more 
prominent or severe in those carrying sodium channel mutations but this would require 
further exploration in larger groups. 
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Results – Genotyping 
 
4.1 Genotyping the sodium channel myotonic disorders  
 
Patient identification 
Using the channelopathy database, patients were identified with a clinical history 
consistent with myotonic sodium channel disease, either paramyotonia congenita, sodium 
channel myotonia or hyperkalaemic periodic paralysis. All patients are screened for the 
most common SCN4A mutations in exons 13, 22 and 24 by the diagnostic genetic lab as 
part of the NCG channelopathy service. I identified 17 patients in whom no such 
mutations were found for further study and performed direct DNA sequencing of all 24 
exons of SCN4A (analysis of exons 13, 22 and 24 was repeated) and quantitative PCR for 
the trinucleotide repeat of ZNF9 known to cause myotonic dystrophy type 2 (DM2). All 
those with a phenotype of PMC or SCM had EMG proven myotonia. Cases of 
hyperkalaemic periodic paralysis included some with atypical features. If no abnormality 
was detected in SCN4A or ZNF9, the CLCN1 gene was kindly sequenced by geneticists 
Dr Robyn Labrum or Dr Richa Sud in the diagnostic lab. Selected patients had additional 
gene sequencing performed by other centres. 
 
 
Sodium channel myotonia – new mutations 
Of the 17 patients identified, I considered 13 to have PMC or SCM and 4 to have features 
of hyerPP. Amino acid substitutions were identified in 9/13 myotonic patients including 3 
previously unreported, V445L, L128P and M135L. Controls were run for all of these 
novel changes including analysis of conservation across species and use of analysis 
websites to predict the likelihood of these changes being pathogenic. V445L and L128P 
were highly conserved, absent in controls and predicted to be deleterious to channel 
function. M135L was not highly conserved, was present in one control sample and 
predicted to be a tolerable amino acid substitution. It was not however listed on any SNP 
database as a known polymorphism. Both the patient and the positive control were 
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believed to be of Jewish origin. Taken together these findings suggest that this 
substitution may be a polymorphism that is more prevalent in certain ethnic groups.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 19: Electropherograms, conservation across species and position in Nav1.4 
channel of new SCN4A mutations 
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 Genotyped SCN4A CLCN1  DM 2  Other Genes Phenotype EMG Myotonia 
1MZ Yes V1293I    Sodium channel myotonia Yes 
2LG Yes V445L*    Sodium channel myotonia Yes 
3LF No  Negative Negative Negative DM1 negative Sodium channel myotonia Yes 
4EC No  Negative Awaited – 
more DNA 
requested 
Negative DM1 negative Infantile myotonia Yes 
5BC Yes Negative   CRYAB gene c.343delT 
(p.Ser115ProfsX14) + 
c.343delT 
(p.Ser115ProfsX14). 
Infantile onset severe limb and 
respiratory muscle stiffness 
First EMG ?myotonia 
Second EMG 
Pseudomyotonia 
6CM No  Negative Negative Negative DM1 negative Sodium channel myotonia Yes 
7MH Yes Negative Mutation 
detected 
Negative  Sodium channel myotonia Yes 
8BB Yes Q270K    Paramyotonia Congenita Yes 
9EL Yes E1702K    Paramyotonia Congenita Yes 
10CO Yes L128P*    Sodium Channel Myotonia Yes 
11DL Yes V1293I    Sodium Channel Myotonia Yes 
12JSC No M135L**    Paramyotonia Congenita Yes 
13RT No  Negative Negative Failed  Paramyotonia Congenita Yes 
14SR No Negative Negative ND RYR1 silent changes only 
Brother congenital 
myasthenic syndrome 
Atypical hyperkalaemic periodic 
paralysis 
No 
15JV Yes Negative Negative Positive  Hyperkalaemic Periodic Paralysis Myotonia – not clear if 
clinical or EMG 
16LD No  Negative Negative Negative Congenital myasthenia 
genes awaited 
Atypical periodic 
paralysis/myasthenia 
No 
17EP No Negative ND ND KCNA1 Negative Hyperkalaemic periodic paralysis No 
*denotes new gene mutations not previously reported. **denotes a new single amino acid substitution, not reported as a mutation or 
polymorphism but probably benign 
Table 11: Summary of genetic results for 17 patients considered clinically to have PMC or hyperPP
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Sodium channel myotonia – non-genotyped cases 
The remaining 4 myotonic cases in whom no mutation was identified are considered in 
detail and are referred to by their order in table 11. 
 
Patient No. 3 (LF) 
This lady is from a large Sicilian family living in Australia. She complained of muscle 
stiffness and paralysis from infancy. She reported the first time she was taken for a 
swimming lesson at age 3 she nearly drowned as the cool water caused her muscles to 
become stiff.  When she was rescued from the bottom of the pool she was found in a 
flexed position which required rewarming over about an hour before her muscles could 
be relaxed and began contracting normally again. If she exerts herself she can be in bed 
with muscle weakness and muscle discomfort for days.  Recently she ran to catch a plane 
(the first time she had run in 20 years) and ended up paralysed in her airplane seat for the 
flight back from Florida to Australia. Cold temperature was a powerful exacerbator of her 
myotonic symptoms especially the peripheries, the eyelids and extraocular muscles.  Her 
neurologist in Australia had ice cooled her eyes for 1 minute after which she could not 
open them very easily, had diplopia for several minutes and a mild facial droop.  She 
spent most of her time “paralysed” in the hotel room after a recent trip to Canada, where 
she got cold on the first day. Cold also produced a tension-like headache and cervical 
muscle “tightness”.  She avoids some foods like olives and some fruits which she thinks 
can precipitate attacks. She had no dysmorphic or systemic features suggestive of 
myotonic dystrophy. 
The long exercise (5minutes) and cooling repetitive stimulation testing were only mildly 
positive.  In contrast muscle cooling down to 20
o
C with needle EMG was very suggestive 
of the transition of changes that have previously been reported in PMC and she had 
associated clinical symptoms which took several hours to resolve. 
She responded well to low dose mexiletine reporting after 3 days that it was the first time 
in the last 20 years she had not woken in the morning with muscle cramp and pain.  
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In terms of family history it was known her son and daughter had similar symptoms. 
They were from a large Sicilian family and her Australian neurologist was making 
attempts to identify affected members of preceding generations. 
 
Patient No. 4 (EC) 
A male infant referred to Great Ormond Street Hospital at the age of 15 months with 
hypotonia. No specific cause had been identified and there was no family history of note. 
EMG had shown unexpected but clear myotonic discharges. Myotonic dystrophy had 
been excluded by the referring paediatric team. 
 
Patient No. 6 (CM) 
A forty-nine year old lady who was first symptomatic during her 3rd pregnancy at the age 
of 42 with muscle stiffness that was worse with stress and after exercise. EMG confirmed 
myotonia and profound CMAP drop after short exercise test. Her parents were 
unaffected, her sister reported vague symptoms but had normal neurophysiology, and 3 
sons were asymptomatic. 
 
Patient No. 13 (RT) 
A forty-three year old Italian lady who experienced her first symptoms at the age of 
twenty. There was evidence of clinical and EMG myotonia, affecting mainly her limbs 
but also face, neck and abdominal muscles, triggered by cold.  She reported episodes of 
muscle paralysis triggered by exercise and cold lasting hours. There was proximal and 
distal limb muscle wasting with moderate to severe proximal and mild to moderate distal 
muscle weakness. Repetitive stimulation caused a 33% CMAP reduction on 
electrophysiological testing. There was no family history of note.  
 
Hyperkalaemic periodic paralysis – non-genotyped cases 
Of the remaining four/seventeen patients (see genotyping section 4.1 and table 11) 
categorized as having a phenotype consistent with possible hyperkalaemic periodic 
paralysis SCN4A mutations were not identified in any. In one a pathological expansion of 
the ZNF9 gene associated with DM2 was present. The remaining three had some atypical 
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clinical features and additional genes were or are being sequenced by other laboratories. 
Their clinical features are considered in detail. 
 
Patient No 14 (SR) 
A 24 year old man previously under the care of paediatric colleagues until the age of 18. 
He had been investigated extensively for myopathy but no specific cause was found and 
he was given a diagnosis of unspecified congenital myopathy. He described brief 
episodes of lower limb weakness that occurred mainly in the cold including one episode 
where he fell down some stairs due to his legs giving way. There was some myalgia but 
no particular history to suggest myotonia. Symptom severity did seem to be fluctuant and 
from the ages of approx 12-14 his limb weakness had been so severe he had required a 
wheelchair but this had improved and at the time of his review in clinic he was 
independently ambulant and attending college.  
On EMG no myotonic discharges were demonstrated. After muscle cooling a reduction in 
CMAP amplitude with increase in CMAP area was observed. At the time the significance 
of this was unclear and it was thought to possibly be pathological. Later studies by Dr 
Veronica Tan (consultant neurophysiologist at the NHNN) of large numbers of patients 
with skeletal muscle channelopathies and healthy volunteers showed this change to 
actually be a normal variant. This man had no prior family history of myopathy. He was 
one of four children and his younger brother was affected with a very similar clinical 
course to his own. 
During the write up of this thesis I was advised a congenital myasthenia mutation has 
been identified in this patient’s brother by another lab but I do not have access to the 
formal report. Confirmation of the same mutation in this patient is apparently pending but 
is very likely to be the explanation for his symptoms. 
 
Patient No 16 (LD) 
A 51 year old male born 7 weeks prematurely. Delayed walking (not until approx 2 
years) was observed and he was never able to run or keep up with peers physically due to 
a feeling of weakness in his arms and legs. From the age of twenty he avoided stairs due 
to limb weakness. There was very slow progression in symptoms until age thirty four 
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following a flu like illness when he complained of worsening muscle weakness. Since 
this episode he has continued to complain of episodes of worsening limb weakness 2-3 
times a year. Clinical examination at age 35 showed ptosis, external opthalmoplegia and 
proximal limb weakness with significantly depressed reflexes. At age 38 he presented 
with an episode of bulbar weakness requiring a nasogastric tube and ultimately a 
percutaneous endoscopic gastrostomy(PEG) tube for feeding. However there was 
spontaneous resolution after 6 months with eventual removal of the PEG. He continues to 
have episodes of limb weakness, with some fatigue and dysphagia in addition to 
permanent proximal myopathy. 
Electrophysiological tests showed myopathic potentials and repetitive nerve stimulation 
showed some decrement in CMAP. Stimulation single fibre EMG showed abnormal jitter 
and blocking. A McMannis test for periodic paralysis was positive.  Muscle biopsy 
showed non-specific myopathic changes only. 
There is no family history of similar illness or symptoms. He is one of four children (2 
brothers and one sister). 
 
Patient No 17 (EP) 
A forty eight year old woman who complained of episodes of paralysis from early 
childhood (at least age five). In addition she suffered from exercise intolerance, pain and 
stiffness especially in the cold, which rendered her unable to walk. She had been given a 
previous diagnosis of fibromyalgia and investigations at another centre had included 
testing voltage gated potassium channel antibodies which were positive. Two EMGs 
performed at our centre on separate occasions did not show any evidence of 
neuromyotonia or myotonia. A Mcmannis test was positive on the first occasion and 
negative on the second. 
This lady extensively researched her family history and provided the following details (as 
quoted from her notes): 
 
Her son  – now 11 yrs 
 “At a few hours old, possibly on the 2nd day, was taken away as he was not 
breathing properly.” 
 89 
 “Many floppy episodes, but also has Congenital Adrenal Hyperplasia (CAH), 
therefore cannot distinguish what may have been PP or CAH.” 
 “Complains of pains in legs after sport and on waking day after exercise, can’t 
walk properly. Sometimes, pains in legs apparent w/o exercise (like football, 
swimming etc), although walking, stairclimbing will have been done.”   
 “Complains of pains in legs and feet on walking distance, though none at outset.” 
 “On holiday Cyprus, Dec 03, aged 6, was swimming in a freezing swimming 
pool. He swam for a short while and then just seized up and sank to the bottom 
and lay there unmoving. I had to dive in and drag him out.” 
 
 Her daughter  – now 16 yrs: 
 “As a toddler, had many floppy episodes following play. Eventually went into 
hospital for week, but attacks did not occur. No diagnosis made. Tested for 
narcolepsy, revealed unusual brainwave pattern, but not connected to episodes.” 
 “Complains of pains in limbs after sport, especially in the arms.” 
 “Had disabling pain in legs as 8 yr old ?osteomyelitis, kept in hospital.” 
 “Age 15 had ?viral illness – couldn’t walk, pain in back too severe to move. MRI 
scan done, revealed Parr’s (sic) Process in formation of spine, but not responsible 
for inability to walk.” 
 “Age 13 -16 suffered intermittently with chronic fatigue type disorder, floppy 
aching limbs, nausea, headaches, GI disturbances. Missed a lot of school. 
Coincided with a passion for eating tomatoes.” 
 
 Her mother  – died in 1997, aged 79, cause of death: myocardial infarction  
 “My mother had persistent weakness, mostly I recall of her arms. She also was 
very fatigued, and needed to sleep during the day. I had little contact with her 
after the age of 18.” 
 
 Her brother – now 63 yrs: 
 “Left home as I was born, joined the Royal Navy, and settled in Scotland where 
he still lives. I do not know him very well.” 
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 “He is my half brother – we share a mother.” 
 “Admits he has suffered from a disabling pain and weakness condition for over 
30 years. Does not like to talk about it at present, but admits he has seen many 
doctors with no positive outcome. He is also very intolerant of illness, but spends 
his life having sporadic episodes of intense pain with weakness, which then ‘clear 
up’. He suffers daily now.” 
 
 Her maternal grandmother – died aged 36 yrs in 1930 
 “Was described as ‘very weak” 
 
Overall the majority of cases studied with a PMC or SCM phenotype could be genotyped 
by analysing known disease causing genes. A small minority however could not. Cases 3 
and 6 (Table 11) particularly case 3 have phenotypes very suggestive of a sodium channel 
myotonic disorder with EMG confirmation of myotonia but no mutation identified. Other 
genetic mechanisms e.g. large scale re-arrangements have not been excluded by the direct 
sequencing I performed and remain a plausible explanation. Such a large family however 
with several living generations of both affected and unaffected individuals offers an ideal 
opportunity to consider the possibility of a new disease causing gene. 
The four cases classed as a phenotype of hyperkalaemic periodic paralysis did have some 
atypical features and the majority of typical cases were again accounted for by mutations 
in SCN4A (and hence not selected for further study or described here). In one case a 
diagnosis of DM2 was made which was somewhat unexpected from the predominant 
complaint of episodes of severe muscle weakness although the description of myotonia 
would be consistent with this diagnosis. The remaining three cases were selected as other 
atypical phenotypes are beginning to be described including congenital myasthenia with 
periodic paralysis(Tsujino et al., 2003) and more recently an atypical periodic paralysis 
phenotype with a ryanodine receptor mutation(Zhou et al., 2010). The more of these 
atypical cases described and genotyped the clearer a picture of their phenotype will 
hopefully emerge, providing future guidance both in terms of diagnosis and 
understanding pathogenesis.     
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4.2 Genotyping hypokalaemic periodic paralysis 
 
All the mutations known to cause hypoPP had been noted to occur exclusively in the S4 
segments of either Cav1.1 or Nav1.4. The pathophysiology of hypoPP is incompletely 
understood but in 2007 an aberrant cation pathway was identified in two of the hypoPP 
SCN4A mutations by two independent groups(Sokolov et al., 2007; Struyk et al., 2007). 
It was proposed that this pathway was integral to the pathomechanism of disease and 
offered a possible explanation as to why the mutations seemed to exclusively affect 
voltage sensors. At this time only four of the eight voltage sensors of both channels had 
been implicated by pathogenic mutations. 
I hypothesized that if the aberrant cation pathway was integral to the disease mechanism 
then all voltage sensors could potentially be implicated in disease. I therefore sequenced 
the coding areas of CACNA1S and SCN4A that corresponded to all the voltage sensors 
in selected hypoPP cases in whom none of the common mutations had been found. 
By searching the channelopathy database I identified and screened a group of 83 patients 
with a clinical diagnosis of hypoPP. In 64 of these, previously reported common 
mutations, either R528G/H (25 cases) or R1239G/H (39 cases) in CACNA1S (DII/S4 and 
DIV/S4), were identified via the clinical diagnostic service. I analysed DNA from the 
remaining 19 cases. After confirming common mutations were negative I looked for the 
less common mutations in exons 12, 13 and 18 of SCN4A(DII/S4 and DIII/S4) known to 
also be associated with hypokalaemic periodic paralysis, hypoPP 2. Six of these were 
positive for mutations that have been reported previously, namely the substitutions 
R672C/H/S and R1132Q in SCN4A. This left 13/83 patients in whom the causative 
genotype was unknown. 
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Fig 20: Illustration of diminishing number of patients with a phenotype of hypoPP 
in whom no genetic diagnosis could be made with escalation of genetic analysis  
 
 
Hypokalaemic periodic paralysis – new mutations 
In 4/13 cases three novel mutations were found, all of which neutralized arginine residues 
in S4 segments. These mutations were absent from 240 control chromosomes. One 
mutation was in the S4 segment of domain III (DIII/S4) of CACNA1S: c.2700G>T; 
p.R900S. The other two mutations neutralized arginine residues in S4 segments of 
SCN4A; the first in DI c.664C>T;p.R222W and the second in DIII 
c.3404G>A;p.R1135H. R222W was found in two apparently unrelated kindreds. All four 
individuals with the new mutations had a typical HypoPP phenotype. Age at onset of 
attacks of muscle paralysis was in the second decade, with attacks usually occurring at 
night or in the early morning, and associated with low serum potassium levels or with 
provocative factors that would induce low serum potassium. The frequency and severity 
of attacks were not different from those in individuals with previously reported 
CACNA1S DIV/S4
CACNA1S DII/S4
SCN4A DII/S4 and DIII/S4
CACNA1S and SCN4A remaining S4 segments
Unknown
KCNJ2
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mutations. To my knowledge, these individuals received no pharmacologic therapy or 
potassium supplementation only. 
 
Fig 21: Electropherograms of new mutations with their relative positions in A: 
Cav1.1 and B: Nav1.4 shown alongside previously described hypoPP mutations. 
*mutations associated with an atypical phenotype of potassium sensitive 
normokalaemic periodic paralysis 
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I then analysed DNA from the remaining 9/13 cases for the entire coding region of 
CACNA1S and the coding regions of SCN4A that correspond to the S1-3 segments of 
Nav1.4. The incomplete sequencing of SCN4A was due to limited available DNA. I took 
a directed approach to the sequencing hypothesizing that if the voltage sensors 
themselves were not implicated it was possible that the S1-3 segments would be as 
theoretically this may produce a similar cation leak. I found no further mutations with this 
analysis. 
Finally I analysed the entire coding region of KCNJ2 associated with ATS. A novel 
mutation was identified in 1/9 cases. Control chromosomes were sequenced but none 
carried the mutation which was highly conserved and predicted to be a deleterious amino 
acid substitution. Eight cases remained in whom no mutation was identified. 
 
 
 
Gene Mutation No of Cases 
CACNA1S R528G/H 25 
CACNA1S R1239G/H 39 
CACNA1S R900S* 1 
SCN4A R672C/H/S 4 
SCN4A R1132Q 2 
SCN4A R222W* 2 
SCN4A R1135H* 1 
KCNJ2 V223E* 1 
Unidentified  8 
*denotes new gene mutations, not previously reported. 
 
Table 12: Summary of genetic results for 83 patients with a phenotype of hypoPP 
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Fig 22: Conservation across species, electropherogram and diagrammatic 
representation of Kir2.1 illustrating the novel sequence change V223E. 
 
 
Ninety percent of this cohort of hypoPP carried voltage sensor mutations that neutralized 
a key arginine residue. Not only does this data emphasise that there is a greater spread of 
residues (both intra and extracellular) and domains implicated in the pathogenesis of 
hypoPP but provides clear genetic support for the gating pore hypothesis. The remaining 
10% also display typical phenotypes however and while alternative genetic mechanisms 
remain unexplored this small but significant minority of patients is a tempting pointer to 
other disease causing genes.  
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Results – Treatment Response 
 
 
5.1 Genotype influences treatment response in hypokalaemic periodic paralysis 
 
The mechanism of action of acetazolamide in hypoPP is not understood although it is 
generally used as the first line therapeutic agent. Despite this there has never been a 
randomized controlled trial to determine its efficacy, partly due to logistical difficulties 
given the relative rareness of the disease. There have been several reports of patients with 
SCN4A mutations (hypoPP2) responding deleteriously to acetazolamide therapy. 
However other reports have disputed this. With the additional discovery of the aberrant 
cation leak (including protons) with certain Nav1.4 mutations it is feasible that disturbed 
pH homeostasis may offer a mechanism to explain why acetazolamide, a carbonic 
anhydrase inhibitor could be beneficial. However histidine substitutions were shown to 
produce a proton selective gating pore whereas glycine substitutions allowed a larger and 
less selective cation leak, suggesting any disruption in pH that occurs and therefore any 
amelioration offered by acetazolamide, may not be equal for all mutations. Whether a 
similar hypothesis applies to mutations of Cav1.1 is unclear as no functional work has yet 
been carried out to determine the presence or absence of a gating pore.    
 
Literature and patient review  
As my aim was to determine if genotype influenced the response to acetazolamide only 
cases of genetically confirmed hypokalaemic periodic paralysis were selected (cohort 1) 
from the published literature. Given the relative rarity of hypoPP, I conducted a literature 
search on Pubmed (www.ncbi.nlm.nih.gov) using the key terms “hypokalaemic periodic 
paralysis”, “periodic paralysis”, “acetazolamide” and “carbonic anhydrase inhibitors”. 
Only articles published in English in or after 1994 (when the genetic basis of hypoPP was 
identified) were considered. Articles meeting these criteria were reviewed and any 
reported treatment and treatment response were recorded (Table 13). The data in table 13 
was then used to summarise the response to acetazolamide by genotype (Table 14). Other 
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treatments were reported but only the response to acetazolamide was summarised as this 
was the most frequently used and the numbers treated with alternatives were very small. 
In order to create a comparison group to test the validity of the findings and to attempt to 
avoid introducing any bias, case records of patients with genetically confirmed hypoPP 
attending the neuromuscular clinic at NHNN under the care of Professor Hanna were 
reviewed (cohort 2) by a visiting fellow Dr Simona Portaro. Patients were reviewed at 
clinic on a six monthly or once yearly basis. Documented frequency, severity and 
duration of paralytic attacks before and after therapy with acetazolamide was analysed to 
ascertain response as either beneficial, detrimental or no change.  I used this data to 
summarise the response to acetazolamide by genotype in the same way as for cohort 1 
(table 15).  
Patients with SCN4A substitutions at the R675 position who had received acetazolamide 
therapy were identified in each cohort. The published phenotype of these mutations 
however has been described as potassium sensitive, normokalaemic periodic paralysis 
and not hypoPP. I met patients from a single kindred in cohort 2 carrying the R675G 
SCN4A mutation many times and they did also demonstrate potassium sensitivity and 
normal serum potassium levels during an attack of paralysis. As such they did not display 
a typical hypoPP phenotype and after consideration all patients carrying SCN4A R675 
substitutions were excluded from analysis as the aim was to determine the efficacy of 
acetazolamide in hypoPP as accurately as possible within the limitations of a 
retrospective analysis. 
 
 
Response to acetazolamide by genotype 
In cohort 1, 54% (21/39) of patients with a CACNA1S mutation treated with 
acetazolamide reported a beneficial response, compared with only 18% (3/17) of those 
with an SCN4A mutation. In the combined cohort this was a benefit for only 43% (24/56) 
of patients. However, if only patients with the most common HypoPP mutations (R528H, 
R1239H) were considered, the benefit improved to 59% (20/34). In cohort 2 the findings 
were similar; with 57% (8/14) of patients with CACNA1S mutations which also 
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represented the cohort as a whole, reporting a beneficial response. The positive response 
rate increased to 62% (8/13) when the R528H and R1239H group were considered alone.  
Closer evaluation of the relationship between precise genotype and treatment response 
showed that in both cohorts when one of the arginine residues located at the extracellular 
side of the sarcolemma (see Fig 21) was substituted for a glycine residue (R528G, 
R1239G, R672G), there was never a beneficial response to acetazolamide, and there was 
often a deleterious effect reported.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 23: Histogram depicting the response rate to acetazolamide by genotype for each 
cohort 
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This data is retrospective and imperfect, but it does provide some indication of response 
rates to acetazolamide and tentatively suggests a correlation with genotype i.e. R to H 
substitutions respond the best and R to G substitutions respond poorly. It is likely the 
poor response rate in the SCN4A group also reflects this as the amino acid substitutions 
are much more varied compared to the CACNA1S group where they are predominantly R 
to H. Overall however only approximately 50% of hypoPP patients are adequately treated 
by the current first line therapeutic agent, acetazolamide. This represents a significant 
unmet need in terms of treatment. Both randomized controlled trials and development of 
alternative therapies are required.  
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Gene Mutation No. of genotyped 
patients in series who 
received treatment 
Treatment Given Response to Treatment Ref 
CACNA1S R528G NS KCL Aborted attacks of paralysis (Wang et al., 
2005) 
CACNA1S R528G 1 Acetazolamide 250mg b.d + potassium salts 
Combination of spirinolactone 25mg b.d, 
amiloride 5mg b.d and potassium salts 
No response to acetazolamide 
Combination of diuretics and potassium 
reduced frequency and severity of attacks 
(Kil et al., 
2010) 
CACNA1S R528H 1 Low carbohydrate diet, potassium 40meq od 
and acetazolamide 250mg tds. 
Reduced frequency and severity of 
attacks. 
(Hecht et al., 
1997) 
CACNA1S R528H 4 
(1 kindred) 
Acetazolamide discontinued for a trial of 
verapamil versus placebo. 
Baseline response to acetazolamide not 
reported. Two patients reported 
significant improvement with verapamil, 
and two no response. 
(Links et al., 
1998) 
CACNA1S R528H 5 
(3 kindreds) 
Dietary modification(3pts) OR 
Acetazolamide(1pt) OR Spirinolactone(1pt) 
All patients attack free following 
treatment 
(Kim et al., 
2001) 
CACNA1S R528H 8 Acetazolamide Beneficial for 5 pts 
No effect on symptoms for 3 pts 
(Sternberg et 
al., 2001) 
CACNA1S R528H 1 Acetazolamide, Spirinolactone, Potassium 
Aspartate and Potassium Chloride 
Little effect on symptoms from any of the 
listed medications. 
(Kawamura et 
al., 2004) 
CACNA1S R528H NS Acetazolamide Beneficial for most pts treated. 
One reported worsening of symptoms 
(Miller et al., 
2004) 
CACNA1S R528H 5 
(no of kindreds NS) 
Acetazolamide Beneficial for 2 pts 
No effect for 3 pts 
(Kim et al., 
2007) 
CACNA1S R1239H 5 
(1 kindred) 
Acetazolamide and potassium supplements 
continued in 4/5 pts consenting to a trial of 
verapamil versus placebo 
Baseline response to acetazolamide not 
reported but no additional response to 
verapamil experienced. 
(Links et al., 
1998) 
CACNA1S R1239H 13 Acetazolamide Beneficial for 8 pts 
No effect on symptoms for 4 pts 
Deleterious effect on symptoms for 1 pt 
(Sternberg et 
al., 2001) 
CACNA1S R1239H 4 
(1 kindred) 
KCL and Acetazolamide Beneficial for 3 pts. 
No effect for 1 pt but medication taken 
irregularly 
(Kusumi et al., 
2001) 
CACNA1S R1239H NS Acetazolamide Beneficial effect for most pts treated (Miller et al., 
2004) 
CACNA1S R1239H 1 Acetazolamide No effect (Kim et al., 
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2007) 
CACNA1S R1239G 1 Spirinolactone 25mg bd Improved symptoms 
Note: 2 clinically affected cousins 
reported no effect with ACZ treatment 
but an improvement with spirinolactone. 
Genetic analysis was not performed on 
these 2 pts. 
(Kim et al., 
2005) 
CACNA1S R1239G 3 
(1 kindred) 
Acetazolamide OR a  
combination of spirinolactone, amiloride 
and potassium supplements 
No effect of ACZ for 2 pts 
Deleterious effect of ACZ for 1 pt but 
then treated successfully with a 
combination of diuretics and potassium 
supplements 
(Kim et al., 
2007) 
CACNA1S R897S 1 Potassium supplements 2-3mmol/kg/day 
and acetazolamide 5-10mg/kg/day 
Treated from age 2-6years. Frequency 
and severity of attacks reduced but 
duration of attacks increased. 
(Chabrier et al., 
2008) 
SCN4A “Sodium 
channel 
mutations”  
NO 
4 Acetazolamide Deleterious effect (Miller et al., 
2004) 
SCN4A R669H 2 Pt 1:  
Dietary regime, potassium supplements and 
a carbonic anhydrase inhibitor (not 
specified) 
Reduced frequency of attacks (Bulman et al., 
1999) 
   Pt 2:  
acetazolamide 250mg bd 
Attack free for 2 months then one severe 
attack responding to potassium infusion. 
No long-term response documented 
 
SCN4A R669H 1 Acetazolamide No response (Kim et al., 
2007) 
SCN4A R669H 1 Potassium supplements No attacks during 12 month follow up 
period 
(Maffe et al., 
2009) 
SCN4A R672G 3  
(1 kindred) 
Acetazolamide Deleterious effect (Sternberg et 
al., 2001) 
SCN4A R672G 1 Acetazolamide OR 
Combination of spirinolactone, amiloride 
and potassium supplements 
Deleterious effect of ACZ but then 
treated successfully with a combination 
of diuretics and potassium supplements 
(Kim et al., 
2007) 
SCN4A R672C NS Either acetazolamide 500mg a day OR 
dichlorphenamide 100mg a day 
Attack free for at least 6 months on 
average 
(Kim et al., 
2004) 
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SCN4A R672C 1 Acetazolamide No response  
SCN4A R672S 3  
(1 kindred) 
acetazolamide 
triamterene 
Severe quadriparesis within 12 - 60 hours 
of acetazolamide. 
Reduction in frequency and severity of 
attacks with Triamterene 
 
(Bendahhou et 
al., 2001) 
SCN4A R672S 1 Acetazolamide 250mg bd and spirinolactone 
100mg per day 
Reduced frequency of attacks (Davies et al., 
2001) 
SCN4A R672S 1 Acetazolamide 250mg per day and 
potassium taken at onset of attack or before 
strenuous exercise 
Reduced frequency of attacks (Venance et al., 
2004) 
SCN4A R675G 5  
(1 kindred) 
Acetazolamide 250mg per day 1 pt no response to 10 years continuous 
treatment  
4 pts reported a reduced duration of 
attacks with intermittent ACZ treatment 
(Vicart et al., 
2004) 
SCN4A R675Q 2 
(2 kindreds) 
Acetazolamide 500mg per day Pt 1: no benefit 
Pt 2: attack free since taking ACZ (length 
of treatment not documented) 
(Vicart et al., 
2004) 
SCN4A R675W 1 Acetazolamide 250mg per day Reduced frequency and severity of 
attacks 
(Vicart et al., 
2004) 
SCN4A R1132Q 1 Acetazolamide 
Potassium peri-attack 
No response to acetazolamide 
Potassium ingestion reduced duration of 
attack 
(Carle et al., 
2006) 
 
 
NS: Not Specified 
 
Table 13: Details of response to therapy for genetically confirmed cases of hypokalaemic periodic paralysis reported in the 
literature. 
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Table 14: Summary of response to acetazolamide by genotype for cohort 1 
(published cases) 
 
 
Table 15: Summary of response to acetazolamide by genotype for cohort 2 (UK 
cases)
Gene Mutation Total 
number of 
genotyped 
pts treated 
with ACZ 
Beneficial 
effect 
Deleterious 
effect 
No response 
CACNA1S All 
mutations 
39 21 2 16 
CACNA1S R528G 1 0 0 1 
CACNA1S R528H 16 9 0 7 
CACNA1S R1239H 18 11 1 6 
CACNA1S R1239G 3 0 1 2 
CACNA1S R897S 1 1 0 0 
SCN4A All 
mutations 
17 3 11 3 
SCN4A Mutations 
not specified 
4 0 4 0 
SCN4A R669H 2 1 0 1 
SCN4A R672G 4 0 4 0 
SCN4A R672C 1 0 0 1 
SCN4A R672S 5 2 3 0 
SCN4A R1132Q 1 0 0 1 
Gene Mutation Total 
number of 
genotyped 
pts treated 
with ACZ 
Beneficial 
effect 
Deleterious 
effect 
No response 
CACNA1S All 
mutations 
14 8 2 4 
CACNA1S R528H 6 4 2 0 
CACNA1S R1239H 7 4 0 3 
CACNA1S R1239G 1 0 0 1 
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Results - Pathophysiology 
 
6.1 How does neutralisation of an intracellular voltage sensor arginine of Nav1.4 
influence the pathomechanism of hypoPP? 
 
It is known that the common mutations in CACNA1S and SCN4A associated with 
hypoPP produce “loss of function” effects on the alpha pore of Cav1.1 and Nav1.4 
although this has failed to explain the mechanism of paradoxical membrane 
depolarisation of the muscle membrane in the presence of hypokalaemia. The gating pore 
hypothesis has offered some new insights into the pathophysiology of hypoPP. It is 
noteworthy however that not all the voltage sensors have equal numbers of positive 
charge and it is likely that each voltage sensor has additional specificities. As the voltage 
sensor moves across the membrane in response to changes in membrane potential it has 
been observed that mutations of variably placed arginines determine whether the aberrant 
gating pore occurs at depolarised or hyperpolarised potentials. 
Mutations of one arginine, R675G/Q/W in DII of Nav1.4 produce a unique phenotype of 
potassium sensitive normokalaemic periodic paralysis. Mutations of this arginine, which 
is placed more toward the intracellular side of the membrane, have recently been shown 
to create a cation leak at depolarised potentials(Sokolov et al., 2008). What is unknown is 
whether mutations of these inwardly placed arginine residues also produce a loss of 
function effect on the alpha pore.   
To investigate the function of the alpha pore, I carried out whole-cell patch clamp 
recording in cultured mammalian HEK293 cells. Patch clamp recordings were made from 
HEK cells co-transfected with human wild type SCN4A or a mutant construct containing 
the R675G mutation and cDNA encoding human SCN1B, the sodium channel beta 
subunit, which although not contributing directly to the main pore of the Nav1.4 channel, 
has been shown to be important for regulating sodium channel function(Isom., 2001). 
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Effects of R675G on the Nav1.4 alpha pore 
 
 
 
 
Fig 24: Comparison of activation, inactivation, peak current and current density 
observed for the R675G mutation and WT Nav1.4 
 
 
A significant reduction (6 fold) in peak current and current density was observed for the 
mutant in comparison to the wild type (Figure 24). There was no difference in the voltage 
dependence of activation. There was a suggestion of enhanced inactivation for the mutant 
but this was not significant, partly because the small currents produced by SCN4A-
R675G were too close to the noise threshold for accurate measurements of inactivating 
currents. 
WT Nav1.4
R675G
-0.2
0
0.2
0.4
0.6
0.8
1
-70 -50 -30 -10
Voltage (mV)
N
o
rm
a
lis
e
d
 c
u
rr
e
n
t
-0.2
0
0.2
0.4
0.6
0.8
1
-110 -90 -70 -50 -30
Voltage (mV)
N
o
rm
a
lis
e
d
 c
u
rr
e
n
t
10ms
1
n
A
0
1000
2000
3000
4000
WT R675G
C
u
rr
e
n
t 
d
e
n
s
it
y
 (
p
A
)
-4000
-3500
-3000
-2500
-2000
-1500
-1000
-500
0
-100 -80 -60 -40 -20 0
Voltage (mV)
C
u
rr
e
n
t 
(p
A
)
N
o
rm
a
lis
e
d
 c
u
rr
e
n
t
N
o
rm
a
lis
e
d
 c
u
rr
e
n
t
1
n
A
1
n
A
C
u
rr
e
n
t 
d
e
n
s
it
y
 (
p
A
)
C
u
rr
e
n
t 
d
e
n
s
it
y
 (
p
A
)
C
u
rr
e
n
t 
(p
A
)
 106 
The large reduction in peak transient currents is consistent with the effects on the alpha 
pore observed for extracellular voltage sensor mutations (R669H, R672G/H/S). All of 
these mutations give reduced current density accompanied by small or non-significant 
effects on inactivation. The 6-fold reduction in current density for R675G was greater 
than that reported for the other mutants (2 to 4 fold reduction).The small differences in 
the kinetics of inactivation introduced by these mutants have been discussed in the 
literature, and there is a consensus that these kinetic changes cannot explain the 
significant reduction in current density that is observed(Struyk et al., 2000; Kuzmenkin et 
al., 2002). Although alternative hypotheses have been postulated, such as altered protein 
folding or trafficking, no work has been carried out to date to address this specific 
question. 
In channels containing mutations affecting external arginines, the gating pore current has 
been estimated to be between 1% and 0.02% of the current through the main alpha 
pore(Cannon., 2010). Given the significantly reduced current density seen in R675G of 
approximately 500pA, any leak current of this size would not have been detectable in 
these recordings, as the noise inherent to whole cell currents is greater than 5 pA rms (1% 
of 500 pA).For this reason although my data show a robust loss of peak current through 
the alpha pore, I was unable to assess whether the R675G mutation also introduced a leak 
current. 
 
6.2 Developing a human myoblast expression system 
 
All published work examining gating pore currents from SCN4A mutants has been in 
xenopus oocytes where very large currents can be obtained. I carried out recordings in 
HEK cells, which allow accurate clamping of peak alpha pore currents, but the total 
current amplitudes were not sufficient for investigation of leak currents. While both of 
these model systems have advantages, they may not replicate the physiology of muscle 
cells sufficiently to recapitulate the mechanism of muscle channelopathies. For example, 
mutations in SCN4A may be modified by endogenous accessory subunits present only in 
muscle cells, or muscle cells may have specialized trafficking or expression machinery 
for regulating highly-expressed channels like SCN4A. In addition the pathology of 
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SCN4A mutations may involve buffering (possibly via carbonic anyhydrases inhibited by 
acetazolamide). Neither HEK cells or xenopus oocytes would test these sorts of muscle-
specific mechanisms. Therefore, I investigated whether it was possible to culture human 
myoblasts and record currents in patch clamp configuration.  
Preliminary recordings were made using a myoblast culture from a healthy control 
teenager that was kindly donated by Dr Carl Adkin working at the Dubowitz 
Neuromuscular Centre. It was established that robust sodium currents can be recorded in 
these cells. Recordings made from isolated myoblasts plated on coverslips for only 48-72 
hours allowed identification of modest sodium currents (Fig 25). When the voltage 
dependence of activation and inactivation of this current was compared with current 
obtained from HEK cells transfected with wild type Nav1.4 there were no detectable 
significant differences (see figure 25). 
 In addition to determine whether SCN4A was expressed endogenously in these cells I 
extracted RNA from an aliquot of the same myoblast culture and performed reverse 
transcription PCR. The cDNA obtained from this procedure underwent further PCR using 
primer pairs specific for SCN4A cDNA. An SCN4A clone was used as a positive control 
and genomic DNA as a negative control. Fragments of anticipated size for SCN4A cDNA 
were amplified for the SCN4A clone and cDNA obtained from the myoblasts. No product 
was obtained from the genomic DNA confirming the SCN4A gene was expressed in the 
cell culture which is consistent with Nav1.4 channels having contributed to the sodium 
current recorded 
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Fig 25: Current density and voltage dependence of activation and inactivation of 
sodium currents obtained after 48-72hours of human myoblasts in culture 
compared with HEK cells transfected with WT Nav1.4. 
 
 
Culture time influenced the density of sodium current and also the voltage dependence of 
activation. There is a much larger sodium current (average 6nA) and a left shift in 
activation of sodium current recorded from more mature myoblasts (day 10) which is 
likely to reflect a contribution to the overall current from both Nav1.4 and Nav1.5 (which 
has a left shift of activation of approx 10-15mv compared to Nav1.4). These preliminary 
experiments have indicated low sodium extracellular solutions will be required to reduce 
sodium currents and to provide better clamp of the sodium current seen in mature 
myoblasts. In addition, given the likely contribution of the Nav1.5 channels, it may be 
necessary to apply tetrodotoxin to quantify the relative contributions of Nav1.4 (TTX 
sensitive) and Nav1.5 (TTX insensitive) to the overall sodium current. 
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Although myoblasts potentially offer a system for recapitulating much more of the 
muscle cell physiology, there are many technical considerations to be made and 
optimized before a myoblast system may be used to study the gating pore in voltage 
sensor mutations of Nav1.4. A major hurdle will be the need for obtaining muscle 
biopsies from willing patients who carry these mutations. However the early recordings 
made suggest endogenous Nav1.4 is expressed, and consequently characterization of 
sodium currents in these cells may be a viable albeit technically challenging future 
project.  
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Discussion - Phenotype 
 
Aim  
 
To examine the phenotype of the skeletal muscle channelopathies in patients referred to 
the NCG service for channelopathies at the NHNN to determine 
c. if there were any clinically useful phenotype-genotype correlations that 
could be made and  
d.  if there were more extensive aspects to the phenotypes than is currently 
recognised. 
 
 
Meeting patients through both the specialist muscle clinic and the natural history trial of 
non-dystrophic myotonia combined with analysis of the existing channelopathy database 
was an enormously valuable and rewarding experience. Using this approach I was able to 
identify several unexplored aspects of the phenotype that had clinically relevant 
correlations. 
 
7.1 Observation of neonatal hypotonia in paramyotonia congenita due to the I693T 
SCN4A mutation 
 
Neonatal paramyotonia congenita often presents with myotonic phenomenon when an 
infant cries or is washed, especially with cool water(Eulenberg A., 1886). Despite the 
recognition that myotonic symptoms may present at birth, this was not generally 
considered to be particularly detrimental to the neonate or to require any specific 
consideration in counseling expectant mothers. Recently a rare lethal neonatal 
paramyotonia case with extreme sensitivity to cold was reported and attributed to an 
SCN4A mutation (N1297K)(Gay et al., 2008). However, neonatal hypotonia had not 
been recognised as a clinical manifestation of muscle sodium channel dysfunction. The 
observations I gathered in the six individuals studied from four unrelated French and 
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English families indicate that neonatal hypotonia with additional symptoms of poor 
feeding and respiratory distress can be a manifestation of muscle sodium channel 
dysfunction common to individuals with the I693T sodium channel mutation. 
Pathological muscle hypotonia is an important neonatal presentation and can be a sign of 
either a peripheral or central abnormality. Careful diagnostic assessment and often 
multiple investigations are required(Laugel et al., 2007). Recognition of a sodium 
channel mutation as a cause of neonatal hypotonia may prevent unnecessary and invasive 
investigations. For example, a muscle biopsy is very unlikely to be contributory. EMG 
assessment has been shown to be beneficial in adults if performed according to specific 
protocols(Fournier et al., 2006; Fournier et al., 2004) but these are not easily applicable 
in neonates. 
Treatment in all the cases studied was supportive as symptoms were self-limiting but it is 
important to recognize that symptoms may be cold-triggered and temperature dependent, 
indicating, a constant warm ambient temperature is essential in such cases.  
All cases studied carried the I693T mutation. The detrimental effects of the I693T 
mutation on sodium channel gating are similar to other PMC mutations i.e. the overall 
effect is one of impaired inactivation(Plassart-Schiess et al., 1998). These detrimental 
effects were exacerbated in vitro by cold temperature but this is not an exclusive finding. 
Whether the association of neonatal hypotonia is entirely specific to the I693T mutation 
is not yet clear. Paramyotonia congenita is rare and it may be that neonatal hypotonia has 
occurred in infants carrying other mutations but the direct association with PMC not been 
made or reported.  
 
 
7.2 Stridor expands the neonatal presentations of skeletal muscle sodium 
channelopathy 
 
Initially it was hard to determine from a single case if the occurrence of stridor in the 
child with PMC was related to PMC itself. However discussion with Dr Damien 
Sternberg in France and his observations of stridor in two other cases was very suggestive 
and hypothetically it seemed likely that stridor could reflect laryngeal myotonia. 
 112 
Hyperkalaemic periodic paralysis (HyperPP) is a dominantly inherited disorder which is 
allelic to PMC and is characterised by episodes of muscle weakness and myotonia, 
although weakness is the predominant symptom(Venance et al., 2006). In both these 
disorders gene mutation results in a “gain of function” sodium channel defect. It has been 
proposed that the two disorders reflect ends of a spectrum of the same disease(Cannon., 
2006). 
Stridor has been described in patients with myotonic dystrophy, in both neonates and 
adults.(Heuschkel et al., 2003; Ahmadian et al., 2002) In addition there are several 
reports of stridor in American Quarter horses affected by the equine form of 
hyperkalaemic periodic paralysis (HyperPP). In one series 63/68 affected horses suffered 
stridor in association with exertion, muscle weakness or excitement(Carr et al., 1996). 
There is also one case report of an adult with PMC in whom provocative testing with 
muscle cooling induced severe laryngeal myotonia with stridor(Ferriby et al., 2006). 
Overall it is likely the stridor reflects myotonia of the laryngeal muscles.  In addition, the 
child described experienced feeding and respiratory difficulties which were also noted in 
the cases of neonatal hypotonia suggesting these are common neonatal features of PMC. 
Dysphagia and respiratory compromise are rarely reported in adult cases(Lerche et al., 
1993).  
Following on from the observations here, another report has recently been published of 
severe neonatal laryngospasm occurring in three neonates carrying de novo SCN4A 
mutations (G1306E and A799S). These infants had life threatening episodes of stridor 
with apnoea and feeding difficulties. Symptoms responded to sodium channel blockers 
although in one infant the diagnosis was made posthumously(Lion-Francois et al., 2010).  
Taken together these observations of hypotonia and stridor with resultant feeding and 
respiratory difficulty indicate that offspring of parents with sodium channel mutations are 
at risk of neonatal complications. This is an important development in understanding the 
phenotypes of skeletal muscle sodium channelopathies and should be reflected 
accordingly in the advice given to patients considering having children and the relevant 
clinicians involved in their delivery and early post-natal care.  
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7.3 Observation of inflammatory infiltrates in skeletal muscle channelopathies  
 
The natural history of the skeletal muscle channelopathies is not extensively documented 
but development of a proximal myopathy is established particularly in the periodic 
paralyses(Becker PE., 1977; Nagamitsu et al., 2000; Miller et al., 2004; Links et al., 
1990; Bradley et al., 1990; Plassart et al., 1996; Vicart et al., 2004). Whether the 
myopathy is related to the severity and frequency of paralytic attacks is unclear(Buruma 
et al., 1978; Links et al., 1990) but there is some evidence that its development may be 
associated with increasing age(Links et al., 1990; Plassart et al., 1994). In addition it is 
common for moderate to severe myalgia to be reported(Rosenfeld et al., 1997; Ptacek et 
al., 1994b; Colding-Jorgensen et al., 2006; Vicart et al., 2004; Fialho et al., 2007) and 
moderately raised creatine kinase(1-2000U/L)(Links et al., 1990; Colding-Jorgensen et 
al., 2006; Plassart et al., 1996; Fialho et al., 2007) to be noted in the skeletal muscle 
channelopathies although there is no evidence to link these to the presence or absence of 
myopathy.  
A characteristic history in conjunction with specialised neurophysiologic 
techniques(Fournier et al., 2004) allows for a diagnosis in the majority of cases of 
skeletal muscle channelopathy and it is rare that a diagnostic muscle biopsy is now 
performed in the UK. 
In the three cases I studied a clinical diagnosis of skeletal muscle channelopathy had been 
made prior to the muscle biopsy and was later genetically confirmed. Biopsy was 
performed due to additional clinical features that were deemed unusual or severe for a 
muscle channelopathy. In case one the proximal myopathy could have been attributed to 
the myopathy that is reported in periodic paralysis but the very high CK (2729U/L) was 
atypical for this. The severe myalgia and moderate elevation of CK (1109U/L) reported 
in case two are also described features of the channelopathies and it is possible that at 
least some of the myalgia is due to myotonia. However as the myalgia became severe 
enough to be the patient’s primary complaint a biopsy was performed. The initial 
complaint of muscle swelling in case three is not a typical feature of the muscle 
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channelopathies and with the later development of significant myalgia a biopsy was felt 
to be warranted. Collectively the clinical features of weakness, myalgia and significantly 
elevated CK in these three cases suggest that these symptoms are secondary, at least in 
part, to the observed inflammatory process.  
The biopsy findings in these cases did not fulfil all morphological criteria for IIM, 
particularly the lack of invasion of intact fibres. However upregulation of MHC class I 
expression (case I and III) is supportive and it is not unreasonable that a diagnosis of IIM 
had been made in these cases, especially when each was considered in isolation. There 
are numerous examples of other genetic muscle disorders in which inflammatory 
infiltrates have been observed and even  diagnosed as IIM(Tidball et al., 2005). It is 
impossible to exclude the possibility that the observed inflammatory process is a co-
incidental finding and two independent pathologies (channelopathy and IIM) are present 
in each of the three individuals, but statistically this seems unlikely.  
Whether this inflammatory response plays a potential pathogenic role in the development 
of the myopathy is not known. Morphology data is reported for the skeletal muscle 
channelopathies, especially the periodic paralyses, but in many cases pre-dates the 
availability of genetic testing. A vacuolar myopathy and or tubular aggregates support the 
diagnosis of periodic paralysis. With improved electrophysiological and genetic 
diagnostic methods muscle biopsy is now less common. Without a larger number of 
biopsy samples from similar cases it is not possible to know how accurately 
inflammatory muscle infiltrates may correlate to clinical presentation. 
Although there was some improvement in symptoms and a reduction in CK with 
prednisone in two cases, in one case high dose prednisone induced a severe paralytic 
attack, although low dose steroids were better tolerated. Worsening of the paralytic 
symptoms of periodic paralysis with glucocorticoids has been reported(rzel-Hezode et al., 
2009a). Other immunosuppressive agents had no clear additional benefit in any of the 
three cases. 
Based on these observations it is reasonable to propose that a diagnostic muscle biopsy 
should be considered in cases of skeletal muscle channelopathy presenting with the 
symptoms of severe myalgia and/or sub acute weakness and an accompanying  elevated 
CK (>1000U/L) to ascertain the presence of any inflammatory infiltrates. The therapeutic 
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benefit of immunosuppressants is not established by this small number of cases but they 
do tentatively indicate steroids could have a role. The optimal dose however is 
undetermined and higher doses may be detrimental.  
The statistical evidence indicates that the co-existence of an inflammatory process and 
skeletal muscle channelopathy is very unlikely to be co-incidental. The possible 
implications this may have for understanding of the mechanisms of muscle damage in the 
skeletal muscle channelopathies will require future exploration. 
 
7.4 Pain and morbidity in the non-dystrophic myotonias 
 
There are almost no studies reporting on the morbidity or quality of life in any of the 
skeletal muscle channelopathies. It was a personal observation that many of the patients I 
met however did report pain as a prominent feature of their illness. Data gathered from 
the patients I studied in the UK arm of the natural history study in the NDMs has 
illustrated pain is a common and prominent aspect of the clinical presentation. It also 
seems to be significantly more common in sodium channelopathies compared with 
chloride channelopathies. These findings support those recently published in one of the 
very few studies that has attempted to analyse morbidity in the channelopathies(Trip et 
al., 2009a). This is very suggestive that pain has been an under-recognised and 
potentially undertreated feature of the muscle channelopathies. These illnesses have often 
been considered to be benign but this data together with the increasing evidence for 
development of myopathy in the literature(Links et al., 1990; Buruma et al., 1978; Miller 
et al., 2004; Nagamitsu et al., 2000) would indicate quality of life deserves more 
consideration. Pain was not exclusively related to symptoms of muscle stiffness 
(myotonia) so it is not entirely clear if treating the myotonia would abolish all pain. 
However this early data does suggest the presence of pain should be a considered factor 
when assessing the benefits or initiation of drug therapy for the NDMs. Analysis of the 
combined cohort of patients across all centres participating in the natural history study 
will be important to further address this issue. 
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Conclusions: Phenotype 
 
1. Neonatal phenotypes of the skeletal muscle sodium channel myotonic disorders 
exist. Severity is variable. Symptoms include hypotonia with feeding and 
respiratory difficulties (including stridor) that is transitory and requires supportive 
care only. Others support the recognition of neonatal phenotypes and have 
additionally reported severe presentations of myotonia, feeding and respiratory 
difficulties (including stridor) that can be fatal. 
2. Inflammatory changes occur in the muscle biopsies of some channelopathy 
patients that statistically seem unlikely to be co-incidental although the exact 
significance and any influence this may have on the development of myopathy 
requires further exploration. 
3. Pain is an under-recognised feature of the skeletal muscle channelopathies and 
morbidity associated with these diseases deserves more consideration. 
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Discussion - Genotype 
 
Aim 
 
To genetically characterize patients to assess if new mutations in known genes existed 
and if these genes could account for 100% of a carefully phenotyped cohort or if new 
genes may be implicated. 
 
 
8.1 Genotyping the sodium channel myotonic disorders 
 
Paramyotonia congenita and sodium channel myotonia 
Of the 17 patients identified with a phenotype consistent with a sodium channel myotonic 
disorder, I considered 13 to have PMC or SCM. Of this group 9/13 was genotyped. 
Previously reported SCN4A mutations (V1293I, Q270K and E1702K) were identified in 
four(Koch et al., 1995; Fournier et al., 2006; Miller et al., 2004) and another three had 
novel amino acid substitutions (L128P, V445L and M135L) although it is probable only 
L128P and V445L are pathogenic and possible that M135L is a rare polymorphism. 
Mutations in SCN4A responsible for myotonic phenotypes appear to affect amino acids 
distributed randomly across the protein with no discernible pattern. The novel changes 
found here illustrate it is likely that new mutations will continue to be reported 
throughout SCN4A. Although exons 13, 22 and 24 represent mutation hotspots screening 
of the entire coding region of SCN4A is still required to make a genetic diagnosis in a 
significant number of patients. 
Of the remaining two patients who were genotyped one carried a CLCN1 mutation. This 
illustrates the difficulty that remains, despite more advanced electrophysiological tests, in 
differentiating some cases of sodium channel myotonia from chloride channel myotonia 
clinically. One group genotyped 93% of their cohort of patients with NDM by employing 
in tandem analysis of SCN4A and CLCN1(Trip et al., 2008). This highlights a real need 
for both genes to be analysed if the first is negative. 
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The final patient was an atypical case under the care of paediatric colleagues, consultant 
paediatrician Dr Elizabeth Wraige. The patient was an infant who had been well until 
approximately four months of age. They were then admitted to intensive care in 
respiratory distress that required long-term tracheostomy. The child was noted to be 
“stiff” and a first EMG suggested difficulty in differentiating between myotonic 
potentials and pseudomyotonic potentials. A trial of mexiletine was initially felt to be 
helpful but later withdrawn as any benefits seemed to plateau. As a result SCN4A 
analysis was undertaken by me but no pathogenic changes were found. A second EMG 
later confirmed pseudomyotonic potentials. An initial biopsy at 5 months was non-
specific but a second biopsy at 6 months of age showed changes of myofibrillar 
myopathy. Many parallels were noted between this child and a group of Indian-Canadian 
children who had been described years earlier as having autosomal recessive fatal 
hypertonic muscular dystrophy although no genetic diagnosis had been reached(Lacson et 
al., 1994). 
As muscle biopsy suggested a myofibrillar myopathy analysis of associated genes was 
undertaken by the NCG genetic laboratory at Newcastle. A homozygous mutation was 
identified in the CRYAB gene(Forrest et al., 2011). Attempts had been made to contact 
the authors of the original hypertonic muscular dystrophy paper but were unsuccessful. 
Shortly after the identification of the CRYAB mutation in this infant the same 
homozygous CRYAB mutation was identified in the Canadian cohort(Del Bigio et al., 
2011). 
From the work done in this thesis and reports in the literature neonatal channelopathy 
phenotypes of varying severity are emerging. This includes fatal cases characterised by 
myotonia, respiratory and feeding difficulties(Gay et al., 2008). Although the infant 
above ultimately displayed evidence of a myofibrillar myopathy the initial presentation 
was potentially in keeping with the described sodium channel neonatal phenotypes. It 
suggests SCN4A analysis should still be considered in similar cases as the number of 
reported neonatal cases and extent of the neonatal phenotype may continue to expand. 
 
The 4/13 patients with a myotonic phenotype in whom no mutation was identified all had 
EMG confirmed myotonia. Of these four, one was an infant being investigated for 
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hypotonia and the EMG myotonia was an unexpected finding. Brief bursts of myotonia 
are seen in other myopathies(Milone et al., 2012) including congenital myopathies and 
the myotonia in this case may ultimately be accounted for in this way, although no 
definite diagnosis has yet been reached. 
The other three cases however, had phenotypes that can be considered strongly consistent 
with non-dystrophic myotonia. Only direct automated sequencing of the coding regions 
of SCN4A and CLCN1 was undertaken. It is possible gene deletions or duplications may 
occur and would not have been picked up by this method. Recently a pathogenic intron 
change has been described in SCN4A in a family with PMC(Kubota et al., 2011). This 
particular change would have been detected as it was close to the intron/exon border and 
the primers I designed overlapped these regions. However other deeper intron changes 
have not been excluded nor have changes in the promoter region of the gene. A final 
possibility is that other myotonia genes exist. One of the non-genotyped cases came from 
a large Sicilian family and a future project could examine linkage in this family to assess 
the possibility. 
 
Hyperkalaemic periodic paralysis 
In the group of 17 patients with a sodium channel myotonic phenotype I identified four 
patients with a phenotype consistent with hyperkalaemic periodic paralysis. In 1/4 I 
identified a pathological expansion of the ZNF9 gene consistent with a diagnosis of 
DM2. This patient was described as having episodes of muscle paralysis since childhood, 
triggered by cold, antihistamines, and corticosteroids. She also complained of paralysis of 
the respiratory muscles and bladder, with fasciculations and myotonia noted during 
episodes. Her mother had the same symptoms, her father was unaffected. Her brother was 
noted to have muscle hypertrophy and an elevated CK. 
The other three cases had some atypical features for hyperkalaemic periodic paralysis and 
it is perhaps not surprising that they do not carry any mutations in SCN4A. During my 
thesis I was asked to sequence another patient with atypical hyperkalaemic periodic 
paralysis by Prof Francesco Muntoni (consultant paediatrician) in whom his team had 
identified a ryanodine receptor gene mutation. This patient had no pathogenic SCN4A 
mutations and functional expression work carried out by Prof Muntoni’s team confirmed 
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the pathogenicity of the RYR1 gene mutation(Zhou et al., 2010). This case illustrates 
however that atypical cases of hyperkalaemic periodic paralysis and potentially other 
muscle channelopathies may reflect new disease causing genes. Additionally the 
identification of an abnormal expansion of the ZNF9 gene in the fourth case of 
hyperkalaemic periodic paralysis I studied was unexpected and emphasises the need to 
reflect on these atypical cases. As more are identified, common phenotypic features may 
help to group some together and aid in the future identification of additional disease 
causing genes. 
   
 
8.2 Genotyping hypokalaemic periodic paralysis 
 
The new mutations found in CACNA1S and SCN4A in patients with a phenotype of 
hypokalaemic periodic paralysis significantly expands the spectrum of S4 segment 
arginine mutations which cause HypoPP and adds new genetic evidence to support the 
hypothesis that loss of positive charge in S4 voltage sensors is important in the molecular 
pathogenesis of this muscle channelopathy. Overall, the 74/83 HypoPP cases genetically 
characterized by voltage sensor charge loss argue that arginine mutations in the voltage 
sensors of both channels are the overwhelmingly most important cause of HypoPP. These 
results, furthermore, suggest that screening for arginine mutations in S4 segments should 
yield a genetic diagnosis in approximately 90% of cases of HypoPP.  
It remains unclear how S4 mutations lead to the HypoPP phenotype. Previous functional 
studies of the effect of the CACNA1S/SCN4A S4 mutations on the gating properties of 
the main pore all pointed to a loss of function defect(Lapie et al., 1996; Morrill et al., 
1999; Struyk et al., 2000; Kuzmenkin et al., 2002; Carle et al., 2006). However, such a 
loss of function mechanism does not readily explain the prolonged depolarization of the 
sarcolemmal membrane associated with attacks of paralysis or the episodic occurrence of 
hypokalaemia(Cannon., 2006). The individual contribution of each S4 segment to 
channel gating is not yet fully understood. Current evidence suggests that the S4 
segments of DIII and IV of Nav1.4 play a more significant role in fast inactivation(Cha et 
al., 1999). It is therefore of interest to note that replacement of the outermost arginine in 
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DIV/S4 of SCN4A does not produce a HypoPP phenotype but rather one of 
paramyotonia congenita(Ptacek et al., 1992). In contrast, replacement of the third 
outermost arginine in DII/S4 of SCN4A produces a potassium-sensitive periodic 
paralysis(Vicart et al., 2004). Only one non-arginine substitution has been described in an 
S4 segment of either channel, G1456E[SCN4A] also in domain IV, which resulted in a 
phenotype of paramyotonia congenita(Sasaki et al., 1999).  
Two recent studies have suggested that a gating pore current may be important in the 
pathogenesis of HypoPP(Struyk et al., 2007; Sokolov et al., 2007), and this data is fully 
consistent with this hypothesis.  
In response to depolarizing voltages, S4 segments undergo a conformational change that 
moves these segments outwards through a gating pore (omega pore) which leads to the 
opening of the central pore of the channel (alpha pore). The outermost arginines in S4 
occupy and occlude the narrowest part of the gating pore at the resting membrane 
potential while internal arginine residues occlude it at depolarized potentials. Recently, it 
was shown that in addition to disrupting the gating of the main pore 
(alpha pore), mutations that neutralize the two outermost arginines (R669/R672) in 
DII/S4 of Nav1.4 also generate a monovalent cation leak through the gating pore at 
hyperpolarized potentials(Sokolov et al., 2007). A histidine substitution at R672 produces 
a proton specific pore leak whereas other amino acid substitutions at this position cause a 
nonselective cation leak(Struyk et al., 2007). The leak current is thought to be mainly 
mediated by protons and could contribute to the pathophysiology of HypoPP, possibly by 
an accumulation of intracellular protons and disruption of the intracellular homeostasis of 
pH. Consistent with the role of arginines in occluding the gating pore, a 10-fold larger 
leak current occurs with a glycine substitution compared with the histidine substitution at 
R663 in the rat isoform of Nav1.4 (comparable to R669 in the human isoform)(Struyk et 
al., 2007).  
The finding of additional mutations that affect S4 arginines adds to the possibility these 
arginines play a central role in HypoPP. Furthermore, it expands the number of channel 
domains and the range of arginines affected, notably including arginines buried more 
deeply in the channel. In the Shaker potassium channel, replacing more intracellular 
arginine residues with histidine residues has been shown to produce proton leak currents 
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at depolarized potentials in contrast to substitutions of outer arginines that generate leak 
currents at hyperpolarized potentials(Starace et al., 2001). If the mutation of intracellular 
arginines associated with hypoPP leads to similar changes in SCN4A, then patients with 
mutations affecting these residues may have leak currents at depolarized potentials rather 
than at rest. Functional characterization of these new mutations will be important for 
determining the pathophysiological effect of these more intracellular arginine residues. 
In summary, the results obtained by sequencing all S4 segments of SCN4A and 
CACNA1S has shown that new mutations do exist, additional S4 segments are implicated 
in disease pathogenesis, and enabled the identification of a mutation in 90% of patients, 
adding significant genetic evidence to support the gating pore hypothesis. 
 
Sequencing the entire coding region of CACNA1S and the remaining sequence of 
SCN4A coding for all S1-3 segments in the remaining nine cases did not add any new 
information. I did hypothesise that neutralisation of key negative charges in the S1-3 
segments that interact with the positive charges in the voltage sensors to maintain the 
integrity of the omega pore could also produce an aberrant leak current that may be 
responsible for some cases of hypoPP. No such mutations were found but only a small 
number of genetically unexplained samples remained (nine cases) and it is still possible 
such mutations will be found if larger numbers of similar cases are sequenced. 
Analysis of the coding region of KCNJ2 identified a novel change in 1/9 remaining cases. 
Mutations of KCNJ2 are associated with Andersen-Tawil Syndrome. This is the only 
skeletal muscle channelopathy that also has systemic features and is characterised by the 
triad of periodic paralysis, dysmorphic features and cardiac conduction defects although 
two out of three is considered acceptable for diagnosis(Venance et al., 2006). The 
dysmorphic features can be very subtle and the cardiac conduction defects may be 
asymptomatic so it is not surprising that occasionally, as in this case, patients are 
diagnosed clinically as hypokalaemic periodic paralysis only. This has important 
implications however as hypoPP is not associated with conduction defects whereas ATS 
is. These conduction defects are often significant and in some cases fatal so it is essential 
this diagnosis is not missed. The conduction defects can be asymptomatic but the resting 
ECG may still show abnormalities(Venance et al., 2006). Overall this data suggests that 
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ATS should be considered in all otherwise unexplained cases of hypoPP, prompting 
performance of a resting ECG and consideration of genetic testing. 
 
Eight cases of hypoPP remain in whom no genetic diagnosis was made. The same genetic 
mechanisms that could explain the unidentified myotonic cases, i.e. gene re-
arrangements, intron or promoter region changes are also relevant to these hypoPP cases. 
The possibility of new genes however is tantalising. A shared observation between all the 
known hypoPP genes (CACNA1S, SCN4A, KCNJ2) is that they all impair inward 
rectifying potassium channel current. Mutations of KCNJ18 have recently been identified 
as the cause of some cases of thyrotoxic periodic paralysis and more recently sporadic 
cases of hypoPP. Future projects could analyse the remaining 8 cases identified here for 
this and other potassium channel gene mutations. 
 
 
Conclusions: Genotype 
 
1. The number of new mutations in known causative genes associated with sodium 
channel myotonic disorders, hypoPP and ATS continues to expand. 
2. Most typical cases of each phenotype are accounted for by known genes but a small 
minority are still genetically unexplained. This may represent a. unexamined genetic 
mechanisms or b. new genes. 
3. More atypical phenotypes tend not to be accounted for by known genes. These cases 
deserve further consideration. 
4. The large proportion of hypoPP cases accounted for by voltage sensor mutations 
supports the recently proposed  “gating pore hypothesis” disease mechanism. 
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Discussion – Treatment 
 
Aim 
 
To assess if genotype has any influence on response to treatment with acetazolamide in 
hypokalaemic periodic paralysis. 
 
9.1 Genotype influences treatment response in hypokalaemic periodic paralysis 
 
There are no consensus guidelines for the treatment of hypoPP. Current pharmacological 
agents commonly used include potassium supplements, potassium sparing diuretics and 
carbonic anhydrase inhibitors (acetazolamide and dichlorphenamide). Dichlorphenamide 
is the only therapy for hypoPP to have undergone a randomised double blind placebo 
controlled cross over trial. This trial showed a significant efficacy of dichlorphenamide in 
reducing attack frequency but the inclusion criteria were based on clinical diagnosis of 
hypoPP and not genetic confirmation(Tawil et al., 2000). Aside from this there is very 
little trial evidence to support the use of any treatment in hypoPP and no randomised 
controlled trial evidence supporting the most common choice; acetazolamide (Sansone et 
al., 2008). 
The data gathered in this thesis from a literature review of cases and retrospective 
analysis of our own patients suggest that at least half the patients treated with 
acetazolamide do not get a satisfactory response. A tentative correlation between 
detrimental response and genotype does emerge and those patients with substitutions to 
glycine of arginine residues situated towards the extracellular side of the voltage sensors 
of either Cav1.1 or Nav1.4 may be predicted not to respond to acetazolamide. The 
highest response rates were seen in the common CACNA1S arginine(R) to Histidine(H) 
substitutions. These observations are particularly noteworthy in light of experimental data 
indicating that the deleterious effects of the R672G substitution on channel gating are 
insensitive to reductions in pH in vitro. This is in contrast to the deleterious effects of the 
R669H mutation which were ameliorated by an acidic pH. These in vitro observations 
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predict that such patients would not respond to acetazolamide which produces a 
metabolic acidosis(Kuzmenkin et al., 2002).  The deleterious effects studied relate to the 
ion selective alpha pore. More recent studies have identified an anomalous proton 
selective gating pore due to R669H and R672H SCN4A mutations and a less selective 
cation conducting pore in the R672G SCN4A mutation(Struyk et al., 2007; Sokolov et 
al., 2007). Similar gating pores have yet to be identified in the CACNA1S mutations but 
are proposed as a likely pathomechanism. This may additionally suggest that the R to H 
substitutions are likely to have a greater effect on pH concentration gradients and as a 
result more likelihood of a beneficial response to acetazolamide therapy compared to the 
R to G substitutions.  
Overall these findings suggest genotype is an important factor in determining treatment 
response to acetazolamide in hypoPP and illustrate an additional benefit of achieving a 
genetic diagnosis where possible. This form of retrospective analysis is imperfect 
however and no correction could be made for dose or duration of treatment or influence 
of co-existing treatments. Additionally only the effect of acetazolamide on episodic 
muscle weakness was studied. Any beneficial effect of acetazolamide on preventing 
myopathy was not considered. Without randomised controlled trials the exact efficacy of 
acetazolamide is unknown. In addition its mechanism of action is unclear although it has 
become  first line therapy and suggested to have benefit for the majority of patients for 
almost half a century(Venance et al., 2006). This data suggest however that the response 
rate may be more modest than currently generally considered. This highlights a need for 
randomised controlled trials but also suggests development of new treatments is 
warranted.   
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Conclusions: Treatment response HypoPP 
 
1. Retrospective analysis suggests acetazolamide is efficacious for only approximately 
50% of patients with hypoPP. 
2. Those with R to H amino acid substitutions have the most favourable response. 
3. Those with R to G amino acid substitutions have the poorest response. 
4. Genotypic differences in response may reflect the specific effects of amino acid 
substitution on the aberrant channel gating pore current produced. 
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Discussion – Pathophysiology 
 
Aim 
 
To functionally characterize voltage sensor mutations of SCN4A in light of the recently 
described gating pore seen in some of the Nav1.4 mutations. 
 
 
10.1 Functional consequences of the R675G SCN4A mutation 
 
The identification of an aberrant current via the gating pore in some SCN4A mutations 
associated with hypoPP has led to significant steps forward in understanding the 
pathophysiology of this disorder.  Much remains unexplained however. Although all S4 
segments act generically as voltage sensors each undoubtedly has its own specificities 
and it is likely this even applies to each individual key positively charged residue. The 
phenotype of the Nav1.4 mutant I studied, (R675G) is not entirely in keeping with 
hypoPP(Vicart et al., 2004). It has many shared features, mainly long attacks of paralysis 
lasting hours to days to even weeks. Potassium levels are normal or reduced but oddly 
attacks can be precipitated by increased potassium levels.  It has been shown however to 
introduce a gating pore current as was demonstrated for substitutions of the adjacent 
R669 and R672 residues(Sokolov et al., 2008). The difference with R675G is that the 
current occurred at depolarising potentials. Clearly R675G shares some phenotypic and 
pathological features of other hypoPP causing mutations but has other exclusive aspects.  
Expression of the SCN4A R675G mutation in HEK cells shows a significant (6 fold) 
reduction in current density through the alpha pore compared with wild type. This is 
similar to the reduced current density seen with substitutions of the adjacent arginines 
R672 and R669. 
These functional experiments confirm that an arginine placed nearer the intracellular 
surface of the S4 segment has a similar effect on the gating of the main pore to one on the 
extracellular surface in that they all produce a loss of function defect. This is most severe 
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however for R675G in that a 6 fold reduction in current density is seen as opposed to the 
2-4 fold reduction described for R669 and R672 substitutions(Struyk et al., 2000; 
Kuzmenkin et al., 2002). 
The reason for the reduction in current density however is not clear. It cannot be 
explained by an impairment of channel opening as the voltage dependence of activation 
is indistinguishable from the wild type. Similarly channel inactivation did not 
significantly differ between WT and mutant. Other possibilities are that the mutation 
interferes with protein production or trafficking such that a reduced number of sodium 
channels are expressed at the sarcolemma. Alternatively it may be that the same number 
of channels is physically present in the membrane but that a significant proportion is non-
functional. 
These hypotheses warrant further exploration by single channel recordings and by 
immunofluorescent staining using a Nav1.4 antibody to give an estimate of channel 
expression at the sarcolemma.  
 
10.2 Establishing a myoblast system 
 
Preliminary studies suggested it would not be possible to study gating pore currents in an 
HEK cell model. Although a system for doing so is established in oocytes, these are far 
removed from human skeletal muscle. Early attempts were made to establish if human 
muscle cell cultures could provide a viable and more physiologically relevant alternative. 
Robust sodium currents were obtained but several limitations were identified even in this 
early work including very large currents that are difficult to stabilise and contribution to 
the sodium current from Nav1.5 channels. Ultimately human tissue is also a relatively 
rare commodity that requires careful handling, storage and culture. However despite the 
challenges, a myoblast system has the attraction of being a more physiologically relevant 
tissue in which to study disease pathomechanisms, making the establishment of such a 
system a worthy future project.  
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Conclusions: Pathophysiology 
 
1. A more intracellularly placed arginine (R675G) in the voltage sensor of domain II, 
Nav1.4, has similar although more severe detrimental effects on the alpha pore to 
extracellularly placed basic residues studied in this domain. 
2. Human muscle cell cultures have potential to be a viable physiologically relevant 
model in which to study gating pore currents but there are many technical challenges to 
be considered. 
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